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The persistence and propagation of bacterial antibiotic resistance 
presents significant challenges to the treatment of drug resistant bacteria with 
current antimicrobial chemotherapies, while a dearth in replacements for these 
drugs persists. The thiopeptide family of antibiotics may represent a potential 
source for new drugs and thiostrepton, the prototypical member of this antibiotic 
class, is the primary subject under study in this thesis. 
Using a facile semi-synthetic approach novel, regioselectively-modified 
thiostrepton derivatives with improved aqueous solubility were prepared. In vivo 
assessments found these derivatives to retain significant antibacterial ability 
which was determined by cell free assays to be due to the inhibition of protein 
synthesis. Moreover, structure-function studies for these derivatives highlighted 
structural elements of the thiostrepton molecule that are important for 
antibacterial activity.  
Organisms that produce thiostrepton become insensitive to the antibiotic 
by producing a resistance enzyme that transfers a methyl group from the co-
factor S-adenosyl-L-methionine (AdoMet) to an adenosine residue at the 
thiostrepton binding site on 23S rRNA, thus preventing binding of the 
antibiotic. Extensive site-directed mutagenesis was performed on this enzyme to 
generate point mutations at key active site residues. Ensuing biochemical assays 
and co-factor binding studies on these variants identified amino acid residues in 
the active site that are essential to the formation of the AdoMet binding pocket 
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and provided direct evidence for the involvement of an active site arginine in 
the catalytic mechanism of the enzyme.  
Certain bacteria that produce neither thiostrepton nor the resistance 
methyltransferase express the thiostrepton binding proteins TIP-AL and TIP-
AS, that irreversibly bind to the antibiotic, thereby conferring resistance by 
sequestration. Here, it was found that the point mutation of the previously 
identified reactive amino acid in TIP-AS did not affect covalent binding to the 
antibiotic, which was immediately suggestive of a specific, high affinity non-
covalent interaction. This was confirmed in binding studies using chemically 
synthesized thiostrepton derivatives. These studies further revealed structural 
features from thiostrepton important in this non-covalent interaction. Together, 
these results indicate that thiostrepton binding by TIP-AS begins with a specific 
non-covalent interaction, which is necessary to properly orient the thiostrepton 
molecule for covalent binding to the protein. 
Finally, the synthesis of a novel AdoMet analogue is reported. The 
methyl group of AdoMet was successfully replaced with a trifluoromethyl 
ketone moiety, however, the hydrated form (germinal diol) of this compound 
was found to predominate in solution. Nevertheless, the transfer of this 
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CHAPTER 1: INTRODUCTION 
 
Antibiotics have been successfully used in the treatment of bacterial 
infections for the last seven decades, undeniably bringing about profound 
improvements in human health. However, upsurging bacterial antibiotic 
reistance has become an immense source of concern and frustration to 
biomedical researchers and clinical health care providers. Antibiotics are 
secondary metabolites whose functions may well extend beyond the inhibition 
of bacterial growth (1, 2). While some debate exists over the evolutionary 
origins and functions of antibiotics, it is clear that the antibiotic producing 
phenotype provides a fitness advantage to antibiotic producers and thus has 
been passed down through natural selection. The evolution of antibiotic 
resistance is by necessity linked to that of the antibiotic production, as the 
organisms producing these toxic compounds would require mechanisms to 
prevent their self-destruction.  
The first recorded clinical case of antibiotic resistance was that observed 
against penicillin, within two years of its discovery in the mid-1940s (3, 4). 
Since then, nosocomial resistance has been observed, on average, within months 
to a few years after the clinical introduction of an antibiotic (4). This emergence 
and the persistence of resistant strains is a direct consequence of the selective 
pressure arising from the overuse and misuse of these drugs. Thus far, 
incidences of infection have been generally contained, yet the possibility of 
widespread, uncontrollable outbreak remains. 
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1.1. Antibiotic action and mechanisms of resistance  
Antibiotics exert bacteriocidal or bacteriostatic effect on bacteria 
through inhibitory or destructive effects on essential bacterial cellular processes 
and/ or organelles. Many structurally diverse classes of these compounds 
(Figure 1.1) exist and the mode of action for numerous antibiotics as well as 
associated resistance mechanisms has been determined. As these topics have 
been extensively researched and thoroughly reviewed, a cursory overview will 


































































































































































































1.1.1. Target sites and modes of action for common antibiotics 
1.1.1.1. Cell wall synthesis and cell membrane disruption 
1.1.1.1.1. Inhibitors of peptidoglycan synthesis  
Modern clinical use of antibiotics for the treatment of bacterial 
infections began with penicillin in the 1940s, the progenitor of the β-lactam 
antibiotics (cephalosporins, monobactams, carbepenems). These compounds 
feature a reactive four-membered ring that serves as the key structure in the 
disruption of cell wall synthesis. The integrity of bacterial cell walls is 
maintained by a peptidoglycan network formed from cross-linked adjacent 
polymers of repeating N-acetylmuramic acid and N-acetylglucosamine units. It 
is believed that the beta-lactam drugs structurally mimic the peptide substrate 
(D-alanine-D-alanine) of the transpeptidases that catalyze this cross-linking, 
thus covalently inhibiting these enzymes (5). Glycopeptides, including 
vancomycin and teicoplanin, are another group of antibiotics that target cell wall 
biosynthesis. In the case of vancomycin, the antibiotic selectively binds 
(through hydrogen bonding) the terminal D-alanyl-D-alanine on the peptide 
precursors of peptidoglycan biosynthesis, which prevents their transglycosylase-
mediated incorporation into peptidoglycan (6). Peptidoglycan synthesis is a 
complex, multistage process and the antibiotic targets of this process are not 
restricted to the transglycosylase enzymes, as seen with additional glycopeptides 





1.1.1.1.2. Bacterial cell membrane 
 Antibiotics that affect the cell membrane (type A lantibiotics, 
daptomycin) include cationic bacteriocins that are able to interact with the 
negatively charged lipid moieties on the outer surfaces of bacterial cells (12). 
Membrane association by these molecules is believed to promote the self-uptake 
that leads to the formation of membrane permeabilizing pores. The mechanism 
of pore formation is unclear but likely varies between molecules and several 
models have been postulated to explain this process (13). Nevertheless, 
membrane permeabilization has been found to impact small molecule transport 
and energy transduction process across the membrane, while facilitating 
internalization of the cationic peptide, with bactericidal consequences to the cell 
(13, 14).  
1.1.1.2. Ribosome targeting antibiotics 
Protein synthesis is an essential cellular process that is a target of several 
antibiotics (Figure 1.2). As well, the eukaryotic process is sufficiently different 
from that occurring in bacteria (15), making this an attractive drug target and 
accordingly, antibiotics that interfere with protein synthesis are well represented 
in the clinic. Antibiotics inhibiting virtually all stages of protein translation have 














The elongation cycle of protein synthesis commences with the decoding 
stage, which follows after initiation. The P Site is occupied with a peptidyl-
tRNA and the A Site displays the codon for the next aminoacyl tRNA (aatRNA) 
encoded by the sequence (16). Tetracyclines act at this stage by binding to the A 
Site which prevents accommodation of the incoming aatRNA (17). The binding 
of aatRNA at the A Site is facilitated by elongation factor Tu (EF-Tu), which 
forms a ternary complex with aatRNA and GTP (18). Subsequent GTP 
hydrolysis allows the requisite conformational change in EF-Tu for its 
dissociation (16). Hence, inhibition of these EF-Tu mediated activities could 
also prevent A Site occupation, as seen with the kirromycins (prevent the 
Figure 1.2. Binding sites of antibiotics on the bacterial ribosome. The 30S 
ribosomal subunit is shown on the left and the 50S ribosomal subunit is shown on 
the right. The antibiotic-binding sites were initially determined by biochemical and 
genetic techniques; subsequently, many sites were revealed in greater detail by X-
ray crystallography. At the overlapping sites, antibiotic binding is usually mutually 
exclusive (for example, for macrolide, lincosamide and streptogramin B 
compounds), however, streptogramin A and B compounds bind synergistically at 
adjacent sites. Subunit models are based on the Thermus thermophilus 70S ribosome 
structure. In this figure, for clarity, part of the r-protein L9 has been omitted. 
Ribosomal RNAs are shown in yellow and grey and r-proteins in bronze and blue. 
Reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews 
Microbiology]. Poehlsgaard and Douthwaite, 2005.The Bacterial Ribosome as a 
target for Antibiotics. Nature Reviews Microbiology. 3, 870 – 881. Copyright (2005) 
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dissociation of EF-Tu), pulvomycin (prevent the formation of the aatRNA-
EF.Tu-GTP complex) and ribotoxins (impede the binding of the aatRNA-
EF.Tu-GTP complex) (17).  
Aminoglycosides (streptomycin, kanamycin) utilize a different approach 
to interfere with A Site processes. These polycationic molecules promote self 
uptake into the bacterial cells through interactions with the negatively charged 
lipopolysaccharides in the bacterial membrane (similar to membrane targeting 
antibiotics discussed above) and their inherent positive charge also directs them 
to the negatively charged rRNA in the 30S subunit of the bacterial ribosome 
where they bind to specific bases at the A-site (19). This binding induces 
structural rearrangements in these bases that are critical to the fidelity of 
translation and the consequent misreading leads to the incorporation of incorrect 
amino acids and the synthesis of useless translational products which are 
ultimately detrimental to the cell (20). As well, aminoglycoside binding at the A 
Site can interfere with translocation of tRNA from the A Site to the P Site (21). 
The peptidyl transfer reaction occurs between the peptidyl-tRNA that 
occupies the P Site and the aatRNA at the A Site after A Site occupation. In this 
RNA catalyzed reaction, the amino group of the A Site tRNA attacks the 
carbonyl group at the ester linking the peptide moiety to tRNA in the P Site 
peptidyl tRNA (22, 23). The end result is the formation of a peptide bond 
between the aatRNA at the A Site and the peptidyl residue formerly associated 
with the P-site peptidyl tRNA (16, 24). Antibiotics that inhibit this stage of the 
elongation typically do so by outcompeting the native substrates of the peptidyl 
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tranferase reaction or by preventing the progression of the immature peptide as 
it is being synthesized. Puromycin and blasticidin resemble the 3’-end of 
aatRNA, and the former is incorporated into the growing polypeptide chain, 
forming an ester linkage to the ribose of tRNA that cannot be cleaved by the 
ribosome (17). Chloroamphenicol and the lincosamides have overlapping 
binding sites at the peptidyl transferase centre and these antibiotics act by 
disrupting tRNA binding at the A Site (25, 26). Likewise, streptogramin A and 
oxazolidinone binding at the peptidyl tranferase center hinders tRNA binding at 
the A and P Sites (27, 28).  
After peptidyl transfer, deacylated tRNA is transferred from the P Site to 
the E Site and peptidyl-tRNA is transferred from the A Site to the P Site in a 
translocation process that makes the A Site available for the next incoming 
aatRNA that is encoded by the sequence. As this cycle repeats, the nascent 
peptide is threaded through the exit tunnel as it grows in length until a stop 
codon is reached (16). The polyketide macrolide antibiotics bind the 50S 
ribosomal subunit at the exit tunnel near the peptidyl transferase center, thereby 
reducing the diameter of this passageway and obstructing the exit path for the 
nascent peptide chain (29, 30). The binding site of streptogramin B antibiotics at 
the peptidyl transferase center overlaps with that of the macrolides, also leading 
to inhibition of the nascent chain progression (26). 
Translocation is linked to directional mRNA movement in a concerted 
process that preserves the reading frame while lengthening the peptide one 
residue at a time (18). This process takes advantage of their differential binding 
9 
 
affinities that tRNA species have for the respective binding sites (aatRNA for 
the A-site, peptidyl tRNA for the P-site and deacylated tRNA for the E-site), but 
is also directly aided by elongation factor G (EF-G) and GTP hydrolysis, which 
mediate structural rearrangements in the ribosome that allow complimentary 
tRNA and mRNA movement (18, 31, 32). Fusidic acid is a classic 
translocational inhibitor and binds at the GTPase center, effectively stalling the 
ribosome by stabilizing the EF-G.GDP complex on the ribosome. Conversely, 
viomycin and spectinomycin operate at the other end of the EF-G cycle by 
interfering with EF-G.GTP binding. The binding of thiopeptide antibiotics at the 
GTPase center also disrupts GTP-dependent activities (17). Thiostrepton, the 
archetypal member of this antibiotic family, is the central focus of study in this 
thesis and the details of its mode of action and that of other thiopeptides will be 
elaborated in following sections. The elongation cycle of protein translation and 









1.1.1.3. Antibiotics targeting DNA synthesis and replication  
 Quinolone antibiotics were discovered in the early 1960s and became 
widely used in the clinic from the mid-1980s (33). Their observed bactericidal 
ability was initially limited to Gram-negative species but later extended to 
Gram-positive species as well as to Mycobacterium tuberculosis, through 
fluorine derivatization, giving rise to the fluoroquinolones which also possess an 
improved pharmokinetic profile (34, 35).  
Figure. 1.3. Antibiotics and the elongation cycle of protein translation. (1) 
Decoding: The A Site on the ribosome is available for the next aatRNA encoded 
by the mRNA sequence. (2) A Site occupation: aatRNA binds at the A Site, aided 
by EF-Tu. (3) Petidyl transfer: A peptide bond forms between the amino acid from 
the aatRNA and the peptidyl moiety from the peptidyl tRNA that is at the P Site, 
lengthening the peptide chain by one residue. (4). Concerted movement of the 
ribosome with respect to mRNA by one codon, aided by EF-G, leaving deactivated 
tRNA in the E Site and the A Site free for and incoming aatRNA. The points of 
action of various antibiotics are indicated. (Adapted from (17)) 
11 
 
Quinolones and fluoroquinolones are broad spectrum antibiotics that 
impede DNA replication by targeting DNA gyrase and topioisomerase IV. DNA 
gyrase acts to relieve the positive supercoiling and torsional stress ahead of the 
transcriptional complex. Quinolone binding induces conformational changes in 
the enzyme that stabilize the DNA-DNA gyrase complex, thus stalling the 
replication fork (36). DNA replication is arrested by quinolone binding to 
topioisomerase IV through the prevention of the decatenation of daughter DNA 
strands that is performed by this enzyme (37).  
 
1.1.2. Mechanisms of antibiotic resistance 
 The diversity in the ways by which antibiotics act is matched by an 
assortment of ways in which bacteria are able to avoid the effects of these drugs. 
These generally fall within four general mechanisms: efflux, antibiotic 
modification, target site modification and drug neutralization.  
1.1.2.1. Drug efflux 
 Antibiotics must accumulate inside the bacterial cell at sufficiently high 
concentrations to be effective. This accumulation is prevented by the actions of 
membrane spanning protein systems that actively transport drug molecules out 
of the cell. Drug efflux was first reported as a cause of tetracycline insensitivity 
(38), but these systems are now known to confer resistance to a broad range of 
antibiotics. They have also been the subject of extensive study, particularly 
those systems of the resistance-nodulation-cell division-class (RND) (39). 
Members of the RND class, such as the Arc-AB-TolC and MexAB-OprM 
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systems in E. coli and P. aeruginosa, respectively, feature a tripartate system of 
an outer membrane pore and a transmembrane pump linked by a bridging 
protein (40). Efflux proteins are not necessarily expressed in direct response to 
antibiotic presence, but rather appear to be integrated into bacterial cellular 
stress response (41). However, the chemical cues that activate the regulatory 
elements for the transcription of the genes encoding these proteins remain 
poorly described (41) 
1.1.2.2. Antibiotic modification  
Antibiotic modifications that result in the direct destruction of the drug 
molecule were first described in β-lactamase catalyzed hydrolytic lactam ring 
opening of penicillin that renders the antibiotic inactive (42). The substrate 
specificity of these enzymes has been expanded by evolution, giving rise to the 
extended spectrum β-lactamases (ESBL) and metallo-β-lactamases that cause 
resistance to later generations of β-lactam antibiotics (cephalosporins, 
carbapenems) (43, 44). In addition, scaffold opening in some macrolides and 
streptogramins leads to deactivation of these drugs (39). Antibiotic 
modifications causing resistance can also take the form of enzyme modification 
by the additional of functional groups that hinder the interaction of the antibiotic 
with its target site. Such is the result of adenylation, phosphorylation or 
acetylation of aminoglycosides by resistance enzymes that leads to their 





1.1.2.3. Target site modification 
 Analogous to the antibiotic addition of chemical groups to the antibiotic 
molecule, antibiotic binding may be prevented by modifications at the antibiotic 
target site. Such target site modifications are particularly important as a 
mechanism of resistance among ribosome targeting antibiotics. Examples 
include the specific adenine methylations on 23S rRNA by Erm 
methyltransferases that averts the binding of macrolide antibiotics to the 
bacterial ribosome; the prevention of ribosomal binding by avilamycin due to 
the methylation of guanosine or uridine by AviRa and AviRb; and the 
methylation of purine nucleotides on 16S rRNA that results in resistance to 
certain aminoglycosides (21, 29, 45, 46). Methylation of rRNA is also an 
important form of resistance to thiopeptides antibiotics, which will be later 
discussed specifically with respect to thiostrepton and from the broader context 
of methylation as a resistance mechanism.  
1.1.2.4. Molecular neutralization 
 Molecular neutralization encompasses bacterial strategies that indirectly 
accomplish antibiotic deactivation. Such is the case for vancomycin resistance 
that results from alterations to the content of the peptidoglycan during its 
synthesis. Organisms exhibiting this form of resistance express enzymes that 
synthesize a depsipeptide mimic that replaces the normal acyl-D-alanyl-D-
alanine in peptidogylcan construction, and another that degrades the D-Ala-D-
Ala (39). Vancomycin binding is dependent on interactions with D-Ala-D-Ala, 
which do not occur with the ester linkage in the depsipeptide, thus rendering the 
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organism resistant (39). A second example is thiopeptide resistance in non-
producing Streptomyces. In the presence of certain thiopeptides, these species 
upregulate the expression of so called TIP proteins, which irreversibly bind the 
antibiotics, thereby preventing binding at their target sites (47, 48). Antibiotic 
binding and sequestration is also the mechanism of bleomycin and mitomycin 
resistance (49–52).  
1.1.3. Emergence and transfer of antibiotic resistance 
Antibiotic resistance genes are believed to have originated from a 
primordial gene pool that favored resistance as a means of forestalling cellular 
death in antibiotic producers and these genes subsequently evolved into the 
resistome in parallel with the antibiotic producing phenotype (2, 53). This 
spawned innate bacterial antibiotic resistance, where the organisms inherently 
posses the genetic information that encodes resistance. Broadly speaking, this 
refers to any genes that enable the bacteria to elicit a resistance response, such 
as non-specific efflux pumps that bestow multidrug resistance, stress response 
proteins or antibiotic binding proteins but also include genes encoding 
resistance to a specific antibiotic or class of antibiotics.  
On the other hand, resistance genes may be acquired through genetic 
mutations or horizontal gene transfer, establishing resistance in a previously 
sensitive species. Mutations have been associated with resistance to antibiotics 
in many classes, but are likely not to be the predominating natural means by 
which resistance is acquired. Nevertheless, the contribution of this mechanism 
cannot be discounted. The broad spectrum resistance exhibited by multi-drug 
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resistant tuberculosis is mediated by mutations and provides an excellent 
example of resistance emerging through spontaneous mutation (54, 55), as well 
as the mutational resistance that frequently develops against synthetic 
antibiotics (28, 56–58). In addition, mutations can affect how resistance genes 
are expressed and undoubtedly contribute to their evolution, which may be of 
particular relevance to the emergence of resistance against newly introduced 
antibiotics (59). It is also believed that a general “housing keeping” gene 
product is duplicated and modified to provide resistance to externally present 
antibacterial agents. 
Once established in the genome of a bacterial species, resistance genes 
become susceptible to horizontal gene transfer (HGT) to other species. Bacteria 
can accomplish HGT by conjugation (conjugative plasmids or transposons), 
transformation (recombination) or transduction (bacteriophages), but 
conjugative plasmid mediated transmission is foremost among these for the 
transfer of resistance genes. These resistance plasmids can be transmittable 
between a narrow set of similar species, or more worryingly, between a large 
number of different species and genera, as well as between Gram-negative and 
Gram-positive organisms. The frequency with which such conjugative transfer 
occurs nature may not be empirically measurable, yet it is believed to happen to 
a far greater extent than that shown under laboratory conditions and plasmid 




It is not uncommon to find several resistance genes on a single plasmid, 
which results from integration of mobile resistance genes. Integrons are the 
capture systems for such genes, which are found on mobile genetic elements 
referred to as cassettes (60–62). They can be found on plasmids or within 
transposons that are on plasmids and basic integron structure consists of an intI 
gene that encodes an integrase and a recombination site, attI, where gene 
cassettes are inserted under the control of a promoter (63–66). Gene cassettes 
are simple DNA segments consisting of a single (promoterless) gene, followed 
by a recombination site (attC) and the integrase gene that catalyzes 
recombination between attI and attC (60, 64). This arrangement can allow for 
the insertion of multiple cassettes under the control of this single strong 
promoter. Over 100 such cassettes, representing all major classes of antibiotics, 
have been discovered (62, 67). 
The presence of resistance genes in nature has provoked discussions on 
their origins and additional functions, but ultimately, the emergence, 
propagation and maintenance of antibiotic resistance genes are subject to natural 
selection. The selective pressure imposed by the widespread use of antibiotics 
has unquestionably been the thrust behind the surge in resistance seen in recent 
times. Moreover, retro-analyses suggest that modern day resistance and 
resistance gene dissemination are relatively recent phenomena, the progression 
of which coincided with increasing antibiotic use (67, 68). This prompted 
notions that removal of selective pressure (widespread antibiotic use) would 
eventually lead to the reversal of resistance due to the biological cost of 
17 
 
maintaining a resistant phenotype (69, 70), however, many instances where 
bacteria are able to compensate for this cost are known (67, 69). 
1.1.4. Antibiotic development  
The overview of antibiotic modes of action and resistance mechanisms 
in the preceding sections serve to illustrate that in spite of the myriad ways by 
which antibiotics are able to exert their toxic effects on the bacterial cell, 
bacteria continue to demonstrate flexibility and versatility in avoiding the 
effects of these drugs. This problem of antibiotic resistance cannot be overstated 
as resistance has been reported to occur against all antibiotics in current clinical 
use, in addition to those drugs that have yet to reach the clinic and underscores 
the need for novel, antibacterial chemotherapies. 
Natural products have historically served as a fruitful source of 
antibiotics. The reservoir was seemingly exhausted by the 1960s, with the major 
classes of antibiotics being discovered (β-lactams, aminoglycosides, 
tetracyclines, macrolides, glycopeptides). This was followed by what is referred 
to by many as an “innovation gap”, where no new antibiotic classes were 
introduced until the discovery of the oxazolidiones in the early 2000s. Even so, 
the emergence of resistance and the characterization of associated molecular 
mechanisms spurred a period of antibiotic development during this time and 
these natural products as scaffolds for drug development by semi-synthetic 
approaches. More recent approaches to the discovery of new antibiotic classes 
have sought to identify new antibiotic targets through genomic screening and 
application of combinatorial chemistry towards drug development. As well, 
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biosynthetic engineering is being explored as a means for antibiotic production 
and derivatization (71–74). These methodologies, however, are in their nascent 
stages and have realized little success beyond proof of principle. Concurrent 
with these efforts, the search for new antibiotic classes among natural products 
continues. New organisms are being considered as potential sources and while 
some species do show promise in this regard, an untapped pool of potential 
“novel” drugs may yet exist among families that have already been discovered. 
The thiopeptide family of antibiotics, of which thiostrepton is the prototypical 
member, is one such group under reconsideration. 
 
1.2. Thiostrepton and the thiopeptide family of antibiotics 
1.2.1. Structure and physical properties  
 Thiopeptide antibiotics are sulfur rich, naturally occurring peptides that 
are produced by actinomycetes, particularly of the Streptomyces genus. These 
compounds typically feature a macrocyclic arrangement of modified amino 
acids and heterocycles and as a family, display extremely poor aqueous 
solubility. More than 80 members are included within this antibiotic family 
which are divided into 5 classes according to the oxidation state of their central 
heterocyclic domain and further subdivided into 29 families based on structural 
























































































































































































































































































































Thiostrepton is considered to be the parent compound of the thiopeptide 
antibiotics and was discovered as an antibacterial secondary metabolite 
produced by Streptomyces azureus in the mid-1950s (78, 79) and later, also by 
and Streptomyces laurentii (80). The molecular structure of the antibiotic was 
deduced from chemical degradation studies, where its various components 
(modified amino acids, heterocycles) were identified (Figure 1.5A) (81). 
Physical evidence of the macrocyclic arrangement of these moieties was first 
suggested in the early crystallographic work of Anderson et al. (82) and later 
confirmed by the solution of  NMR derived structures of thiostrepton (83) and 
most recently, by the solution of the crystal structure of thiostrepton (84), all of 
which portray a globular-type conformation of the thiostrepton macrocycles, 
from which extends a tail region that was later found to be flexible in solution 
(Figure 1.5B) (85).  Thiostrepton is assigned to the a series of thiopeptides, a 
class typified by their central dehydropiperidine and bis-macrocyclic peptide 
backbone that features a quinaldic acid residue (75). The central 
dehydropiperidine that acts as a lynchpin that connects the two macrocycles, 
which contain modified amino acids, thiazoles and the quinaldic acid residue, to 


















1.2.2. Total synthesis and biosynthesis of thiostrepton 
The complexity of thiostrepton and the thiopeptides in general, adds a 
substantial amount of difficulty to their total syntheses, yet such syntheses 
frequently provide insights into the biosynthesis of natural products such as 
these. Retrosynthesic analyses outlined chemical routes to the various 
heterocycles and modified amino acids that form the building blocks of 
thiostrepton (and other thiopeptides), yet pragmatically obtaining these proved 
to be a synthetic challenge. Nevertheless, through tremendous efforts, total 
Figure 1.5. Thiostrepton. (A) Important structural features of the thiostrepton 
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syntheses of thiopeptides were achieved, with promothiacin and amythiamycin 
D being the first compounds being synthesized (86–88). Both compounds 
present simpler structures than thiostrepton, each possessing a single 
macrocycle composed primarily of thiazoles (Figure 1.4). Thiostrepton 
eventually succumbed to total synthesis through the remarkable efforts of 
Nicolaou and co-workers (89, 90). These researchers divided thiostrepton into 4 
fragments, corresponding to each of the macrocycles, the bis-dehydroalanine 
tail and the central dehydropiperidine core, which were subsequently assembled 
into the intact thiostrepton molecule (89, 91). The preparation of these 
fragments was not trivial, particularly the dehydropiperidine core, which was 
obtained through an elegant cascade sequence (92). A detailed description of the 
approaches is beyond the scope of this thesis and the reader is directed to 
reference (93) for an excellent review. At the time of writing, total and partial 
synthesis for a number of additional thiopeptides has been reported (94–99). 
 Insights into thiostepton biosynthesis have been intertwined with efforts 
at its total synthesis, with each contributing towards the greater understanding of 
the other. The exploration of thiostrepton biosynthesis was initially performed 
by feeding isotopically labeled precursor amino acids to cultures of 
Streptomyces (S. azureus, S. laurentii), then monitoring the incorporation of 
these isotopic labels in the thiostrepton that was produced. These experiments 
revealed that the dehydroalanine and dehydrobutyrine residues derived from 
threonine and serine, the thiostreptine moiety from isoleucine and 
cyclodehydrations involving cysteine and serine or threonine gave rise to 
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thiazoles and oxazoles respectively (100). More complicated descriptions were 
suggested for the formation of the dehydropiperidine core and the quinaldic acid 
residue. Although quinaldic acid was demonstrated to derive from methionine 
and tryptophan, arrival at quinaldic acid requires indole ring breakage then 
expansion, followed by the installation of the hydroxyl and amine groups which 
may include (NADPH dependent) reduction and concluding with esterification/ 
epoxidation, then epoxide ring opening (101–103). Serine and cysteine were 
identified as the progenitors of the dehydropiperidine moiety, which was 
proposed to occur from a hetero-Diels-Alder cycloaddition similar to that 
suggested for the formation of the pyridine core in micrococcin (104). Both 
mechanisms were somewhat synthetically validated on course to total 
thiostrepton synthesis (92, 105). 
An important observation from these early investigations was that all the 
carbon atoms present in thiostrepton originated from a conventional amino 
acids. When considered in light of practical demonstrations of chemical 
syntheses of thiostrepton fragments, this hinted at the possibility that 
thiostrepton biogenesis commences with its initial synthesis as a linear peptide 
of the sequence that is subsequently subjected to the host of post translational 
modifications that results in the macrocyclic, highly modified thiostrepton 





















 However, it was still unclear whether biogenesis was ribosomally 
directed or the result of non-ribosomal enzymatic processes. Also unknown was 
the sequence in the events leading to macrocyclyzation, amino acid 
modification, the formation of the dehydropiperidine core and the attachment 
quinaldic.  These were clarified by the recent discovery of the gene cluster 
responsible for thiostrepton biosynthesis, which unequivocally confirm the 
hypothesis of ribosomal synthesis (106). 
Whole genome scanning of S. laurentii, identified a gene encoding a 
thiostrepton precursor consisting of a leader peptide, followed by sequence 
Macrocyclization? 
Completion of Macrocyclization/ 
attachment of qunialdic acid? 
Modification of amino acids? 
Figure 1.6. Proposed formation of mature thiostrepton. Schematic depiction of 
the cyclization of the thiostrepton from a linear prepeptide predicted from isotopic 
labeling studies. According to this model, the attachment of the quinaldic acid 
residue is one of the last steps in the formation of mature thiostrepton. 
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identical to that predicted for a thiostrepton prepeptide. The deletion of this gene 
completely abolished thiostrepton production. The region surrounding this gene 
included 21 potential open reading frames that were deduced to encode putative 
enzymes responsible for post translational modifications of thiostrepton 
precursor, including the dehydratases that would render dehydroalanine (DHA) 
and dehydrobutyrine (DHB) residues from serine and threonine, the 
dehydrogenases that would enable the cyclodehydration of cysteine with the 
peptide backbone to generate thiazoles and the putative enzymes responsible for 
the terminal amidation of thiostrepton and dihydroxylation of I10 (106). 
Amidation at the C-termius of thiostrepton has been since shown to result from 
the desterification-amidation of a methyl ester thiostrepton intermediate and is 
accomplished by two enzymes encoded in the gene cluster (107).  
Almost concurrently, similar results showing thiostrepton to be the result 
of post-translational modifications to a ribosomally encoded precursor peptide 
were obtained independently by Liao et al. (108). These researchers further 
identified putative genes for enzymes that accomplish the cycloaddition reaction 
that produces the dehydropiperidine core and demonstrated their requirement in 
thiostrepton production through deletion studies. In addition, open reading 
frames for enzymes carrying out all the necessary chemical steps in quinaldic 
acid biosynthesis were identified. This expanded upon the work by Kelly et 
al.(106), in which a putative methyltransferase that sequentially resembled 
members of the radical SAM family (SAM = S-adenosyl-L-methionine) was 
identified, along with a putative aminotransferase were identified and together, 
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these enzymes could accomplish early steps in the biosynthesis of qunialdic acid 
from tryptophan as proposed by Mocek (101). Most recently, Duan and 
coworkers assigned unambiguous functions to these putative enzymes by 
monitoring thiostrepton production in S. laurentii strains engineered to be 
deficient in specific genes from the cluster, after they were fed an intermediate 
that would occur during the proposed mechanism for quinaldic acid biosynthesis 
(109). These results were largely consistent with earlier mechanisms and 
implicated a radical SAM enzyme in the initial methylation of the indole from 
tryotophan. 
Continued research will undoubtedly seek to describe the attachment of 
quinaldic acid to the thiostrepton macrocycle, as current evidence indicates that 
this residue is formed separately from the rest of the molecule. As well, the 
mechanisms of macrocyclization and detachment of the structural peptide 
remain to be elucidated. Parallel investigations on the biosynthetic pathways of 
related thiopeptides have revealed the common theme in thiopeptide 
biosynthesis thus far: ribosomal synthesis as a precursor, followed by extensive 
post translational modifications by a host of enzymes included within the same 
gene cluster (110–115).  
 
1.2.3. Biological properties of thiostrepton 
1.2.3.1. Antibacterial activity  
 Upon its discovery, thiostrepton was found to exhibit potent bactericidal 
effects against Gram-positive bacteria (116). Species of the Gram-negative 
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genera are insensitive to the antibiotic, which is most likely the result of its 
inability to penetrate the Gram-negative cell wall, since the functions of isolated 
Gram-negative ribosomes are indeed inhibited by thiostrepton (117, 118). The 
bacterial ribosome is the organelle targeted by thiostrepton, where the antibiotic 
impedes the elongation cycle during protein translation, ultimately leading to 
cell death.  
The thiostrepton binding site has been mapped to the GTPase center on 
the 50S subunit of bacterial ribosomes, where a high affinity interaction occurs 
with 23S rRNA (Figure 1.7A) (117, 119, 120). This interaction occurs with 
rRNA on cell-free ribosomes from either Gram-positive of Gram-negative 
species, and involves a 58 nucleotide region that includes H43 and H44 from 
domain II of 23S rRNA and is critically dependent on thiostrepton interactions 
with A1067 and A1095 (Figure 1.7B, 1.7C) (120, 121). This region of 23S 
rRNA is also the binding site for ribosomal protein L11 (122–124) and this 
protein enhances the affinity of the thiostrepton-binding interaction through 
cooperative interactions mediated by its N-terminal domain (118, 125–130). 
This effect appears to be contingent on a key proline residue that is conserved 
among bacteria and the absence of this residue in the equivalent eukaryotic 
protein presumably accounts for the insensitivity of eukaryotic ribosomes to 




















Figure 1.7. The binding of thiostrepton to the bacterial ribosome. (A) 
Thiostrepton binding site on the 50S subunit of the ribosome from Deinococcus 
radiodurans (PDB: 3CF5). The figure is colored as follows: thiostrepton – yellow; 
rRNA – red; ribosomal proteins (except L11) – blue; L11 - magenta. (B) Secondary 
structure of the thiostrepton binding motif from 23S rRNA. (C) Magnified view of 
thiostrepoton binding to the ribosome showing the interaction between the 
thiostrepton macrocycles and A1067 and A1095 from rRNA, and the bis-DHA tail 








The GTPase center of the bacterial ribosome oversees the hydrolysis of 
GTP, which is coupled to the decoding and elongation stages of protein 
translation with the involvement of elongation factors EF-Tu and EF-G 
respectively (18). Thiostrepton binding at the GTPase center induces 
conformational changes in this region of the ribosome that leads to the 
inhibition of these processes. Although thiostrepton primarily affects the 
elongation cycle of protein translation, the antibiotic has been reported to inhibit 
tRNA delivery during decoding, A Site occupation as well as translation 
termination (134, 135). This may not be surprising given the GTP-dependent 
nature of these processes (18).  
With respect to the elongation cycle, there was early disagreement on 
whether the antibiotic acted by preventing the dissociation or association of EF-
G from the ribosomal complex, as evidence in support of both scenarios was 
presented (136, 137). Subsequent work has placed emphasis on the latter as the 
predominant mechanism of drug action, with the involvement of ribosomal 
protein L11, which was shown to be important for the structural integrity of the 
ribosome (122) and for conformational changes requisite for EF-G dependent 
translocation (138–141). Taken together, the sum of available biochemical and 
structural evidence implies that the enhancement of thiostrepton binding affinity 
caused by L11 imposes conformational restrictions on the protein that impede 
EF-G binding to the rRNA, which consequently halts protein synthesis (127, 




1.2.3.2. Additional biological properties of thiostrepton 
Thiostrepton is known to be toxic to the malaria parasite Plasmodium 
falciparum, which was attributed to binding of the drug to ribosomal RNA in 
the apicoplast of the parasite and the resultant inhibition of protein synthesis by 
this organelle (146–150). This was reminiscent of the mode of action of 
thiostrepton in bacteria, however, the immediate cell death brought about in 
Plasmodium by thiostrepton was contrary to the effects of other apicoplast-
targeting drugs (151, 152). Some clarity of this apparent anomaly was offered in 
recent studies that presented evidence suggesting that the rRNA of the 
apicoplast is a secondary drug target and the immediate killing effect of 
thiostrepton primarily results from its inhibition of protein translation by the 
proteosome (153, 154) or by thiostrepton-induced  alteration in gene expression 
profiles (155).  
 Anti-cancer properties for thiostrepton were first reported by Nicolaou 
(156) and subsequently found to result from the selective induction of apoptosis 
in cancer cells, in response to thiostrepton mediated down regulation of the 
expression of transcription factor forkhead box M1(FOXM1) and accordingly, 
the inhibition of the activities of its downstream targets (157–161). 
Interestingly, inhibitors of FOXM1 were also shown to inhibit protesome 
activity (162), which is consistent with the descriptions of the anti-plasmodial 
effect of thiostrepton discussed above. Most recent evidence has found that 
thiostrepton directly interacts with FOXM1, thereby hindering its binding to 
genomic targets (163). Such a mechanism would account for the observed 
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reduction in the activities of downstream FOXM1 targets, but does not 
completely discount transcriptional inhibition of FOXM1 by thiostrepton. 
 Finally, thiostrepton is reportedly a potent inhibitor of the growth of 
Mycobacterium tuberculosis, the predominant causative agent of tuberculosis 
(164, 165). However, the mechanism by which this is accomplished remains to 
be described. 
 
1.3. Thiostrepton resistance 
1.3.1. Resistance in thiostrepton-producing organisms 
 Streptomyces species that produce thiostrepton also possess the means to 
avert self-toxicity by the antibiotic. The first insights into this innate resistance 
came from observations of the differential abilities of reconstituted ribosomes to 
bind the antibiotic; ribosomes reconstituted fully or in part from components 
derived from S. azureus (the producing organism) were unable to bind the 
antibiotic (166). This was determined to be the result of the 2’-O-methylation of 
ribose on an adenine in the rRNA of S. azureus (167) by an enzyme present in a 
crude cellular protein extract prepared from S. azureus. Purification and 
characterization of the enzyme responsible for rRNA methylation revealed that 
this enzyme catalyzed the specific transfer of a methyl group from S-adenosyl-
L-methionine (AdoMet) to 23S rRNA, rather than the intact ribosome, implying 
that this modification occurs at an early stage in ribosome assembly, prior to 
subunit association or the incorporation of proteins to the ribosomal complex 
(168). The binding site of this enzyme on the ribosomal complex overlaps with 
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that of ribosomal protein L11/ thiostrepton and accordingly, the enzyme will not 
methylate RNA in the presence of either (169). In addition, extensive 
mutagenesis in combination with biochemical assays revealed the nucleotides 
within the L11 binding necessary for binding of this methyltransferase, with 
A1067 being the likely recipient of the methyl group from AdoMet (169, 170) 
(Figure 1.7).  
 In a recent collaborative effort by our group, the moleular structure of 
the resistance conferring 23S rRNA 2’-O-methyltransferase (TSR) has been 
solved (Figure 1.8A) (171). The enzyme’s structure definitively placed TSR 
within the SPOUT family of Methyltransferases, as predicted by comparative 
sequence analysis and homology modeling using known members of this class 
(171–174). The enzyme was crystallized as a homodimer, with one AdoMet 
molecule bound to each monomer. Each monomer features an N-terminal 
(NTD) and C-terminal domain (CTD), the latter of which includes the AdoMet 
binding pocket (Figure 1.8A). The binding pocket is formed mostly from one 
monomer, although amino acids from the other monomer make vital 
contributions to its architecture. Also critical to the formation of the binding 
pocket is the presence of a deep trefoil knot, which keeps the AdoMet molecule 
entrenched within the binding pocket by maintaining close contacts with the 










The binding of RNA by TSR appears to be governed by electrostatic 
interactions between the negatively charged RNA and a region of positive 
charge that is wedged between the NTD from each monomer (Figure 1.9). 
Productive RNA binding is also dependent on RNA tertiary structure, 
particularly a stem-loop structure that comprises 29 nucleotides including the 
Figure 1.8. The TSR-AdoMet complex. A) Stereoview of the TSR dimer with 
individual subunits colored blue and green (PDB: 3GYQ). (B) Magnified stereoview of 






target A1067, which was consistent with earlier work by Bechthold and Floss 
(169) (Figure 1.5B). In addition, the modeled binding of RNA by TSR implies 
that while only one monomer functions in a catalytic capacity, both are required 






1.3.1.1. RNA methylation and antibiotic resistance 
 The 23S rRNA methylation accomplished by TSR was the first instance 
described in the literature where specific RNA methylation conferred antibiotic 
resistance but this mechanism has since been found to be responsible for 
resistance to a number of antibiotics. Included among these is the nosiheptide 
resistance methyltransferase that renders Streptomyces actuosus, that produces 
this antibiotic, resistant to the drug (175, 176). The recent solution of the crystal 
structure for this enzyme showed high structural similarity to TSR (in addition 
to high sequence similarity) and accompanying biochemical investigations 
Figure 1.9. The interaction of RNA with TSR. A) The TSR dimer is overlaid 
with an electrostatic surface potential map (blue: positive, red: negative). (B) Two 
orthogonal views of RNA (green) interacting with the zone of positive charge from 





indicated a similar mode of action similar to TSR (177). Streptomyces 
viridochromogenes, the producer of the orthosomycin antibiotic avilmycin, is 
protected from the effects of the drug by producing the methyltransferases 
AviRa and AviRb, which carry out the N-methylation at G2535 and the 2’-O-
methylation at U2479 that disrupts drug binding at the target site (46). 
Among the clinically relevant antibiotic classes, resistance to macrolides 
and aminoglycosides is known to result from methylation at their respective 
binding sites. Erythromycin and related drugs are prevented from binding to 
their target site at the peptidyl transferase center on the 50S subunit of the 
ribosome by mono-or dimethylation at N6 of the adenosine moiety from A2058 
(178). This base resides on the peptidyl transferase loop in domain V of 23S 
rRNA, which together with hairpin 35 from domain II, forms the macrolide 
binding site (179).  
Although direct, enzymatic modification of aminoglycosides is the 
primary resistance mechanism to this class of drugs, methylations inactivating 
aminoglycosides occur to 16S rRNA in the decoding region of the A-site from 
30S ribosomal subunit, at either A1405 (Kgm and Arm families) or A 1408 
(Kam and Pam families) (180–182). The former is methylated at the N7 position 
and the latter at N1(182). The resistant phentotype depends on the site where 
modification occurs but in either case, resistance results from the disruption of 





1.3.1.2. AdoMet-dependent methyltransferases 
 TSR belongs to the large family of AdoMet-dependent 
methyltransferases (E.C. 2.1.1.X) that catalyze the transfer of a methyl group 
from the ubiquitous co-factor AdoMet, to small molecule, protein, or nucleic 
acid targets. Along with the role in antibiotic defense  described in the previous 
section, the transmethylations carried out by these enzymes are known to be 
crucial to important cellular processes including metabolite synthesis and cell 
signaling (185).  
It was initially believed that methyltransferases shared the same core 
structure, embodied by a Rossmann-like fold that constructed the AdoMet 
binding pocket (185). The subsequent discovery and structural characterization 
of additional members of this family found diversities in protein tertiary 
structure and AdoMet binding that led to the creation of 4 additional classes, 
although most members of the methyltransferase family belong to Class I 
(Rossmann-like fold) (186). As well, in spite of relatively low sequence 
similarities, members within a given class display a high degree of structural 
similarity (187).  
As earlier stated, TSR is part of the SPOUT class of methyltransferases 
(Class IV). This group represents the unification of the SpoU and TrmD 
families, which were discovered to share conserved motifs, particularly in the 
AdoMet binding region (173). Crystal structures of SPOUT methyltransferases, 
including the TSR and the nosiheptide-resistance methyltransferase, revealed 
defining structural features of this class, which include an active site located 
37 
 
near the homodimeric interface that is formed by residues from both subunits 
and a deep trefoil knot in the AdoMet binding region of the CTD of the protein 









1.3.1.3. Mechanism of transmethylation 
 The acceptors of the electron deficient methyl group from AdoMet are 
nucleophilic atoms on targets of methyltransferases, such as oxygen (ribose 
hydroxyl, aromatic hydroxyl), nitrogen (exocyclic nitrogens from adenosine) or 
sulfur (aromatic thiols). Transmethylation proceeds via an energetically 
favoured SN2-type mechanism, with an inversion of methyl group 
stereochemistry and the concomitant generation of S-adenosylhomocysteine 
(Figure 1.11) (186, 192). Invariably, the nucleophilic acceptor requires 
activation prior to methylation, which contributes to the observed differences in 
active site architecture within and between class members (193).  
 
Figure 1.10. Topological diagram of the SPOUT Methyltransferases (Class 








While the above mechanism accounts for most biological 
transmethylation reactions, it is believed that a significant number of 
methyltransferases accomplish methylation to a non-nucleophilic acceptor atom 
through the generation of a radical species (194, 195). Members of this large 
Radical SAM superfamily of enzymes accomplish reductive cleavage of 
AdoMet utilizing an iron-sulfur cluster that is coordinated by a conserved “Cys-
xxx-Cys-xx-Cys” motif, generating the highly reactive 5’-deoxyadenosine 
radical in the process (196, 197). The mechanisms for two RNA methylating 
enzymes, RlmN and Cfr, that belong to this family, have been recently 
described and in each case, RNA methylation is initiated by the transfer of the 
methyl group to one of the cysteines that coordinates the iron cluster, followed 
by the reductive cleavage of a second AdoMet molecule with a concomitant 
generation of the 5’-deoxyadenosyl radical. This radical subsequently removes a 
proton from the methyl group attached to the cysteine to generate a carbon-
centered radical that attacks the non-nucleophilic carbon atom on the adenine 
from RNA (Figure 1.12) (198).  




1.3.1.4. AdoMet-dependent methyltransferases as tools 
The favorable energetics for the transfer of a methyl group from AdoMet 
relative to other cellular sources (eg. methionine) makes this cofactor the 
preferred methyl donor in the cell. Accordingly, AdoMet is the second most 
prevelant cofactor present in the cell (199) and AdoMet-dependent 
methyltransferases account for a not insignificant proportion of cellular proteins. 
The family currently includes over 200 members (according to the nomenclature 
of the Enzyme Commission) and many more are predicted to exist based on 
bioinfomatics studies. Although crystal structures for several dozen of these 
Figure 1.12. Postulated mechanism of RlmN. BH, unidentified general acid; B-, 
unidentified general base. From [Poehlsgaard and Douthwaite, 2011. A Radically 
Different Mechanism for S-Adenosylmethionine-Dependent Methyltransferases. 
Science 332, 604 – 607]. Reprinted with permission from AAAS. 
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have been deposited into the Protein Database (PDB), the majority of the 
enzymes from this family remain uncharacterized and their cellular targets, 
unknown. However, it is believed that the methylations carried out by these 
enzymes will continue to prove to be involved in important cellular processes. 
Biochemical characterization of methyltransferases, particularly the 
identification of novel or unknown methyltransferase targets, is often difficult 
due to the absence of straightforward means for detection of modified 
substrates. The methyl group itself is devoid of conspicuous physical 
characteristics (fluorescence, absorbance) and physical or chemical changes that 
occur to the target are generally useful in cases of a priori knowledge of the 
target. As a result, much effort has been directed towards the development of 
AdoMet analogues from which groups that enable substrate specific labeling are 
transferred. 
In the first reported instance of such analogues, the methionine region of 
AdoMet was replaced by the reactive aziridine group which enabled the 
addition of the ribonucleoside region of AdoMet to a DNA methyltransferase 
target (Figure 1.13A) (200). Further modification of these analogues at the 8 
position of the ribonucleoside with an extended linker terminating in a primary 
amine or an azido group allowed for the attachment of reporter molecules for 
site-specific substrate labeling, or site specific DNA scission after coupling with 
triarylphosphines via Staudinger ligation (201–203). Preparation of an N-
mustard AdoMet analogue featuring a propargyl alkyne resulted in in situ 
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formation of an aziridinium ion and subsequent addition of a riboadenosyl  





Methyltransferases were initially thought to be unable to catalyze the 
transfer of extended alkyl chains to their targets, however, it was found that 
rates of transfer were improved by the introduction of α-β- unsaturation within 
the alkyl chain (207, 208). Moreover, the placement of an additional alkynyl 
Figure 1.13. Riboadenosyl transfer from AdoMet analogues. The aziridine 
containing AdoMet analogue is either directly synthesized (A) or forms in situ from 
an N-mustard precursor (B). Nucleophilic ring opening of the aziridine group results 
in the transfer of the whole cofactor molecule to the Mtase target.  Additional 
appendages on the adenosine moiety allow for coupling to reporters. 
Aziridinium ion 
In situ formation of 





group at the end of the alkyl chain facilitated substrate labeling via click 
chemistry (209–211). Likewise, the elaboration of such alkyl chains by 
attachment of a terminal amine group (instead of the propargyl group) via an 







The methyltransferase targets for the transfer of alternative groups 
described above have included protein, DNA and small molecules, highlighting 
the versatility and applicability of this technology to different classes of 
methyltransferases. However, alternative group transfer has been mainly 
demonstrated when these analogues have been present in stoichiometric 
Figure 1.14. Mtase catalyzed transfer of extended alkyl chains. Substitution of 
the methyl group for the alkyl chains shown results in the alkylation of the Mtase 
target (except in the case of the ethyl or propyl group). The presence of a terminal 




amounts, a situation not likely to be conducive to the discovery of novel or 
unknown methyltransferase targets. One notable exception to this was the 
reported transfer of a methyl ketone group to small molecule substrates of the 
catechol-O-methyltransferase and the thiopurine-S-methyltransferase (213). The 
use of this keto-AdoMet analogue marks one of the few instances where an 
AdoMet analogue was used to successfully identify a previously unknown 
methyltransferase target, which was enabled by the presence of the reactive 
ketone group that allowed for bio-orthagonal conjugation (213). 
The development of AdoMet analogues is a promising area that can be 
potentially be utilized for the transfer of “unnatural” groups to a variety of 
biomolecules. Such analogues can be further used as novel reagents for the 
introduction of molecular probes to biomolecules. Their widespread application 
may, however, be limited by the reactivity of these alternate groups, which 
could potentially engage in spurious reactions that either inhibit the enzyme 
under study or lead to misleading conclusions about substrate identity.  
 
1.3.2. Resistance in organisms that do not produce thiostrepton 
1.3.2.1. Thiostrepton resistant mutants 
 Along with the specific methylation of A1067 (or an equivalent base), 
thiostrepton binding leading to the inhibition of protein biosynthesis is reliant 
upon the structure of the RNA region surrounding this nucleotide and the 
presence of ribosomal protein L11. The characterization of the 23S rRNA 
thiostrepton and TSR binding site necessarily involved the use of RNA 
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transcripts that differed in sequence from that of native 23S rRNA (119, 128, 
169, 214). As could therefore be expected, nucleotides vital to thiostrepton 
binding were unveiled in in vitro experiments that utilized such transcripts or 
ribosomes possessing mutations to the L11 binding domain on 23S rRNA (214). 
As well, various thiostrepton-resistant strains were determined to possess 
mutations to the corresponding region in the 23S rRNA (121, 132, 215–217) .  
The complete absence of L11 (or its equivalent) not surprisingly results 
in thiostrepton resistance, as was discovered in mutant strains of Bacillus and 
Chlamydomonas (129, 218, 219). In addition, thiostrepton insensitivity results 
from alterations to the sequence of L11 protein itself. The was first observed in 
Halobacterium halobarium and subsequently shown to be due to the mutation 
of the conserved proline residue  (132, 216) and these findings also contributed 
to the understanding of the role played by L11 in thiostrepton binding, as 
discussed in section 1.2.3.1. Sequencing and characterization of the genes 
encoding L11 from a series thiostrepton sensitive Thermus thermophilus isolates 
found a correlation between the conformational flexibility of these L11 mutants 
and the level of thiostrepton sensitivity; decreasing sensitivity with increasing 
L11 flexibility (131). These findings highlighted the importance of L11 not only 
for thiostrepton binding, but in ribosome structure and protein synthesis and 
were later supported by the demonstration of the interaction of thiostrepton with 
the ribosome, in which the protein is essentially immobilized and thus prevented 
from undergoing conformational dynamics that are requisite for EF-G and EF-
G-dependent activities (127, 142, 143). 
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1.3.2.2. Thiostrepton binding proteins 
After its discovery, the gene encoding TSR became routinely used in the 
construction of Streptomyces cloning vectors that employed thiostrepton as a 
selectable marker for use in organisms that may have possessed natural 
sensitivity to the antibiotic (47). Such vectors also enabled the study of 
additional effects of thiostrepton in these species. One of these was the elevated 
levels in the expression of several genes in response to the presence of the drug, 
which correlated with increased resistance to thiostrepton and related 
thiopeptides (47, 220).  
The expression of the two most abundant of these proteins was due to 
transcriptional activation of the promoter for the tipA gene by thiostrepton (47). 
In the presence of thiostrepton, this gene encodes the in-frame expression of 
both proteins, designated TIP-AL and TIP-AS, from independent transcription 
start sites on the gene. The transcription of TIP-AS commences downstream 
from that of TIP-AL and the expression of TIP-AS is several fold greater than 
that of TIP-AL  (48). Both proteins were found to bind thiostrepton, indicating 
that TIP-AS represents the thiostrepton binding CTD of TIP-AL, however TIP-
AL was found to additionally bind to the tipA promoter and the affinity of this 
interaction was increased by thiostrepton (48). Additional structural evidence 
suggests that thiostrepton binding at the CTD of TIP-AL, initiates 
conformational changes that are translated to the NTD of the protein which 
enables its binding to the tipA promoter (221). At the same time, the 
thiostrepton-TIPAS interaction serves as a means to prevent unbridled 
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overexpression of tipA. Therefore, by operating in tandem to regulate their 
expression, TIP proteins induce thiostrepton (and thiopeptide) resistance 
through sequestration. Moreover, TipA genes have been identified in several 
Streptomyces species that do not produce thiostrepton  (222–224), which may 
not only reflect their importance in thiostrepton resistance, but an additional, 
unknown cellular function. 
Binding between thiostrepton and the TIP proteins occurs irreversibly by 
covalent bonding between a cysteine residue from the protein and a DHA from 
the thiostrepton tail (225). The solution of the NMR structure for TIP-AS, along 
with NMR ligand binding studies pointed to covalent bonding between Cys 214 
(TIP-AL numbering according to Holmes et al (48)) and the terminal DHA in 
the thiostrepton tail (226). This was also found to be the case for a series of 
related thiopeptide also possessing a DHA tail region, although the extent to 
which functions dependent on these protein-antibiotic interaction were executed 
appeared to be affected by the length of the tail as well as the structure of the 
thiopeptide core (220). These findings implied the significance of non-covalent 
interaction in the formation of stable protein-antibiotic complexes, which was in 
line with demonstrable activity in tail-less thiopeptide derivatives, along with 
earlier observations where TIP proteins non-covalently bound to thiostrepton  
required harsh denaturing conditions to be released (48). Moreover, the 
interaction between thiostrepton and TIP proteins modeled from the NMR data 
by Kahmann et al. (226) indicates extensive non-covalent associations between 
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the antibiotic and protein, however, this aspect of the thiostrepton-TIP 
interaction has not been well studied.  
 
1.4. Research Objectives 
In light of the dire problems posed by bacterial antibiotic resistance, this 
thesis aims to illustrate the potential of the thiopeptides as a source for novel 
alternative antimicrobial chemotherapies, using thiostrepton as a paradigm.  
In spite of diverse biological and clinically relevant properties, the 
aqueous insolubility of thiostrepton has limited its use to veterinary applications 
and as a research tool in the study of ribosome function. The research herein 
will expand upon work begun in this laboratory and describes a semi-synthetic 
approach towards the selective and controllable modification of thiostrepton, to 
generate antibacterial derivatives with improved aqueous solubility. These 
derivatives can be used as platforms for future structure-activity studies in drug 
development. The mode of action of these derivatives will be evaluated using 
cell free and whole cell approaches, which will be further used to probe the 
molecular determinants of thiostrepton interactions on the bacterial ribosome.  
A deepened understanding of processes conferring thiostrepton 
resistance will not only increase the fundamental knowledge on thiopeptide 
resistance, but may prove to be useful in the rational design of drugs that evade 
resistance mechanisms. To this end, extensive mutagenesis studies, in 
conjunction with biochemical and biophysical investigations will be applied 
towards elucidating the molecular mechanisms responsible for TSR mediated 
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resistance in thiostrepton-producing organisms and the TIP protein mediated 
resistance seen in organisms that do not produce the drug.  
Finally, the synthesis of a novel AdoMet analogue from which a 
trifluoromethyl ketone group would be transferred was pursued. This analogue 
would contribute added diversity to the functional groups that are transferrable 
























 In spite of their poor aqueous solubility (75), the thiopeptide family of 
antibiotics is an attractive source for novel antimicrobial compounds owing to 
their diverse biological activities and low (or non-existent) incidence of clinical 
observed resistance. For this reason, recent attention has been directed toward 
the improvement of this physical property while maintaining their antibacterial 
activity.  
 As illustrated in Chapter 1, thiopeptides have remarkably complex 
structures, including highly modified amino acids and multiple chiral centers, 
which is not atypical of natural products. More often than not, the biological 
activities of thiopeptides are contingent upon the presence of such moieties, 
which invariably present nontrivial synthetic challenges, thus making the total 
synthesis of these compounds an arduous undertaking (75, 76, 88–90, 227–230). 
This limits the practicality and feasibility of de novo syntheses in the generation 
of thiopeptide analogues with improved physicochemical properties. More 
recently, the biosynthetic gene clusters for thiostrepton and other thiopeptides 
have been discovered, highlighting the intricacy of the natural biogenesis of 
these compounds, in which numerous enzymes accomplish the concerted 
prepeptide processing, post translation modifications and cyclizations required 
for the formation of the active compound (Chapter 1; (106, 108, 111, 113, 231, 
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232)). Hence, the derivation of thiopeptide analogues through synthetic 
bioengineering would present different but equally formidable challenges as 
those presented by de novo synthesis. Nevertheless, the continual expansion of 
genomic information concerning thiopeptide biosynthesis has drawn some 
attention to this approach (233, 234). 
 In this chapter, a semi-synthetic approach towards the preparation of 
biologically active thiostrepton analogues will be illustrated. Among the many 
sites for potential elaboration on the thiostrepton molecule, the alkene groups on 
its three DHA residues and lone DHB residue seem most attractive as these 
groups should be susceptible to nucleophilic Michael addition reactions. Such 
reactions have been demonstrated with free DHA or its analogues, as well as 
with a DHA resident on another antibiotic, nocathicin (235–238). This approach 
was applied by our laboratory to the more complicated thiostrepton molecule, 
which features four potential Michael acceptors. Polar thiols were used as 
Michael donors to regioselectively append thiostrepton with groups that should 
impart aqueous solubility (Figure. 2.1). During the course of our work, Schoof 
and coworkers (239) employed a similar modification approach in the 
preparation of  a fluorescent thiostrepton derivative.  
The antibacterial activities of the synthesized analogues were assessed 
utilizing bacterial strains known to be susceptible to thiostrepton. Since 
thiostrepton is an inhibitor of bacterial protein synthesis, the mode of activity of 
these analogues was also investigated using analysis of in vitro translation 
efficiencies of a model protein. In addition, the derivatization of thiostrepton 
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with structurally dissimilar groups was attempted, for preliminary evaluations of 
the structure-activity relationship of a range of thiostrepton analogues. 
 
2.2. Materials and Methods 
2.2.1. Chemicals and Reagents 
 Thiostrepton (≥ 90% purity), 2-mercaptoethanesulfonic acid (≥ 98% 
purity), captopril (≥ 98% purity) and 1-thio-2-β-D-glucose (≥ 98% purity) were 
all purchased from Sigma (Oakville, Canada). Anhydrous dimethylformamide, 
dimethylsulfoxide, acetonitrile and trifluoroacetic acid were purchased from 
Caledon Laboratory Chemicals (Georgetown, Canada). Triethylamine was 
obtained from EMD Sciences (Gibbstown, USA) and deuterated chloroform and 
methanol were from Cambridge Isotopes (Andover, USA). 
Figure 2.1. Mechanism for Michael addition of thiols to DHA. The reaction 
commences with the abstraction of the thiol proton by a base to generate a 
nucleophilic thiolate (1). Attack on the electron deficient carbon on the DHA olefin 
leads to addition of the donor group (2) and rearrangement of the double bond (3). 
Delocalization of the negative charge from the oxyanion (4) results in attack of the 





 High performance liquid chromatography was performed using a Waters 
625 Chromatography System equipped with a 996 photodiode array detector 
and Millennium 3.20 software (Millford, USA). Compound purification was 
carried out using a Zorbax Eclipse C-8 column (5µM, 4.6 × 150 mm) (Agilent, 
Mississauga, Canada), with 0.1% TFA in MilliQ grade water and acetonitrile as 
the polar and non-polar mobile phases, respectively, at a flow rate of 0.5 ml/ 
minute.  
2.2.2.2. Mass spectrometry  
High resolution ESI-mass spectrometry was performed with a 
Micromass™ Quadropole-time of flight (Q-TOF) Ultima Global mass 
spectrometer in positive ion mode and the data analyzed using MaxEnt software 
(Waters, Millford, USA). 
2.2.2.3. Luminescence 
 Total luminescence (total light emitted) was recorded in white 96-well 
microplates (BD Biosciences, Mississauga, Canada) with a SpectraMax M5 
(Molecular Devices, Downingtown, USA) that was calibrated to an internal 
standard. 
2.2.2.4. Nuclear magnetic resonance 
NMR spectra were acquired on a Bruker Advance 600 MHz 
spectrometer. 1H chemical shifts are in ppm relative to residual solvent peaks 
(7.24 ppm for CDCl3). Typical NMR samples were prepared by dissolving 2 – 4 
53 
 
mg of analyte in 0.6-0.7 mL of mixture of deuterated chloroform and deuterated 
methanol (4:1). TOCSY spectra were acquired using the pulse sequence for 
homonuclear Hartman-Hahn transfer (240), with 80 ms mixing time. 
  
 
2.2.3. General methods 
2.2.3.1 Synthesis of thiostrepton analogues 
In an inert (argon) atmosphere, thiostrepton (50 mg; 0.03 mmoles) was 
dissolved in 1 mL of anhydrous DMF. To this solution, triethylamine (10 
equivalents; 42 µL) was added, followed by 1 equivalent of aqueous thiol (2-
mercaptoethanesulfonic acid, captopril or 1-thio-2-β-D-glucose), prepared as 
150 mM stock solutions. Reactions were mixed on a platform shaker for 18-24 
hours at 4 °C and then dried under vacuum, leaving an orange-yellow solid. 
Michael adducts were isolated by RP-HPLC utilizing different elution 
conditions: Method 1; purification of 1.2. The solid reaction product obtained 
after vacuum drying was dissolved in deionized H2O (1.5 mg/mL), filtered 
using a 0.2 micron syringe filter, then separated over a linear increasing gradient 
of acetonitrile (0.5 %/min), with flow rates of 0.5 or 1 ml/ minute.  
Method 2; purification of 1.3 & 1.4. Vacuum dried reaction product was 
dissolved in 50% DMSO (1.4 mg/ml) and then separated over a linear 




2-Mercaptoethanesulfonic acid adduct: (1.2): HPLC (Method 1): tR= 31 
minutes. 1H NMR (600MHz, CDCl3: CD3OD (4:1)): δ 8.15, (s, 1H), 8.12 (s, 
1H), 8.04 (s, 1H), 7.43 (d, J = 9.65 Hz, 1H), 7.40 (s, 1H), 7.18 (s, 1H), 7.06 (s, 
1H), 6.77 (d, J = 9.84 Hz, 1H), 6.27, (dd, J = 5.92, 10.02 Hz, 1H), 6.23 (m, 
1H),6.21 (s, 1H), 6.10 (q, J = 6.562 Hz, 1H), 5.71 (s, 1H), 5.64 (d, J = 3.45 Hz, 
1H), 5.60 (s,1H),5.52 (s, 1H), 5.20 (s, 1H), 5.19 (s, 1H), 5.17 (s, 1H), 4.86 (dd, J 
= 9.19, 12.74 Hz, 1H), 4.82-4.78 (m, 1H), 4.60 (m, 1H), 4.29 (m, 1H), 4.09-4.03 
(m, 4H), 3.95 (m, 1H), 3.68 (dq, J = 6.20,12.47 Hz, 1H), 3.53 (m, 1H), 2.84 (d, 
J = 3.98 Hz, 1H), 2.50 (s, 1H), 2.19-2.15 (m, 1H), 1.78 (s, 1H), 1.59 (d, J = 6.57 
Hz, 3H ),1.48 (d, J = 7.08 Hz, 3H), 1.43 (m, 1H), 1.32 (dd, J = 3.65, 6.21 Hz, 
3H), 1.26 (d, J = 6.61, Hz, 3H), 1.16 (d, J = 6.30 Hz, 3H),1.10 (s, 1H), 1.04 (d, J 
= 6.67 Hz, 3H), 1.02 (s, 3H), 0.99 (m, 2H), 0.88, (d, J = 6.88 Hz, 3H), 0.79 (m, 
1H), 0.67 (d, J = 6.21 Hz, 3H). HRMS (ESI) calculated for C74H91N19O21S7 (M 
+ H+) m/z 1807.4682; found: 1807.4820.  
Captopril adduct (1.3): HPLC (Method 2): tR = 37.2 minutes. 
1H NMR 
(600MHz, CDCl3: CD3OD (4:1)): δ 9.76 (s, 1H), 8.67 (d, J = 8.90 Hz, 1H), 8.50 
(s, 1H), 8.15 (s, 1H), 8.13 (d, 1.21 Hz, 1H), 8.03 (s, 1H), 7.86 (s, 1H), 7.66 (s, 
1H), 7.46 (d, J = 10.05 Hz, 1H), 7.43 (s, 1H), 7.41 (d, J = 1.23 Hz, 1H), 7.17 (s, 
1H), 7.06 (d, J = 1.23 Hz, 1H), 7.01 (d, J = 7.93 Hz, 1H), 6.94 (d, J = 7.07 Hz, 
1H), 6.77 (d, J = 10.17 Hz, 1H), 6.26 (dd, obscure), 6.25 (s, 1H), 6.23-6.18 (m, 
1H), 6.11 (q, J = 7.01, Hz), 5.70 (s, 1H), 5.65 (d, J = 8.61 Hz, 1H), 5.62 (d, J = 
10.01 Hz, 1H), 5.51 (s, 1H), 5.21 (s, 1H), 5.20 (d, J = 9.89 Hz, 1H), 5.16 (s, 
1H), 4.86 (dd, J =9.27,12.53, 1H), 4.70 - 4.62 (m, 2H), 4.38-4.36 (m, 2H), 3.94-
55 
 
3.91 ( m, 1H), 3.69 (dq, J=5.68, 6.46 Hz,1H), 3.54 (m, 1H), 3.51 (m, 1H), 2.95 
– 2.86 (m, 1H), 2.77 -2.74 (m, 1H), 2.51 (d, J = 6.06, 1.38 Hz, 1H), 2.19 (m, 
1H), 2.14 (m, 2H), 2.08 (m, 2H), 1.95 -1.90 (m, 2H), 1.60 (d, J = 6.44 Hz, 3H), 
1.49 (d, J = 7.03 Hz, 3H),  1.31 (d, J = 6.14 Hz, 3H), 1.25 (d, J = 6.57 Hz, 
3H),1.18 (d, J = 6.38 Hz, 3H), 1.09 (d, J = 6.73 Hz, 3H), 1.06 (d, J = 6.61 Hz, 
3H), 1.02 (s, 3H) 1.00 - 0.95 (m, 2H), 0.87 (d, J = 6.81 Hz, 3H), 0.77 (d, J = 
6.67 Hz, 3H), 0.71 (d, J = 6.15 Hz, 3H). HRMS (ESI) calculated for 
C81H100N20O21S6 (M + H
+) m/z 1881.5696; found: 1881.5864 
Captopril adduct (1.4): HPLC (Method 2): tR = 39.4 minutes. 
1H NMR 
(600MHz, CDCl3: CD3OD (4:1)): δ 9.76 (s, 1H), 8.15 (s, 1H), 8.12 (s, 1H), 8.03 
(s, 1H), 7.87 (s, 1H), 7.45 (d, J = 10.01 Hz, 1H), 7.43 (d, J = 10.29 Hz, 1H), 
7.41, 7.17 (s, 1H), 7.06, 6.98 (d, J = 7.61 Hz, 1H), 6.95 (d, J = 7.78 Hz,1H), 
6.77 (d, J = 9.87 Hz, 1H), 6.26 (dd, J = 5.58, 9.99Hz, 1H), 6.23 (d, J = 6.23 Hz, 
1H), 6.21 (s, 1H), 6.11 (q, J = 7.03 Hz, 1H), 5.70 (s, 1H), 5.66 (d, J = 8.65, 1H), 
5.62 (d, J =10.06 Hz, 1H), 5.55 (s, 1H), 5.21 (s, 1H), 5.19 (d, J =6.62 Hz, 1H), 
5.17 (d, J = 2.73 Hz, 1H), 4.86 (dd, J = 8.98, 12.59 Hz,1H), 4.76 - 4.73 (m, 2H), 
4.34 -4.30 (m, 2H), 3.95 - 3.93 (m, 1H), 3.69 (dq, J =6.06, 6.42 Hz, 1H), 3.54 
(m, 1H), 3.53 -3.48 (m, 1H), 2.95 - 2.87 (m,1H), 2.79 - 2.75 (m, 1H), 2.51 (d, J 
= 6.63, 1H), 2.18 - 2.16 (m, 1H), 1.60 (d, J = 6.48 Hz, 3H), 1.49 (d, J = 6.98 Hz, 
3H), (d, J = 6.28 Hz, 3H), 1.26 (d, J = 6.44 Hz, 3H), 1.18 (d, J = 6.37 Hz, 3H), 
1.09 (d, J = 6.07, 3H), 1.05 (d, J = 6.70 Hz, 3H), 1.02 (s, 3H), 0.99 - 0.94 (m, 
2H), 0.87 (d, J = 6.81 Hz, 3H), 0.77 (d, J = 7.21 Hz, 3H), 0.70 (d, J = 6.12 Hz, 
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3H). HRMS (ESI) calculated for C81H100N20O21S6  (M + H
+) m/z 1881.5696; 
found: 1881.5860 . 
2.2.3.2. Computational determination of the solubility properties for 
thiostrepton and its derivatives.  
The aqueous solubility of thiostrepton and its derivatives was assessed 
through computational determinations of the octanol/ water partition coefficient 
(LogP).  Predictions (miLogP) were performed using the online Molinspiration 
Property Engine v2007.04 after determination of physico-chemical properties 
using the JME molecular editor (version January 2008) (Molinspiration 
Cheminfomatics, http://www.molinspiration.com). For comparative purposes, 
LogP was also calculated according to the methods described in (241) and 
(242), using the structure prediction and calculation plugins for Marvin 5.3.01, 
2010, ChemAxon (http://www.chemaxon.com). Chemical structures for 
thiostrepton and it Michael adducts, as well as for tetracycline and 
erythromycin, were drawn in ChemBioDraw Ultra (CambridgeSoft, USA) and 
exported in SMILES structure format, which were then imported into the 
various LogP prediction software. 
2.2.3.3. Inhibition of bacterial growth 
 Antimicrobial susceptibility testing was performed by the broth 
microdilution technique, in sterile, 96-well microplates, in accordance with 
methods prescribed by the National Committee for Clinical Laboratory 
Standards (243). Test concentrations for compounds 1.1 – 1.4 against S. aureus, 
B. subtilis and for compound 1.1 against E. coli were 32, 16, 8, 4, 2, 1, 0.5, 0.25, 
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0.125 and 0.0625 µg/ mL. Compounds 1.2 – 1.4 were tested against E. coli at 
concentrations of 128, 64, 32, 16, 8, 4, 2, 1, 0.5 and 0.25 µg/ mL. The minimum 
inhibitory concentration of bacterial growth was the lowest compound 
concentration that resulted in no visible bacterial growth. All tests were 
performed in triplicate. 
2.2.3.4. In vitro inhibition of protein synthesis.  
Inhibition of in vitro prokaryotic translation was quantified using the E. 
coli S30 Extract System for Circular DNA (Promega, Madison, USA) with the 
pBESTluc plasmid (Promega) according to the manufacturer’s protocol. 
Individual translation reactions (25 µL) contained 10 µL of Premix without 
amino acids, 7.5 µL of S30 extract, 2.5 µL of complete amino acid mix, 2.5 µL 
of pBESTluc (700 ng/ µL) and 2.5 µl of test compound. Control reactions 
received 2.5 µL of 50% DMSO. Test compounds were initially dissolved in 
DMSO and then diluted to appropriate working concentrations with deionized 
water. The final concentration of DMSO in the reactions was 2.5% (v/v). 
Control reactions received 2.5 µL of 50% DMSO in place of test compound. 
Reactions were incubated for 60 minutes at 37 °C and then placed on ice for 5 
minutes, after which the luciferase assay reagent was added. Luminescence was 
recorded 5 minutes after the addition of 25 µL of SteadyGlo Luciferase assay 
reagent (Promega).  
2.2.3.5. Reaction of thiostrepton with ionic copper 
The complexation of thiostrepton with copper performed according to 
previously described methods  (244). To a solution of thiostrepton prepared in 
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dioxane was added a large (5 – 10 fold) molar excess of aqueous CuCl2 and the 
resultant solution incubated at 37 °C for 24 hours. Dioxane was then added and 
the resulting light green precipitate washed successively with dioxane and ether 
and the residual solvent removed under vacuum. Parallel reactions performed in 
DMF found this solvent to be unsuitable, causing an “oiling out” effect upon 
vacuum drying of the reaction mixture. Crystallization of a copper-thiostrepton 
complex from the dried dioxane precipate was attempted using various solvent 
systems, detailed in Section 2.3.4. 
 
2.3. Results and Discussion 
2.3.1. Synthesis of thiostrepton derivatives 
 The conditions for the preparation of the thiostrepton derivatives were 
established in this laboratory (172) and are shown in Scheme 2.1. Qualitative 
mass spectrometric analysis of the crude product mixture resulting from the 
reaction of thiostrepton with 2-mercaptoethanesulfonate (MENSA), indicated 
substantial formation of a product consistent with the single-addition of 
MENSA to thiostrepton. However, prior attempts at obtaining pure amounts of 
this compound were not successful, which prevented reliable determination of 







2.3.2. Purification & characterization of thiostrepton derivatives 
2.3.2.1. Optimization of purification conditions 
 Previous attempts at HPLC-based purification of the thiostrepton-
Michael adducts using reverse phase C-18 chromatography did not achieve 
adequate resolution of the composite products of the reaction mixture. This 
necessitated multiple rounds of purification, which when coupled with long run 
times, was an impractical approach for obtaining sufficient material for full 
physical characterization and biological testing.  
Optimization of the purification scheme began with the use of a C-8 
reverse phase column instead of a C-18 column. The difference in column 
chemistry and the shorter column length (150 mm for the C-8, versus 250 mm 
for the C-18) reduced the run time, while product resolution was significantly 
improved due to the reduced particle size of the C-8 column (5 µM for the C8 
column, versus 10 µM for the C18). Purification conditions were then optimized 
with respect to the acetonitrile gradient, flow rate, injection volume and sample 
load (Figure. 2.2), culminating in final purification conditions that provided 
Scheme 2.1. Synthesis of Michael adducts of thiostrepton 
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excellent resolution of the target materials, in separate fractions, eluting at 29.2 
minutes and 31 minutes, which were identified by ESI-MS.  
 
Figure 2.2. Optimization of the HPLC purification of thiostrepton-MENSA 
derivatives. The bottom panel shows the final purification conditions. Fractions 
containing the thiostrepton-MENSA derivatives (indicated by arrows) were 
identified by analysis of the ESI-mass spectra (29.2 minutes, 31 minutes). 
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2.3.2.2. Physical characterization of the thiostrepton-MENSA derivative 
Although the mass of the purified product indicated the single addition 
of MENSA to thiostrepton, the site of addition on the thiostrepton molecule 
remained to be deduced as there are four different potential sites for attachment. 
In addition, two HPLC fractions were identified which contained products 
consistent with the single addition of MENSA to thiostrepton. The entire proton 
spectrum for thiostrepton itself had been fully assigned (83, 245), hence the 
determination of the addition site was initially attempted using proton NMR. It 
was presumed that addition of MENSA would bring about the loss of the 
corresponding olefin chemical shifts, but as can be seen from Figure. 2.3, this 
was not entirely observed. While the chemical shifts from DHA3 were absent, 











Figure 2.3. Proton NMR of the MENSA derivative of thiostrepton. A section of 
the NMR spectra encompassing the chemical shifts of the olefin protons from the 
DHA and DHB residues in thiostrepton (bottom trace) and the thiostrepton-MENSA 
adduct (top trace) are shown. A unique peak (marked by an asterisk) is apparent in the 




Unambiguous assignment of these olefin chemical shifts was sought 
with 2-dimensional NMR. A proton COSY experiment was first performed with 
unmodified thiostrepton to verify proton coupling between the olefin protons 






As expected, correlations were observed between the chemical shifts attributed 
to DHA olefin protons (DHA1: 5.38, 5.84; DHA2: 5.52, 6.54 ppm; DHA3: 5.47, 
6.37 ppm). The proton TOCSY spectrum of unmodified thiostrepton confirmed 
that the observed COSY correlations indeed arose from the olefin protons from 
the respective DHA residues (Figure. 2.5). 
Figure 2.4. Proton COSY spectrum of thiostrepton. Cross peaks resulting from 




Figure 2.5. Proton TOCSY spectrum of thiostrepton. The displayed region is 
superimposable with that observed from the COSY spectrum, indicating that the 
observed cross peaks arise from protons residing on the same carbon atom, thus 
confirming the proton assignment for the olefin protons.  
 
Under identical conditions, TOCSY spectra for the purified single 
addition products were devoid of cross-peaks corresponding to DHA3 protons, 
which upon analysis confirmed this residue to be the site of nucleophilic 
addition (Figure 2.6).  In addition, the correlation between the chemical shifts at 
5.52 ppm and the unique chemical shift at 6.42 ppm in the spectrum of the 
product eluting after 29.2 minutes (Figure. 2.6A), identifies the proton 
responsible for this new chemical shift as the second DHA2 olefin proton, 
meaning that the chemical shift for one of the DHA2 olefin protons was 
perturbed in response to the presence of the MENSA appendage. Likewise, the 
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cross peak between the chemical shifts at 5.52 ppm and 6.20 ppm in the 




Figure 2.6. TOCSY spectra of thiostrepton-MENSA derivatives. Partial TOCSY 






compound to be a single site MENSA adduct, with addition occurring at DHA3. 
Therefore, these two products represent a diastereomeric pair, which accounts 






2.3.2.3. Modification of thiostrepton by bulky, polar thiols 
The tail region of thiostepton appears to make important contributions to 
the high affinity binding of the antibiotic to the bacterial ribosome (120, 126, 
127, 142, 143) however, the demonstrated amenability of this region to facile 
chemical modification potentially allows for extensive derivatization of the 
thiostrepton molecule. In order to more deeply assess the effect that 
modifications in this region may have on the physical and biological properties 
of thiostrepton, derivatives that featured bulky tail appendages were prepared.  
Under the conditions detailed by Scheme 2.1, modification was first 
attempted with 2-thio-β-D glucose, which possesses a very different structure 
than MENSA. Mass spectrometry and 1H NMR analyses suggested the presence 
of the desired thiostrepton-glucose adduct, but multiple reaction side products 
Figure 2.7. Configurations of the MENSA appendage in the thiostrepton 
derivatives. The absolute stereochemistry of each compound is unknown, however 
HPLC indicated that one of these conformations is favored. 
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were also evident and unfortunately, (diastereomerically) pure samples of this 
single-site Michael adduct could not be obtained. It is likely that the sugar 
moiety contributed to the formation of undesired products and hampered 
chromatography separation. Thiostrepton modification was therefore attempted 
with captopril, as it was thought that five-membered ring of this molecule would 
mimic the steric interactions brought on by 2-thio-β-D glucose (Figure 2.8). 
Modifications with captopril produced a similar outcome as that with MENSA, 
with the desired captopril adducts being detected in two separate HPLC 
fractions, representing a total overall yield of 45% (Figure 2.9A)). Further 
characterization of these compounds by NMR confirmed them to be a 















Figure 2.8. Structures of 2-thio-β-D glucose and captopril. 3D structures 
for 2-thio-β-D-glucose and captopril were generated from SMILES 






















2.3.2.4. Aqueous solubility of thiostrepon derivatives 
 The solubility of the thiostrepton derivatives relative to the highly 
hydrophobic unmodified thiostrepton was qualitatively assessed by analytical 
HPLC. Under identical conditions for gradient or isocratic separation, the 
derivatives exhibited shorter retention times than thiostrepton, indicating their 
greater polarity/ aqueous solubility (Figure 2.10). The order of decreasing 
aqueous solubility was reflected by computational determinations of compound 





Figure 2.9. Purification and characterization of the thiostrepton-captopril 
derivative. A) HPLC chromatogram of the products from the reaction of 
thiostrepton with captopril. Captopril adducts were identified by ESI mass 
spectrometry in the fractions eluting after 37.2 minutes and 39.4 minutes. B) 
1H NMR showing the chemical shifts in the olefin region of the thiostrepton-
captopril derivatives. C) and D), TOCSY spectra of thiostrepton-captopril 






















Figure 2.10. Relative (aqueous) solubility of Michael adducts. From Myers et al. 
(246). RP-HPLC chromatograms for the separation of a mixture of thiostrepton and its 
derivatives using a C-18 column with A) gradient elution: 0-100% acetonitrile over 100 
minutes; and B) isocratic elution: 0.1% TFA/ acetonitrile (50:50). 2: MENSA 
derivative, 3 & 4: captopril derivatives 
 
Table 2.1. Theoretical solubility of Thiostrepton and Michael adducts 
  LogP (predicted) 
Compound miLogP* Viswanadhan et al. (241) † Klopman et al. (242)† 
Thiostrepton -1.567 -1.01 -0.97 
2 (neutral) -4.151 -4.41 -1.91 
2 (negative) -4.796 -6.67 -4.38 
3/4 (neutral) -2.969 -3.03 -0.85 
3/4 (negative) -4.205 -6.71 -4.35 
TBG adduct -3.569 -5.89 -3.45 
Erythromycin 2.281 1.22 4.20 
Tetracycline -0.978 -0.16 0.39 
*miLogP = Molinspiration predicted LogP value. † LogP calculation using the structure 
prediction and calculation plugins for Marvin 5.3.01, 2010, ChemAxon 






2.3.3. Biological activity of various thiostrepton derivatives 
The inhibition of bacterial growth by the thiostrepton analogues was 
assessed against the Gram-positive bacteria Staphylococcus aureus and Bacillus 
subtilis as well as the Gram-negative Escherichia coli. Table 2.2 shows that the 
thiostrepton derivatives were less potent antibacterial agents against these 
organisms than unmodified thiostrepton, as seen by their higher MIC values. 
Encouragingly, the antibacterial activity displayed by 1.2 against S. aureus and 
B. subtilis compared favorably with that which has been reported for 
conventional antibiotics (247) and compounds 1.3 and 1.4, though less potent 
than 1.2, exhibited notable antibacterial activity.  Like thiostrepton, none of its 
derivatives displayed any activity against E. coli, indicating no extension of 
antibacterial activity to Gram-negative bacteria. 
 
Table 2.2.  Antibacterial activity of thiostrepton analogues. 
Compound Minimum Inhibitory Concentration (µg/ mL)† 
S. aureus (ATCC 6338) B. subtilus (ATCC 6633) E. coli 
Thiostrepton ≤ 0.0625 ≤ 0.25 ≥ 32 
2 ≤ 2 ≤ 8 ≥ 128 
3 ≤ 32 ≤ 32 ≥ 128 
4 ≤ 32 ≤ 32 ≥ 128 
TBG adduct‡ ≥ 50 ≥ 50 ≥ 50 
† Minimum inhibitory concentrations are reported as less than or equal to lowest 
compound concentration that inhibited visible bacterial growth. Antimicrobial 
susceptibility tests were performed in triplicate, with DMSO present at 5% (v/v). 
‡Activity was assessed by disc diffusion, for a partially purified sample. 
 
Preliminary screens for antibacterial activity by the suspected 2-thio-β-D-
glucose derivative using disc diffusion found no activity up to the highest 
concentration tested (50 µg/ mL), but it should be pointed out that this 
assessment was performed on an impure sample of this compound.  
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Thiostrepton exerts its antibacterial activity through the inhibition of 
protein synthesis. In vivo antibacterial activity is restricted to Gram-positive 
bacteria but protein translation by the ribosomes of both Gram-positive and 
Gram-negative species is inhibited by the antibiotic (120, 132, 167). To 
establish the inhibition of protein synthesis as the mechanism of antibacterial 
activity for the thiostrepton derivatives, in vitro translation reactions using E. 
coli ribosomes were performed in the presence of the derivatives. A plasmid 
bearing the firefly luciferase gene was used as the template DNA in these 
reactions, which allowed for convenient monitoring of protein expression by 
measuring the luminescence of the gene product (248–251). Prior to measuring 
in vitro translation in the presence of thiostrepton or its derivatives, the linear 
range for light output by the luciferase was determined, as well as the linear 
range for the assay duration. In addition, the effect of DMSO on light output 
was measured. These experiments (detailed in Appendix 2) served to define the 
parameters of the assays for inhibition of translation with respect to duration, 
maximum concentration of compound, maximum proportion of DMSO and the 
acceptable range of luminescence. 
Overall, luciferase expression was observed to decrease with increasing 
concentrations of thiostrepton or its derivatives, which is consistent with the 
inhibition of protein synthesis being responsible for the observed inhibition of 
bacterial growth (Figure. 2.11). This effect was more evident in the presence of 
1.2, where a marked reduction in protein expression occurred in a dose-




Figure 2.11. Effect of thiostrepton and its derivatives on in vitro protein synthesis. 
From Myers et al. (246). The expression or luciferase  or the inhibition  of 
luciferase synthesis was observed by the luminescence output of translation reactions 
containing different amounts of thiostrepton (1.1) or its derivatives and are expressed 
relative to control reactions containing no antibiotic. Values reflect the means of at least 
2 experiments. Error bars represent one standard deviation of the mean. 
 
Interestingly, the results suggest a lower apparent IC50 for the MENSA 
analogue (≤ 0.05 µM) as compared to unmodified thiostrepton (0.15 – 0.38 
µM). This is likely a consequence of the increased aqueous solubility of the 
MENSA derivative with respect to thiostrepton, which would possibly enable its 
greater availability to affect its activities in the largely aqueous environment of 





presence of the captopril derivatives 1.3 and 1.4 occurred to a lesser extent that 
seen with derivative 1.2 and luciferase expression/ inhibition of luciferase 
expression appeared to approach a constant value of approximately 50%. Since 
1.3 and 1.4 are a diastereomeric pair, the finding of similar levels of in vivo and 
in vitro activity for these suggests that the stereochemistry at the new chiral 
centre generated upon thiostrepton modification does not affect compound 
binding or activity.  
It is worth mentioning that the effect of 1.2 on protein synthesis was not 
directly reflected by its inhibition of bacterial growth. The results from the 
assays of the inhibition of protein synthesis imply that 1.2 would exhibit a lower 
MIC value than thiostrepton, which was contrary to what was observed 
experimentally. A similar discrepancy was also noted between the inhibition of 
protein synthesis and inhibition of bacterial growth by 1.3 and 1.4. These 
observations may be indicative of another factor limiting to antibacterial 
activity, one of which may be the impeded uptake of the analogues by the 
bacterial cells. The uptake of thiostrepton by bacterial cells has not been studied 
in detail, however, the increased size and hydrophilicity of the analogues may 
hamper their ability to transverse the hydrophobic bacterial cell membrane. 
As earlier stated, the thiostrepton-MENSA derivatives proved to be more 
potent inhibitors of bacterial growth than the thiostrepton-captopril derivatives. 
The results from the in vitro luciferase translation assays show this was due to 
differential abilities at inhibiting protein synthesis. The appendages of the 
thiostrepton derivatives present distinct structures; MENSA adopting a linear, 
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extended conformation compared to the globular and more voluminous structure 












Figure 2.12. Space-filling structures of the polar thiols used to modifiy 
thiostrepton. Structures were generated using Chem 3D Pro version 12.0.2.1076 
(Cambridgesoft, Cambridge, USA). 
 
The site of addition was located to the tail region of thiostrepton and the 
different conformations and sizes of these appendages would result in different 
steric and spatial interactions at this region of the thiostrepton molecule and by 
extension, any activities in which this region of the molecule participates.  
As earlier stated, the interaction between the L11-NTD and thiostrepton 
is crucial for tight binding to thiostrepton to the bacterial ribosome and 
extensive biochemical and structural data show that the tail region of 
thiostrepton increases the affinity of thiostrepton for the bacterial ribosome 
through its non-covalent interactions with the L11-NTD (120, 126, 127, 142, 
143). Therefore, the finding of a correlation between tail structure and 
biological abilities for the thiostrepton derivatives coincides with this important 




interaction with the L11-NTD. This further implies there to be conformational 
and spatial limitations to modifications of the tail region that do not compromise 
activity. These limitations are not evident from the available crystal structure of 
the 50S ribosomal subunit from Deinococcus radiodurans bound with 
thiostrepton (143); the  50S subunit of the D. radiodurans ribosome being 
virtually identical to that of E. coli (252). The structure implies that the space 
surrounding the tail of thiostrepton can accommodate sizeable appendages in 
this region.  At the same time, upon closer examination, this structure highlights 
the potential for localized disruptions to the interaction between the tail and the 
L11-NTD and such disruptions would be to a degree dependent on the nature of 
the appendage (Figure. 2.13). It should be noted that although the crystal 
structure shows the “bound” position for the thiostrepton tail, the inherent 
rotational flexibility of the tail (85) could lead to diminished, eliminated or 
repulsive interactions with the L11-NTD and this could be magnified by larger 
appendages. Therefore, given the importance of the interaction between L11-
NTD and the tail region for binding and activity, captopril induces more 
extensive disruptions than MENSA (Figure 2.13C), which is consistent with the 
finding of similar inhibition of translation by thiostrepton and its MENSA 






Figure 2.13.  Importance of the thiostrepton tail in ribosome binding. (From Myers 
et al. (246)) A) Thiostrepton (magenta) bound to the 50S ribosomal subunit (rRNA in 
red; ribosomal proteins in green) from D. radiodurans. B) Magnified view of the boxed 
region from A); the site of Michael addition is indicated by arrow. C) MENSA and 
captopril shown next to a region of the thiostrepton-50S complex. Images were 
generated using Sybyl 8.1 software. The structure of the 50S subunit from the 
Deinococcus radiodurans bound with thiostrepton was imported as a PDB file (3CF5) 
into the software. MENSA and captopril were drawn using the drawing component and 
energy minimized using the Tripos force field, with default parameters. 
 
2.3.4. Thiostrepton-Copper Interactions 
 The interaction of thiostrepton with copper is unlikely to be of biological 
relevance, however, the antibacterial activity of thiostrepton has been shown to 
sigmoidally fall off in the presence of Cu2+, with relative activity approaching 
zero at a 4:1 ratio of Cu2+ to thiostrepton (253).  This would imply a maximum 
copper binding capacity for thiostrepton of 4 copper atoms per molecule of 





studies (254). The reduction in thiostrepton activity in response to copper 
binding therefore suggests there to be a structural change to the thiostrepton 
molecule that would interfere with its interactions with the ribosome. However, 
spectroscopic data has thus far only allowed for tentative hypotheses of the 
ligand coordination at these supposed copper binding sites, with the oxygen 
from amide carbonyl groups and the nitrogen from thiazole groups being 
implicated (244, 254). Hence, with the view towards the structural 
characterization of the thiostrepton-copper interaction, crystallization of the 
purported thiostrepton-copper complex was attempted. 
The complexation of thiostrepton with copper was initially attempted 
using previously described methods, but mass spectrometric analysis of the 
product precipitated by dioxane was inconclusive, yielding a spectrum 



















Figure 2.14. Effect of copper on UV absorbance of thiostrepton. Spectra obtained in 20% 
DMSO for thiostrepton (black) and the filtrate (blue) and precipitate (red) after dioxane-induced 
precipitation of the complexation reaction are shown. The filtrate from the dioxane precipitation 
resembles that of thiostrepton. Note the increased absorbance in the 275 – 325 nm range for the 
precipitate obtained by dioxane precipitation. 
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However, it is likely that the conditions of mass spectrometry resulted in 
the loss of thiostrepton-bound copper. On the other hand, the 
spectrophotometric analysis of the product showed increased absorbance 
between 275 nm and 325 nm, which coincided with previous analyses of the 
thiostrepton-copper complex (244) (Figure. 2.14).  
Initial attempts at crystallization of this product from ethanol and water1 
were unsuccessful, with poor quality crystals remaining only after total 
evaporation of the solvent. This was not improved by varying the ratio of 
thiostrepton to ionic copper, therefore different crystallization solvent systems 
were explored. First among these solvent systems was chloroform/ methanol. 
Crystallization did not result from the use of various fixed starting ratios for 
these solvents, but was eventually induced after the initial dissolution of the 
product in methanol, followed by the slow addition of chloroform2. These 
crystals unfortunately were determined to be CuCl2 by X-ray analysis 
experiments. Similar results were obtained from solvent systems consisting of 
pyridine, pyridine/ dichloromethane, pyridine/ chloroform, pyridine/ dioxane, 
while solvent systems comprised of 2-propanol/ pyridine, 2-propanol/ methanol 
and dioxane/ methanol did not yield crystals suitable for X-ray diffraction.  
 Molecular structures have been determined for copper complexes with 
aliphatic ketones and haloketones as well as aromatic ketones (255–258) and it 
                                                            
1 The precipitate was dissolved in a minimum amount of ethanol heated to near boiling. ddH2O 
was added slowly until the precipitation was first observed, which was removed by the further 
addition of small amount of  hot ethanol. Crystallization was allowed to proceed through slow 
evaporation. 
2 The precipitate was dissolved in minimum methanol at ambient temperature, followed by the 
slow addition of chloroform. Crystallization was allowed to proceed by slow evaporation. 
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was thought that the inclusion of such organic molecules could aid 
crystallization of thiostrepton-copper complexes. Presumably, the copper in 
these organic complexes would coordinate with specific atoms in thiostrepton, 
while crystal lattice formation would be promoted by interactions between the 
organic complexes (Figure. 2.15). 
 
 
Complexation reactions were therefore attempted with three different organic 
compounds: copper (II)-2,4-pentanedionate; copper (II) hexafluoro-2,4-
pentandionate and benzoyl acetone (Figure. 2.16). 
 
Figure 2.15. Interaction of thiostrepton with organic copper complexes. (A) 
Depiction of the molecular structure for thiostrepton (green) in complex with copper 
(brown) and an organic molecule (red). (B) Possible lattice arrangement of the   
molecule from (A). Lattice stability (and crystallization) is promoted by interactions 





UV absorbance spectra for the dioxane precipitates resulting from 
complexation reactions in the presence of these compounds showed 
dramatically increased absorbance from 275 nm – 325 nm (Figure. 2.17A). 
However, very little absorbance was observed in the region where maximum 
thiostrepton absorbance occurs (250-280 nm), suggesting that the precipitated 
material consisted largely of these organic ketones. Hence, the reaction 
conditions were modified such that thiostrepton was present in a 2-fold excess 
of CuCl2 and the organic ketone. UV spectra for dioxane precipitates from these 
reactions featured two absorbance maxima, occurring between 250-275 nm and 
275-325 nm, which was suggestive of complex formation. Crystals were 
eventually obtained from the benzoylacetone reactions, however, these were 
found to be a complex of benzoylacetone and copper, featuring a 
hexacoordinate copper with octahedral geometry (Figure. 2.17D). 
The existence of a stable thiostrepton-copper complex remains unproven 
and its non-occurrence cannot be excluded. Yet, in spite of the inability to 
Benzoylacetone Cu(II)-2,4-pentanedionate Cu(II)hexafluoro-2,4-
pentanedionate 
Figure 2.16. Ketones used to aid thiostrepton-copper complexation 
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obtain crystals and the corresponding molecular structure of this proposed 
complex, the spectrophotometric analyses of thiostrepton in the presence of 
ionic copper was suggestive of an interaction between this metal and 
thiostrepton. This would imply that the observed absorbance changes, 
particularly in complexation reactions performed in the absence of organic 
ketones, resulted from structural changes occurring in the thiostrepton molecule 
in response to its interaction with copper. 
A broader evaluation of solvent systems may lead to the crystallization 
of the thiostrepton-copper complex, but it remains possible that this complex is 
inherently not amenable to crystallization. On the other hand, thiostrepton has 
proved to be well suited to study by NMR (PDB: 2L2W, 2L2Y, 2L2X, 2L2Z). 
Hence, further study of the thiostrepton-copper interaction might include 
monitoring chemical shift changes in thiostrepton in response to copper 
titration. From these, the ligand binding sites could be unequivocally identified 
and the global changes to thiostrepton structure revealed, which undoubtedly 

















































Figure 2.17. UV-absorbance spectra for thiostrepton in complex with copper 
and ketones. (A) Complexation reactions performed at a 1:4 ratio of thiostrepton 
and copper(II) pentanedionate (yellow), copper(II) hexafluoro-2,4-pentanedionate 
(blue), benzoyl acetone and copper chloride (green). (B) Modified conditions for the 
complexation reaction with benzoyl acetone where the components were added 
individually (brown) or thiostrepton was added to an incubating mixture of benzoyl 
acetone and CuCl2. In both cases, the components were present at a 2:1:1 ratio 
(thiostrepton: benzoylacetone: CuCl2. (C) Reaction of thiostrepton with copper (II) 
pentanedionate (red), copper (II) hexafluoro-2,4-pentane dionate (green) at a 2:1 
ratio (thiostrepton: ketone). (D) Molecular structure of the crystals obtained using 
benzoylacetone. The carbonyl oxygens from benzoylacetone occupy equatorial 








2.4. Conclusions, perspectives and future work 
A facile semi-synthetic approach has been used to prepare novel, regio-
specific derivatives of thiostrepton. These derivatives display improved aqueous 
solubility over the parent molecule and in the case of MENSA derivatives, 
exhibit significant antibacterial effects against Gram-positive bacteria. In 
addition, the importance of the tail region of thiostrepton for its antibacterial 
properties has been shown though the preparation and evaluation of derivatives 
featuring structurally contrasting modifications to this area of the molecule. 
These findings were consistent with previous reports of the enhancement of 
thiostrepton binding to the bacterial ribosome by the tail region of the molecule. 
Finally, the absorbance changes to thiostrepton that occur in the presence of 
copper may be indicative that structural changes are induced in the antibiotic by 
its binding of copper. 
The results of this work highlight the thiostrepton tail as an attractive 
area for modifications, particularly with respect to improving the aqueous 
solubility of the molecule. However, a caveat to the generation of practically 
useful derivatives, with respect to antibacterial activity, has been illustrated; 
future derivitizations of thiostrepton in this region should take into account the 
consequences that potential steric and spatial interaction of the modifying group 
may have on antibacterial activity.  Therefore, this work can serve as a platform 
for the development of novel thiostrepton derivatives, with improved 
physicochemical properties and increased potency as antibacterial agents. As 
well, this study assessed the susceptibility of two Gram-positive bacteria to 
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thiostrepton derivatives, but a broader species evaluation would likely prove to 
be more informative and demonstrate the applicability of these compounds.  
As earlier stated, Gram-negative species are excluded from the effects of 
thiostrepton, presumably because of the inability of the antibiotic to penetrate 
the Gram-negative cell wall. Thiostrepton will, however, bind to and inhibit 
translation from the ribosomes of these bacteria. Hence, future studies can 
address the extension of the spectrum of thiostrepton activity to the Gram-
negative genera by preparing derivatives that target such bacteria. While this 
may involve detailed studies of the mechanism of thiostrepton uptake by cells, 
Gram-negative uptake of thiostrepton can theoretically be achieved by 
appending thiostrepton with a short peptide sequence that will target it to the 
interior of Gram-negative cells, analogous to the utilization of cell-penetrating 
proteins for the cellular internalization of (macro)molecules (259–261). In 
addition, such a sequence can be coupled to a reporter molecule for proof-of-
principle studies of the internalization of thiostrepton derivatives in Gram-
negative cells. Finally, thiostrepton derivatives of the kind described here may 
be used in the study of the mechanism(s) by which thiostrepton exerts its 
antagonistic effects against causative agents for malaria and tuberculosis and 
certain cancers and may serve as lead compounds in the development of novel 







CHAPTER 3: DETERMINANTS OF ADOMET BINDING AND METHYL 




The molecular structure of the thiostrepton-resistance methyltransferase 
(TSR) bound with AdoMet showed several active site residues in positions that 
imply important functional roles in enzyme activity. A subsequent report on the 
molecular structure of the related nosiheptide-resistance methyltransferase 
(NHR) drew similar conclusions regarding the relevance of equivalent residues. 
For instance, the mutation of R135 or R165 (TSR numbering) in NHR to 
alanine resulted in drastic reductions in enzyme activity, indicating the 
importance of these residues and additional residues of potential significance 
were similarly identified (171, 262). However, the details on the specific roles 
of these residues in methyl group transfer were not made clear. 
 This chapter focuses on clarifying the specific functions of several TSR 
active site residues. Residues of possible importance were identified according 
to their proximity and side chain orientation in relation to AdoMet, which could 
potentially allow for binding interactions or reactions (Figure 3.1). The 
significance of these residues was determined from comparative enzyme 
activity assays between the native enzyme and variants featuring engineered 
point mutations which abolished, conserved or altered the possible structure of 
the selected amino acid side chains. In addition, the determination of the kinetic 
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parameters of RNA methylation by these select TSR variants, in conjunction 
with studies on AdoMet binding, was used to determine which residues played 
important roles in substrate/co-substrate binding and methyl group transfer. 
 
3.2. Materials and Methods 
3.2.1. Chemicals and Reagents 
3.2.1.1. PCR and DNA manipulation 
 DNA polymerase (Pyrococcus furious) and its buffer (200 mM Tris-HCl 
(pH 8.8), 100 mM (NH4)2SO4, 100 Mm KCl, 1 mg/ mL BSA, 20 mM MgSO4, 
1% (v/v) Triton X-100), dinucleotide triphosphates (dNTPs; supplied as an 
aqueous mixture titrated to pH 7.0 with NaOH, containing 10 mM of each base), 








Figure 3.1. Potentially relevant amino acid residues in the TSR active site.  
Point mutations generated were: N129A, N129D, R135A, R135K, R165A, 
R165K, E220A, E220Q, K221A, S246A, N248A and N248D. Image was 
generated from the PDB file 3GYQ using UCSF Chimera software v. 1.5.2. 
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DTT, 5 mM ATP (pH 7.8) and DNA ladders (1kB and 100bp) were from 
Fermentas (Now ThermoFisherScientific, Ottawa, Canada ). The restriction 
enzymes BamH1 and Nde1 as well as the restriction enzyme buffer NEB3 
(100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM Dithiothreitol, pH 7.9) 
were obtained from New England Biolabs (Ipswich, USA). All enzymes were 
used according to the manufacturer’s specifications. Oligonuleotide primers for 
PCRs were synthesized by Sigma (Oakville, Canada). 
3.2.1.2 Media 
 Bacto-tryptone, imidazole, isopropyl β-D-1-thiogalactopyranoside 
(IPTG) yeast extract, tris (hydroxymethyl) aminoethane (Tris), potassium 
chloride and dithiothreitol (DTT) were all from Bioshop (Burlington, Canada). 
Glycerol and kanamycin sulphate were from EMD Millipore (Toronto, Canada) 
and ethylenediaminetetraacetic acid (EDTA) from BioBasics Inc. (Markam, 
Canada).  
3.2.1.3. Enzyme substrates 
 Ribosomal RNA (16S/23S; E. coli MRE600) was supplied by Roche 
Diagnostics (Laval, Canada) as a 2.67 µM solution in a buffer comprised of 10 
mM Tris-HCl (pH 7.5), 100 mM NaCl and 1 mM MgCl2. This solution was 
concentrated to prepare 7 µM working stock solutions using a Nanosep filtration 
device with a 30 kDa molecular weight cut-off (Pall Life Sciences).  







 Growth of liquid bacterial cultures was performed in a Series 25 
controlled environment incubator shaker (New Brunswick Scientific Co., Inc., 
Edison, USA). A Precision® gravity convection incubator from Precision 
Scientific Inc. (Chicago, USA) was used for the growth of plated bacterial 
cultures. 
3.2.2.2. Centrifugation 
 Large volume sample (≥ 10 mL) centrifugation was performed with a 
Beckman Coulter AvantiJE centrifuge (Fullerton, USA). A Heraeus Biofuge 
microcentrifuge (Sepatech GmbH, Germany) was used for samples of a volume 
≤ 1.5 mL. 
3.2.2.3. Cell disruption 
 Prior to cell lysis, bacterial cell suspensions were sonicated to uniformity  
using a Sonicator™ cell disruptor model W225 from Heat Systems-Ultrasonics 
Inc. (Plainview, USA) converter model #2 with a standard tapered mircrotip, at 
an output control setting at 5. The cells were lysed using an EmulsiFlex-C5 
homogenizer (Avestin, Ottawa, Canada). Ice cooling was utilized to prevent 
protein denaturation from the heat generated during these procedures.  
3.2.2.4. Chromatography 
 HisTrap™ HP (1 mL), HiTrap Benzamidine FF™ (1 mL), MonoQ and 
Supedex-75 columns were all from GE Healthcare (formerly Amersham 
Biosciences, Uppsala, Sweden). Protein purification was carried out using a 
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Waters Chromatography system (Waters 626 pump, 600s controller and 2996 
photodiode array detector and Millennium 3.20 software). Buffers were 
prepared using Milli-Q grade water and filtered (0.2 µM membrane filter; Pall 
Life Sciences, East Hills, USA) and degassed before use. Protein samples were 
passed through a 0.45 µM cellulose acetate filter (Pall Life Sciences) prior to 
introduction on to a column.  
3.2.2.5. Spectrophotometry 
Absorbance measurements for protein quantification using the Bradford 
method (263) were performed with an Ultrospec 2100 pro UV/VIS 
spectrophotometer (GE Healthcare). DNA quantification was carried out using a 
Nanodrop 2000 spectrophotometer (Thermo Scientific, Ottawa, Canada). 
Circular dichroism was performed with a Jasco J715 spectropolarimeter, 
in the low UV region (190 – 250 nm), with a band width of 1 nm, at a scanning 
speed of 100 nm/ min. Spectra from 15 scans were averaged. Samples were 
prepared at 0.16 mg/ mL (~ 2.7 µM) in a buffer comprised of 50 mM Tris (pH 
7.5), 150 mM KCl and 10% glycerol (v/v).  
3.2.2.6. Fluorescence spectroscopy 
 Fluorescence measurements were carried out in black 96 well 
microplates (Corning Life Science, Tewksbury, USA) using a SpectraMax M5 






3.2.2.7. Isothermal Titration Calorimetry 
  Isothermal titration calorimetry was performed with an ITC200 
(Microcal, Piscataway, USA) calorimeter and the data analyzed with Origin 
software v. 5.0 (Microcal). 
3.2.2.8. Mass Spectrometry 
 Electrospray ionization mass spectrometry was performed in positive ion 
mode with a Micromass™ QTOF Ultima Global mass spectrometer (Waters, 
Millford, USA) and the data processed with MaxEnt software (Waters). 
3.2.2.9. Polymerase chain reactions (PCR) 
 Polymerase chain reactions were carried out with a Techne TC-512 
thermal cycler (Keison Products, Chelmsford, UK).  
 
3.2.3. General Methods 
3.2.3.1. Electrophoresis 
 Sized based DNA separation was performed by agarose gel 
electrophoresis. Agarose gels were prepared by dissolving reagent grade agarose 
to a final concentration of 1% (w/v), in TAE buffer (40 mM Tris base, 20 mM 
glacial acetic acid and 1 mM EDTA). A microwave oven was used to 
completely dissolve the agarose and upon cooling, ethidium bromide was added 
to a final concentration of 0.5 µg/ mL. This mixture was then poured into a 
casting tray and allowed to solidify. DNA samples were prepared by mixing 
with loading buffer (10 mM Tris-HCl, pH 7.5, 50 mM EDTA, 10% glycerol, 
0.25% Bromophenol Blue) at a ratio of 5:1 (DNA/ loading buffer). Sample 
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electrophoresis was performed at 80 volts, in parallel with a 100 bp or 1kb DNA 
ladder for size estimation after visualization under UV light.  
 Protein separations were performed by reducing SDS-polyacrylamide 
gel electrophoresis, using the PhastSystem™ (Pharmacia, now GE Healthcare, 
Uppsala, Sweden). Samples were mixed with loading buffer (150 mM Tris-OH, 
2% SDS, 1% -mercaptoethanol, 10% glycerol, 0.1% Bromophenol blue pH 
8.0) and boiled for 10 minutes before separation. The samples were then applied 
to precast acrylamide gels with a 10-15% gradient of acrylamide, 112 mM 
acetate, 112 mM Tris, pH 6.4 and separated using buffer strips containing 0.20 
M tricine, 0.20 M Tris, 0.55% SDS, 3% agarose at a pH of 8.1 (gels and buffer 
strips from Pharmacia). Upon completion of electrophoresis, gels were stained 
with 0.1% Comassie brilliant blue G-250 in 30% methanol and 10% acetic acid 
and the protein bands visualized after destaining in methanol/acetic acid/ ddH2O 
(3:1:6). 
3.2.3.2. Protein Mass Spectrometry 
 Protein samples were prepared for mass spectrometry by exchanging the 
sample buffer for Milli-Q grade water (5 exchanges, each with 10 volumes of 
H2O) using a Nanosep® centrifugal device (Pall Life Sciences) with a 10 kDa 
molecular weight cutoff. These samples were then diluted into a 1:1 mixture of 
acetonitrile/ water with 0.2% formic acid and injected into the mass 
spectrometer in positive ion mode. Molecular ion spectra were deconvoluted 




3.2.3.3. Protein Quantification 
 Protein concentration was determined by the Bradford assay. The assay 
dye was prepared by dissolving 100 mg of Coomassie Brilliant Blue G-250 in 
50 mL of 95% ethanol, to which 100 mL of 85% phosphoric acid were added. 
The mixture was diluted to 0.5 L by the addition of ddH2O and filtered through 
Whatman 1 filter paper. Bovine serum albumin (supplied as a lyophilized 
powder, ≥ 96% purity; Sigma) was prepared as a 1 mg/mL solution in the assay 
buffer and then diluted to make standard protein solutions. Standard protein 
solutions were mixed with 2.5 mL of the assay dye and the absorbance 
measured at 595 nm to generate a standard curve correlating protein 
concentration with the absorbance. Sample concentration was thus determined 
by extrapolation of absorbance readings from the standard curve, after similar 
treatment as the standards. Samples falling outside the linear range of the 
standard curve were diluted.  
3.2.3.4. DNA Manipulation 
 DNA manipulation and cloning were performed in accordance with 
standard protocols outlined by Sambrook et al. (264).  
3.3.2.5. Site Directed Mutagenesis of TSR  
The TSR gene was previously cloned into the plasmid vector pET28a 
(172), which appends a DNA sequence encoding 6 histidines to the 5’ end of the 
gene. The hexa-histidine encoding sequence is separated from the TSR gene by 
a DNA sequence encoding a thrombin protease cleavage site and the entire 
sequence (hexahistidine-thrombin cleavage site-TSR) is flanked by the T7 
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promoter and terminator, at the 5’ and 3’ ends respectively. The protein of 
interest is therefore expressed with a thrombin cleavage site and 6 histidine 





















Figure 3.2. Schematic of the pET28a plasmid bearing the TSR gene. The TSR 
gene is inserted in the multiple cloning site (MCS) between the restriction sites for 
Nde1 and BamH1. Transcription from the indicated starting point leads to the 
























Table 3.1: PCR primers for site directed mutagenesis of TSR 
 Forward Reverse 
N129A ATCGGCGCG ATA GTA CGC ACG TCG GCG TAC TAT CGC GCC GAT CGC CCC GAC GAT CTT CAC CCC 
N129D ATCGGCGCG ATA GTA CGC ACG TCG GCG TAC TAT CGC GCC GAT GTC CCC GAC GAT CTT CAC CCC 
R135A ACGTCGCTC GCG CTC GGA GCG TCG TCC GAG CGC GAG CGA CGT CGC TAC TAT CGC GCC GAT GTT 
R135K ACGTCGCTC GCG CTC GGA GCG TCG TCC GAG CGC GAG CGA CGT CTT TAC TAT CGC GCC GAT GTT 
R165A ACGTCGCTC GCG CTC GGA GCG TCG TCC GAG CGC GAG CGA CGT CGC TAC TAT CGC GCC GAT GTT 
R165K ACGTCGCTC GCG CTC GGA GCG TCG CGC TCC GAG CGC GAG CGA  CGT CTT TAC TAT CGC GCC GAT GTT CCC 
E220A AAGGGTGGG CCT TCC GAC CTG TTC GTC GGA AGG CCC ACC CTT CGC GCT GCC GAA CAG CAA GGC 
E220Q AAGGGTGGG CCT TCC GAC CTG TTC GTC GGA AGG CCC ACC CTT CTG GCT GCC GAA CAG CAA GGC 
K221A AAGGGTGGG CCT TCC GAC CTG TTC GTC GGA AGG CCC ACC CTT CGC GCT GCC GAA CAG CAA GGC 
S246A CTCAACGTT TCC GTT TCC CTC GGA GGA AAC GGA AAC GTT GAG CGC CTC GGT CTG GCT CAT CAT 
N248A GTTTCCGTT TCC CTC GGA ATC GCG TCC GAG GGA AAC GGA AAC CGC GAG AGA CTC GGT CTG GCT 
N248D GTTTCCGTT TCC CTC GGA ATC GCG GAT TCC GAG GGA AAC GGA AAC GTC GAG AGA CTC GGT CTG GCT 
Oligonucleotides are shown left – right  in the 5’ – 3’ direction 
 
Table 3.2. Experimental conditions for PCR reactions to generate 
full length mutant TSR genes 
 Minutes Temperature ( ºC) 
Initial denaturation 5 95 
Hot  start   
10 cycles   
Denaturation 2 95 
Annealing 1 60 – 50 (reduce by 1º every cycle) 
Extension 2.5 72 
PAUSE – ADD T7 
PRIMERS 
5 72 
25 cycles   
Denaturation 2 95 
Annealing 1 50 
Extension 2.5 72 
Final Extension 10 72 
Reactions were carried out in a total volume of 50 µL and contained 1 unit of 
polymerase, 2.5 mM of dNTPs, equal concentrations of 5’ and 3’ gene 
fragments with the total of DNA not exceeding 100 ng and 10% DMSO (v/v). 
 M    1    2    3    4    5    6    7     8    9   10  M   1    2   3    4   5   6   7         8        9  10 M    1     2     3     4      5     6     7     8     9    10 
A) B) C)
Figure 3.3. Site directed mutagenesis of TSR. UV-imaged ethidium bromide stained agarose 
gels containing the products for the first (A) and second (B) PCR reactions and products from 
the ligation of complementary TSR gene fragments (C). M, 100 bp DNA ladder; 1, E220A; 2, 




Attempts at introducing point mutations into the TSR sequence using the 
QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, USA) were 
unsuccessful, therefore the PCR overlap and extension method was employed to 
effect the desired mutations (265). For each mutant, two primers were designed 
to allow extension from a region encompassing the targeted codon on the sense 
and anti-sense strand, when used with the corresponding T7 primer (Table 3.1); 
essentially creating 5’ and 3’ gene fragments. Since the mutation-containing 
primers for the generation of each of these fragments feature a short span of 
complementarity with each other, the full length mutated TSR gene is produced 
upon the ligation of these two complementary PCR products, in a reaction 
utilizing only the T7 primers. High amounts of the mutagenized gene fragments 
were obtained with standard PCR conditions3 using a hot start protocol (Figures 
3.3A, 3.3B), but initial attempts at the creation of the full length gene were 
unsuccessful. Various trouble shooting approaches were investigated, including 
variation of annealing time, gradient PCR and concentration adjustments of the 
template(s). These alterations brought about slight improvements to the success 
of fragment ligation, but also revealed that the reaction was sensitive to the 
relative concentrations of the templates as well as the total DNA concentration. 
The fragments were eventually annealed by using identical amounts of the 
templates and adding the T7 primers after 10 cycles of PCR in the absence of 
the T7 primers. The annealing temperature was successively decreased with 
each cycle, which allowed the product to form in appreciable amounts prior to 
                                                            




addition of the T7 primers (Table 3.2, Figure 3.3C). The full length product was 
excised and purified from the gel (Gel extraction Kit, Qiagen, Toronto, Canada), 
then doubly digested with BamH1 and Nde1. This digested product was inserted 
into pET28a plasmid doubly digested with the same enzymes using T4 DNA 
ligase (1 unit of T4 ligase per 100 ng of total DNA (vector/ insert (1:3)) to 
produce plasmids bearing the mutated TSR gene. 
3.2.2.6. Expression, Purification & Characterization of TSR Mutants 
  The expression and purification of TSR was performed according to 
previously established methods (171, 172). Plasmids bearing the TSR gene were 
used to transform E. coli XL1 Blue cells and the transformants selected by 
kanamycin resistance on nutrient agar plates containing kanamycin at 30 µg/ 
mL). Plasmids recovered from these cells (Plasmid miniprep Kit, Qiagen,) were 
used to transform E. coli BL21 cells, which were plated onto nutrient agar 
containing kanamycin (30 µg/ mL). A single colony of these successful 
transformants was cultured in 1L of Luria-Bertani broth containing kanamycin 
(30 µg/ mL) and  protein expression was induced at the mid-log stage of 
bacterial growth (O.D. 0.6-0.8) by the addition of IPTG to a final concentration 
of 1 mM (Figure 3.3). Protein expression was continued for an additional 2 – 4 
hours at 30 °C and the cells collected by centrifugation (6000 × g for 15 minutes 
at 4 °C). Pelleted cells were resuspended in buffer A (50 mM Tris pH 8, 500 
mM KCl, 20 mM imidazole and 10% glycerol (v/v)) and sonicated to 
uniformity (6 cycles of 10 pulses lasting 1-2 seconds each, with cycles 
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interspersed by 1 minute. Performed on ice4), after which cell lysis was 
completed by liquid homogenization at 15000 – 18000 p.s.i. The cell debris was 
removed by centrifugation (48, 300 × g for 20 minutes at 4 °C) and the soluble 
proteins injected on to a nickel affinity column attached to a Waters 
Chromatography System (10 mL/ injection). Non-binding proteins eluted 
isocratically with buffer A, after which His-tagged TSR was obtained by 
isocratic elution with buffer B (50 mM Tris pH 8, 500 mM KCl, 500 mM 
imidazole, 10% glycerol (v/v)) (Figure 3.3). EDTA was immediately added 
upon elution at a final concentration of 2 mM, and the protein solution dialyzed 
against 0.5 L of buffer C (50 mM Tris pH 7.5, 150 mM KCl, 10% glycerol 
(v/v)) for 6 hours, with replacement of the buffer after the first three hours and 
then overnight against 1L of fresh buffer.  
The protein concentration was determined by the Bradford assay, with 
typical yields between 30 and 40 mg of protein from 5 – 6 g of pelleted cells. 
The hexa-histidine affinity tag was removed by incubation with thrombin 
protease (1unit per 0.1 mg of protein in buffer C, with CaCl2 added to a final 
concentration of 2.5 mM, overnight at 4 °C). TSR was obtained by isocratic 
elution in buffer A, after the introduction of the completed thrombin cleavage 
reaction mixture to nickel affinity and benzamidine columns attached in series. 
The purity of the protein was assessed by SDS-PAGE and ESI-mass 
spectrometry was used to confirm the expected protein molecular mass. 
 
                                                            
4 Sonication was performed on ice to prevent protein denaturation as this 


















If necessary, an additional purification step of anion exchange 
chromatography was performed. The protein solution was introduced onto a 
Mono-Q anion exchanger (GE Healthcare, formerly Pharmacia) and non-
binding proteins eluted isocratically in a buffer comprised of 50 mM Tris pH 8, 
50 mM KCl and 10% glycerol (v/v). TSR was obtained over a linear increasing 
gradient of KCl (50 – 500 mM in 100 minutes), eluting between 250-300 mM of 
KCl. Point mutants were purified in an identical manner as the native protein 
and their identity was confirmed by ESI-mass spectrometry of the respective 
Figure 3.4. Overexpression and purification of TSR and its variants in E. coli. 
(A) Chromatogram showing the separation of His-tagged TSR from cellular proteins 
by nickel affinity chromatography. (B) Recovery of TSR after thrombin cleavage of 
the hexahistidine tag (C) Sample SDS-PAGE showing the various stages of TSR 



























































purified proteins as well as by DNA sequencing of the plasmids bearing the 
corresponding gene. 
3.2.2.6.1. Size exclusion chromatography 
 Size exclusion chromatography was performed in buffer C, using a 
Superdex-75 column attached to a Waters chromatography system. A standard 
solution comprised of blue dextran, bovine serum albumin, carbonic anhydrase 
and cytochrome c was used for the estimation of sample relative molecular 
weight. 
3.2.2.7. RNA methylation by TSR 
 The methylation of rRNA by TSR and its point mutants was monitored 
with a commercially available Methyltransferase Fluorometric Assay Kit 
(Cayman Chemical Company, Michigan USA), according to the manufacturer’s 
specifications. Fluorescence measurements were performed using an excitation 
wavelength of 530 nm and emission at 584 nm, with an emission filter at 570 
nm and the photomultiplier (gain) set to low. The supplied assay buffer was 
supplemented with 5 mM MgCl2 and 25 mM NH4Cl and the pH adjusted to 7.5 
to satisfy the optimum requirements for TSR activity (168, 172). Activity assays 
contained 0.35 µM of 16S/23S rRNA, 1mM AdoMet and various concentrations 
of enzyme, while kinetic assays contained 0.35 µM of 16S/23S rRNA, 0.1 µM 






3.2.2.8. Isothermal Titration Calorimetry 
The dissociation constant for the binding of AdoMet to TSR has not been 
previously measured, hence the experimental parameters were optimized prior 
to the investigation of the effects of point mutations to TSR-AdoMet binding. 
Initial experiments used 16 or 20 injections of AdoMet (1mM) into TSR (0.05 
mM). From these, the binding stoichometry was estimated to be 2 from non-
linear curve fitting of the integrated heats of injection utilizing the model for a 
one binding site per subunit model. This coincides with the crystal structure of 
the TSR-AdoMet complex which found two molecules of AdoMet bound per 
dimer of enzyme (171). However, this approach did not achieve sufficient 
coverage of the binding isotherm, which when combined with the inherently 
low quantity of heat released per injection, contributed to unreliable values for 
the binding constants. This was not solved by using a higher starting 
concentration of AdoMet as it was observed that concentrations exceeding 2.5 
mM caused an erratic experimental baseline. These problems were remedied by 
increasing the number of injections to 30, reducing the volume of the injection 
to 1.25 µl from 2.47 µl and increasing the duration between injections from 180 
to 360 seconds, to allow ample time for the system to re-equilibrate between 
injections. Figure 3.5 compares the results between ITC experiments utilizing 
the initial and optimized experimental conditions and it is evident that the latter 
offers increased coverage of the isotherm, which constitutes reduced errors in 
the non-linear regression and greater accuracy and reliability in the determined 



























Enzyme used in ITC experiments was dialyzed overnight against 1L of a 
buffer comprised of 50 mM Tris (pH 7.5), 75 mM KCl and 10% glycerol (v/v). 
The dialysate was used to freshly prepare working solutions of protein and 
AdoMet. Titrations were performed at 25 °C and consisted of 30 injections of 
1.25 µL of AdoMet (1.98 - 2.50 mM) into a sample cell containing protein 
solution (0.0822 - 0.098 mM). The heat of dilution/ mixing was obtained from 
injections of AdoMet into buffer lacking protein. After subtraction of the heats 
of dilution/ mixing obtained from injections of AdoMet into a cell containing 
the ITC buffer, titration curves were analyzed using Origin software and the 
A) B) 
Figure 3.5. Optimization of ITC experiments for investigation of the binding of 
AdoMet to TSR. Titration of AdoMet into TSR using (A) the initial experimental 
conditions and (B) optimized experimental conditions as described in the text. The 
top panel shows the raw data after subtraction of the experimental baseline. Bottom 
panels show the binding isotherm, obtained from non-linear fitting of the integrated 
heats per injection, fitted to the model for one set of binding sites.  
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data fit using the model for one set of binding sites (per subunit) (Please refer to 
Appendix 4 for a detailed description of the data fitting)  
 
3.3. Results & Discussion 
3.3.1. Development of the coupled fluorometric assay  
Ahead of experimental measurements, the suitability of the 
Methyltransferase Fluorometric Assay kit for determining TSR activity was 
investigated (266).  Examination of an alternate commercially available assay 
(Assay Designs, Brockville, Canada) revealed several technical problems, 
particularly an unstable assay background that caused wide variability between 
replicates. This was attributed to incomplete quenching of the reaction by the 
prescribed method. A variable background would undoubtedly complicate 
measurements of enzyme activity where the SAH output would be expected to 
be low, such as in the lower substrate concentrations required for performing 
enzyme kinetics or with the assays of TSR variants in which enzyme activity 
may be reduced. In addition, an unknown AdoMet concentration was included 
in the reagents from the commercial supplier which prevented the determination 
of the kinetic constants for enzyme turnover of this substrate. These technical 
limitations were circumvented with the assay from the Cayman Chemical 
Company. In its continuous format, this assay removed the requirement for 
quenching of the enzyme reaction, thereby providing stable, consistent 
measurements of the assay background. Moreover, AdoMet could be added 
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exogenously which allowed for the determination of kinetic parameters for its 
utilization by TSR. 
The conditions of the coupled fluorescence assay required additional 
optimization before being used to monitor the initial rate of AdoMet turnover by 
TSR. Previous assays of TSR had been performed using enzyme concentrations 
of 40 – 60 nM (130, 169), therefore exploratory assays were performed with 
100 nM of enzyme and monitored continuously for 30 minutes. Fluorescence 
was observed to increase linearly with time during the first 3 minutes of the 
assay, indicating this to be the appropriate duration for the calculation of the 
initial rate (Figure 3.6A). As well, the initial rate of enzyme activity was found 






































Figure 3.6. Development of the coupled fluorometric assay for TSR. (A). 
Reaction progress curve for TSR activity monitored by the coupled fluorometric 
assay. Background fluorescence in the absence of enzyme has been subtracted. 
Assays contained 100 nm of TSR, 1 mM of AdoMet and 0.35 µM 16S/ 23S rRNA. 
Data points are the mean of duplicate experiments. (B). Dependence of initial rate 
of TSR activity on enzyme concentration in the presence of 1mM of AdoMet and 
0.35 µM 16S/ 23S rRNA.  
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3.3.2. Effect of point mutations on TSR activity 
The molecular structure for TSR has the amino acid residues N129, 
R135, R165, E220, K221, S246 and N248 within suitable proximity to make 
potentially important interactions with AdoMet.  Point mutations were therefore 
generated at these sites and the activities of these variants relative to native TSR 
were assessed using the optimized coupled fluorometric assay. In some cases, 
different point mutants of the same site were generated in order to probe the 
chemical significance of these residues in enzyme activity.  
The results of these assays are presented in Figure 3.7 where it can be 
seen that substitution at N129 had the most deleterious effect on enzyme 
activity, with both variants exhibiting approximately 20% of the wild type 
activity. The sensitivity of this residue to mutation may not be surprising given 




















Figure 3.7. Relative activity of point mutants of TSR. The initial enzymatic 
reaction rates (rate of SAH formation) by TSR variants relative to that of the 
native enzyme (WT) are shown. Assays were performed with 100 nM of enzyme, 
1 mM of AdoMet and 3.5 µM of 16S/ 23S rRNA. Error bars represent the 
standard deviation of duplicate experiments. 
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Interestingly, there was no significant difference in activity between N129 
variants with alanine or an aspartic acid residue in place of asparagine, despite 
the contrasting properties that would be exhibited by these respective side 
chains.  
The substitution of alanine for R135 or R165 caused notable reductions 
in activity, with enzyme activity appearing to be more sensitive to the R135 
mutations. This finding matched the reported relative activities of equivalent 
point mutants of the nosiheptide resistance methyltransferase (262). Unlike that 
study where only the alanine mutants of R135 and R165 were investigated, 
lysine substitutions at these sites were generated here. It was found that the 
R165K mutant displayed markedly higher relative activity than R165A (65% for 
R165K versus 40% for R165A), while a comparatively lower difference was 
observed between the R135 mutants (35% for R135K versus 30% for R135A). 
Both residues are situated in favorable positions for hydrogen bonding with 
AdoMet (Figure 3.8) and the loss of this capability upon replacement with the 
non-polar alanine could account for the reduced activity of these mutants. Even 
so, the lack of significant recovery of activity for the R135K mutant relative to 
R135A is suggestive of an additional function for this residue, although 















The catalytic mechanism proposed for the nosiheptide resistance 
methyltransferase implicates S246 as an active participant in methyl group 
transfer by hydrogen bonding with R135 which presumably keeps this arginine 
in position to withdraw a proton from the 2’ hydroxyl from RNA (262). No 
evidence confirming the importance of this residue in TSR activity was found 
here, as this variant displayed near 80% of the native enzyme’s activity. A 
comparison of the active sites of these two enzymes highlights differences with 
respect to the orientation of the side chain of S246 and well as AdoMet in their 
respective active sites. In the catalytic subunit of the nosiheptide resistance 
methyltransferase, S246 is within hydrogen bonding distance of R135, with the 
hydroxyl group of S246 pointing towards the guanidino group of R135 (Figure 
3.9A). These two residues are further apart in the catalytic subunit of TSR, with 
R135 
Figure 3.8. Hydrogen bonding between AdoMet and R135 and R165. Possible 
hydrogen bonds are depicted as dashed lines between amine hydrogens from R135 
and R165 and the oxygen from the carboxylate of AdoMet. The figure was 




the hydroxyl from S246 pointing away from the side chain of R135 (Figure 
3.9B). Such positioning of S246 in the TSR active site would not be conducive 
to hydrogen bonding with R135, although it is possible that the static crystal 
structure fails to capture rotational movement of this hydroxyl. In any case, such 
movement would be of negligible significance for TSR activity (as seen from 
the activity assays of the S246A mutant) and therefore, S246 is likely not to 









Noteworthy reductions in enzyme activity were seen for the E220 and 
K221 variants, with relative activities of approximately half that of the native 
enzyme. The crystal structure of TSR positions the side chains of E220 and 
K221 facing away from AdoMet moieties with which they could possibly 
engage in an interaction (Figure 3.10). Hence, these residues may be important 
for polar or electrostatic interactions with RNA or secondary interactions with 
AdoMet that correctly position either substrate in the active site. The N248 




Figure 3.9. Orientation of S246 in the active sites of (A) the nosiheptide 
resistance methyltransferase and (B) TSR 
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The comparative activity assays of the TSR variants highlighted the 
importance of N129, R135 and R165 in enzyme function. However, these 
results were ambiguous as the observed reduction in activity could be due to 
diminished capacity for AdoMet binding or the loss of the ability to catalyze 
methyl group transfer. In addition, the possibility of RNA interactions with 
these residues adds some difficulty to the interpretation of these results. The 
placement of the N129 side chain in the crystal structure of the native TSR does 
not imply a direct interaction between N129 and AdoMet, nor does the modeled 
binding of RNA to TSR suggest an important interaction of N129 with RNA 
(171). Therefore, the diminished activity of the N129 variants may reflect its 
importance in either methyl group transfer, or mask a more subtle, indirect 
AdoMet K221 
E220 




interaction with AdoMet. On the other hand, R135 and R165 are well situated to 
make electrostatic or hydrogen bonding interactions with the amino or carboxyl 
groups of AdoMet, yet these residues are also well situated to participate in 
methyl group transfer. Resolution of these ambiguities was sought by studying 
the kinetic parameters for AdoMet utilization by a select group of TSR variants, 
along with parallel AdoMet binding studies. 
 
3.3.3. Enzyme Kinetics of AdoMet for TSR Mutants 
Kinetic constants for AdoMet-dependent TSR catalyzed rRNA 
methylation determined using the coupled fluorometric assay were in agreement 
with previously reported values for these constants that were obtained using 
radiometric assays, which validated this assay (differences in the RNA substrate 
notwithstanding). Michaelis-Menten plots for AdoMet dependent activity of 
TSR and variants R165A, E220Q and K221A are shown in Figure 3.11 and the 
kinetic parameters derived from non-linear curve fitting to the Michaelis-
Menten equation are presented in Table 3.3 (curve fitting methodologies are 













Figure 3.11. Michaelis-Menten plots for TSR and its variants. Error bars represent the standard 
error of the mean from triplicate experiments. 
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  With the exception of N129A and R135A for which kinetic parameters 
could not be determined under the conditions of the assay, the apparent Km for 
AdoMet remained largely unaffected in the variants assessed. Significant 
reductions in the apparent maximum velocity (Vmax), turnover number (kcat) and 
substrate specificity (kcat/ Km) were, however, noted for R165A and K221A. 
This pointed towards compromised AdoMet turnover in these variants, which 
can be taken to signify a role in AdoMet binding. 
 
The possibility of hydrogen bonding between R165 and AdoMet has 
been discussed earlier and these findings are in agreement with this. On the 
other hand, the position of the K221 side chain suggests that this residue is 
relevant in the formation of the AdoMet binding pocket. As illustrated in Figure 
3.12, K221 completes the enclosure of AdoMet in the binding pocket, with the 
alkyl chain of the lysine R-group facing the methyl group from AdoMet. This 
Table 3.3 Kinetic parameters for enzyme catalyzed RNA methylation by 












TSR 155.16 ± 36 1.87 ± 0.18 1.81 ± 0.17 1.16 
   Reference     
(172) 40.0 ± 5.0 1.00 ± 0.1 ND ND 
(168)† 100 ± - - - 
(169)‡ 150 ± 30 - - - 
N129A ND ND ND ND 
R135A ND ND ND ND 
R165A 116.60 ± 19.40 1.07 ± 0.069 1.02 ± 0.067 0.87 
E220Q 102.70 ± 17.23 1.85 ± 0.120 1.79 ± 0.120 1.74 
K221A 104.20 ± 7.78 0.96 ± 0.026 0.93 ± 0.025  0.89 
For the determination of kinetic values, RNA concentration was kept at 0.35 µM, while the 
concentration of AdoMet was varied between 0 and 0.4 mM. †: Methylation of total E.coli 
rRNA was assayed. ‡: An RNA fragment containing nucleotides 1029 – 1122 from E. coli 
rRNA was used as a substrate. 
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complete enclosure of AdoMet is not likely be achieved by the smaller methyl 
group from alanine, leading to improper orientation and binding of AdoMet and 









Interestingly, the kinetic parameters for E220Q were unchanged with respect to 
the native enzyme, in spite of an approximate 50% reduction in activity relative 
to the native enzyme. The equivalent residue in the nosiheptide resistance 
methyltransferase has been proposed to stabilize the amine-terminal end of 
AdoMet (262) and a similar role for this residue has been suggested in TSR 
(171). Indeed, the carboxyl group of E220 is oriented such that H-bonding or 
electrostatic interactions between the E220 (side chain) carboxylate and the 
amine group from AdoMet is conceivable. This may account for the reduced 
activity of the E220A and E220Q variants, which would present uncharged side 
chains at the experimental pH, although glutamine may participate in H-bonding 
or polar interactions. Given the similar levels of reduced activity for these 
variants, it may be speculated that this loss of activity was due to the absence of 
Figure 3.12. The importance of K221 in the AdoMet binding pocket of TSR. 
(Left) Amino acid residues surrounding AdoMet have been overlayed with an 
electrostatic surface potential in blue (positive) and red (negative), revealing the 
AdoMet binding pocket. (Middle) The position of K221 is shown relative to bound 
AdoMet. (Right) The AdoMet binding pocket is colored in green and AdoMet is 
shown as a space-filling model. Surfaces were added to the PDB structure file for 




a negative charge at this position. Enzyme kinetic data indicates this to be of 
little significance with respect to AdoMet, hence, this may reflect the loss of an 







Figure 3.13. Possible role of E220 in RNA binding. Top panel shows a stereo 
view of TSR dimer mapped with an electrostatic potential surface in blue 
(positive) and red (negative). Note the stripe of positive charge that spans the 
length of the molecule, which is believed to be the area of RNA contact (163). In 
the stereo-view shown in the bottom panel, the subunits of the TSR dimer are 
depicted as ribbons (catalytic subunit in red and non-catalytic in blue). AdoMet 
bound to the catalytic subunit has been rendered as sticks and E220 is shown as a 
space-fill. The proposed region of RNA interaction is shaded gray and 
encompasses the side chain of E220.  Figures were generated from the PDB 
structure file for TSR (3GYQ) using UCSF Chimera v.1.5.2. 
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3.3.4. AdoMet binding in point mutants of TSR 
Further clarification of the functional roles played by active site residues 
of demonstrable importance from the enzyme assays was obtained by studying 
the binding of AdoMet to TSR variants. The binding stoichometry remained at 2 
molecules of AdoMet per dimer of enzyme, however marked differences in 
binding affinity were observed (Table 3.4, Fig. 3.14).  
 
AdoMet binding affinity was decreased for both N129 mutants, which 
indicates that the poor relative activity of these variants can be attributed, at 
least partially, to their diminished AdoMet binding capacity. As earlier stated, 
the crystal structure of the TSR-AdoMet complex does not indicate a direct 
interaction between AdoMet and N129, but the replacement of N129 by aspartic 
acid would introduce a negatively charged carboxylate group in proximity to the 
carboxylate group from AdoMet. It is therefore plausible that the charge 
Table 3.4. Parameters for AdoMet binding to TSR and its variants 
 n 
(stoichiometry) 
Kd (µM) ΔH  (kcal/ mol) ΔS  (cal.mol
-1.deg-1) 
TSR 2.03 ± 0.11 108.21 ± 7.32 -3.96 ± 0.26 4.64 ± 0.76 
N129A 1.98 ± 0.30 507.34 ± 92.70 -10.16 ± 1.70 -19.55 ± 0.64 
N129D 2.32 ± 0.37 620.00 ± 65.43 -29.75 ± 6.13 -86.75 ± 7.08 
R135A 1.98 ± 0.52 894.39 ± 17.18 -72.52 ± 25.39 -233 ± 39.6 
R135K 1.89 ± 0.06 147.49 ± 7.94 -9.37 ± 0.43 -14.40 ± 0.42 
R165A 1.78 ± 0.15 150.15 ± 11.80 -7.81 ± 1.24 -10.95 ± 2.05 
R165K 1.90 ± 0.09 94.29 ± 17.52 -6.60 ± 0.34 -4.07 ± 1.13 
Binding constants were determined from non-linear curve fitting using the model for 
one set of sites, using concentration of enzyme dimer. Errors represent the standard 
deviation of three replicates, with the errors of individual replicates ≤ 15%. 
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repulsion between these neighboring negatively charged groups would disrupt 





















Fig. 3.14. Measurement of AdoMet binding to point mutants of TSR by 
isothermal titration calroimetry. Top panels from each figure show the heat 
released per injection of AdoMet into a sample cell containing TSR variant. The 
background heat from the injection of AdoMet into a sample cell containing buffer 
has been subtracted. Bottom panels show the binding isotherm for the integrated 
heats/ injection fitted to a model for one set of binding sites. 
N129A R135A R165A 
N129D R165K R135K 
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This explanation does not account for the poor AdoMet binding (and 
activity) observed for N129A variant. Closer inspection of the TSR crystal 
structure shows that N129 resides near the end of helix 6 (Figure 3.15A) and 
both N129 and helix 6 are highly conserved among AdoMet-dependent 
methyltransferases in this class (189, 191, 267–269). Helix 6 is a pivotal 
structural feature that is integral to the overall structure of TSR, particularly in 
the formation of the dimer interface through its interactions with helix 11 (171, 
262). Yet, as illustrated in Figure 3.15B, this association between helices 6 and 
11, also appears to be important in the formation of the AdoMet binding pocket. 
Residues at the ends of helices 6 and 11 (including N129) directly contribute a 
significant area to the binding pocket surrounding the carboxyl end of AdoMet 
and helix 11 is held in position through extensive hydrophobic contacts along its 
length with helix 6 (Figure 3.15C). This positioning for helix 11 allows for the 
formation of the binding pocket surrounding the adenine moiety of AdoMet by 
residues I238 – L247 (Figure 3.14C). Moreover, R135, demonstrated earlier to 
be crucial for AdoMet binding and enzyme activity, is also located on helix 6 
with its side chain ideally oriented for interactions with AdoMet. 
According to the above interpretation, N129 mediates key structural 
elements that are required for proper AdoMet binding. As such, it could be 
expected that the effects of an alanine or aspartic acid substitution at N129 
would be manifested by observable changes to protein structure, in addition to 






























Figure 3.15. Importance of N129/ Helix 6 for the AdoMet binding site. A) The figure 
centers on the TSR dimer interface, with AdoMet bound in the CTD of each monomer. The 
catalytic subunit is shown in blue, with helices 6, 7, and 11 in green and the non – catalytic 
subunit is colored red, with helices 6, 7 and 11 in magenta. Helices have been numbered 
according to (163). (B) AdoMet binding pocket for the catalytic subunit of TSR. The surface 
of the binding pocket contributed by V124, I126 (α 6), N129 (α 6), S219, E220, K221, N248 
(α 11), V249 (α 11), is colored gray. (C) 90º x-axis rotation of the orientation shown in (B). 
The adenosine binding loop, consisting of residues 238 – 248, is shown in red. Residues likely 













  Since it has been put forth that N129 is important for the proper 
formation and positioning of helix 6, an integral feature in the formation of the 
TSR dimer interface, the mutation of N129 could be reasonably expected to 
disrupt TSR dimerization. Size exclusion chromatography was thus performed 
on the N129D variant using conditions known to maintain TSR in its native 















 Figure 3.16. Size exclusion chromatography of TSR and its N129D variant. 
Chromatograms show that TSR and the N129D variant both elute after 16 minutes. 
This corresponds to a relative molecular weight of approximately 65 kDa, which is 
in agreement with the dimeric molecular weight of TSR (58364 Da). Top panel 
shows the separation of a standard protein mixture using the identical conditions. 
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The resultant chromatogram was identical to that obtained from native TSR, 
indicating subunit dissociation was not responsible for the observed properties 
of this variant (Figure 3.16).  
The hypothesized importance of N129 towards helices 6 and 11 also 
implies that the effects of an N129 mutation would cause alterations in protein 
secondary structure. Therefore, the gross secondary structure of the N129D 
variant was compared to that of native TSR using circular dichroism. In contrast 
to the results of size exclusion chromatography, the CD spectrum for N129D 
diverged appreciably from that of native TSR (Figure 3.17). This was indicative 
of differences in the secondary structure of these two proteins, which by and 
large appear to be the result of reduced helical content of the N129D variant 
relative to TSR.  
This finding is in agreement with the suggested structural role of N129 
and offers some evidence supporting the notion that the formation of α-helical 
regions that are critical to AdoMet binding is dependent on N129.  Hence, the 
altered landscape of the binding pocket caused by perturbations to these regions 
of the enzyme in N129 variants, would result in diminished or eliminated 
AdoMet stabilizing interactions, with a simultaneous expansion of the internal 
cavity of the binding pocket. The net effect of these would serve to reduce 










As mentioned earlier, it is believed that the withdrawal of the hydrogen 
from the 2’ hydroxyl of A1067 by a neighboring amino acid promotes the 
nucleophilic attack on the methyl group from AdoMet that results in RNA 
methylation. The positions of R135 and R165 relative to AdoMet makes one of 
these residues a likely candidate to act in this capacity, and indeed, a 
substitution of alanine at either of these sites caused a reduction in enzyme 
activity. The comparative effects of alanine and lysine substitutions at these 
sites showed that binding affinity was virtually unchanged by a substitution to 
lysine, but alanine mutations caused reduced affinity, particularly at R135. With 
respect to R165, these differential binding affinities were reflected in the 
enzyme activity assays, where the relative activity of R165K was greater than 
that of R165A.  Interestingly, although the binding affinity of R135K was 
similar to that of the native enzyme, both R135 variants exhibited similar 
Figure 3.17. Circular dichroism spectra for TSR and its N129D variant. Near 
UV spectra for TSR (dashed line) and its N129D variant are shown. Both proteins 
are predominantly α-helical, however secondary structural features differ between 
the two, as denoted by the shift in the N129D spectra with respect to TSR 
(indicated by and arrow). 
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activity (~ 20% activity of the native enzyme). This indicates that R135 is more 
critical to AdoMet binding than R165, but also offers evidence of an additional 
important role for this residue.  
The reported pKa of the proton from the 2’hydroxyl group on adenosine 
is approximately 12.0 (270). Therefore, a sufficiently basic side chain, such as 
that of the guanidino group from arginine (pKa ~12.5(271)), would be required 
to effect its withdrawal. The pKa of the primary amino group from the lysine 
side chain is typically 2 units lower than that of arginine (271), hence the low 
activity of the R135K variant undoubtedly reflects the inability of the lysine side 
chain to accomplish sufficient proton removal/ polarization. At the same time, 
although methyl group transfer is impeded with this R135K variant, polar/ 
electrostatic interactions or hydrogen bonding with AdoMet would be 
maintained, which would account for an AdoMet binding affinity comparable to 
that of the native enzyme in this variant.  
 
3.4. Conclusions, perspectives and future work 
The factors underlying AdoMet binding and AdoMet dependent RNA 
methylation by TSR have been investigated. AdoMet binding was also shown to 
be heavily dependent on an active site asparagine (N129), which appears to be 
vital for maintaining the structural integrity of the AdoMet binding pocket by 
facilitating the formation of important secondary structures. Direct interactions 
between AdoMet R135 and R165 were also shown to be important in AdoMet 
binding and these interactions most likely take the form of hydrogen bonding 
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between amine and carboxyl groups from arginine and AdoMet, respectively. 
As well, the kinetic parameters for AdoMet-dependent TSR catalyzed methyl 
group transfer have been determined using an adapted and validated 
fluorometric assay. By determining these kinetic parameters for TSR variants 
that featured point mutations at key active site residues, in conjunction with 
AdoMet binding studies, uncertainties in the details surrounding the mechanism 
of methyl group transfer by TSR have been addressed. It can be concluded that 
R135 from the non-catalytic subunit acts in a basic capacity, increasing the 
nucleophilicity of the oxygen from the 2’-hydroxyl on A1067 in rRNA, thus 
enabling the attack of the methyl group from AdoMet bound in the catalytic 
subunit of the TSR dimer. 
Future work in this area can address the significance of the structurally 
different subunits in the TSR dimer and related Mtases. The dimeric enzyme 
was crystallized with AdoMet occupying the binding site of both subunits (171, 
262), and the current interpretation of crystallographic data implies that one 
subunit functions in a catalytic capacity. This can be explored through ligand 
competition/ displacement experiments aimed at comparing AdoMet affinities 
between these two sites. Similar studies on TSR composed of sequentially 
different subunits (hetero-dimers) may prove to be additionally informative. 
A greater understanding of the role played by the proposed non-catalytic 
subunit would be provided from the solution of the structure for the ternary 
TSR-AdoMet-rRNA complex. Such studies would supply the lacking 
information on TSR-RNA interactions and would highlight the consequences of 
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dual substrate binding, which may include cooperative effects. These endeavors 
may potentially reveal additional mechanistic details of TSR catalysis 
(sequential versus ping-pong) which may present a more accurate portrayal of in 
vivo processes. In the absence of X-ray derived structures, residue specific 
labels may be exploited to monitor changes that occur to enzyme secondary 
structure in combination with biophysical techniques such as NMR or 
fluorescence. This approach may also aid in the confirmation of the proposed 



















CHAPTER 4: SYNTHESIS OF A NOVEL ADOMET ANALOGUE AND 
EVALUATION AS AN ADOMET METHYLTRANSFERASE CO-SUBSTRATE 
 
4.1. Preface 
The transmethylation carried out by AdoMet-dependent 
methyltransferases (MTases) is not accompanied by an easily assayable physical 
or chemical characteristic, making the study of the kinetics of these enzymes 
challenging. This is compounded by the typically low substrate turnover by 
these enzymes as well as the product inhibition resulting from the 
accompanying production S-adenosyl-L-homocysteine (AdoHcy). Usually, 
AdoMet containing a radiolabel at the methyl group is utilized in these assays 
(169, 171). Isolation of the methylated product of the enzyme reaction, usually 
by chromatography, followed by scintillation counting, yields data which can be 
utilized to determine Mtase enzyme kinetics. The advent of various assays that 
couple the degradation of AdoHcy to Mtase activity have circumvented these 
tedious proceduress (see Appendix 6) and provide a continuous assay protocol. 
However, the utility of such assays to investigate new but uncharacterized 
Mtases (which represent the vast majority of MTases) may be limited, 
particularly with respect to substrate identification.  
Current intense interest is also being focused in the literature (Chapter 1) 
on the use of various Mtases to transfer non-methyl groups from analogues of 
AdoMet. These groups have featured chemical moieties that allow subsequent 
facile conjugation to convenient reporter molecules, enabling substrate-specific 
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labeling. The development of such analogues has been reported in many recent 
studies (Chapter 1), however the transfer of these alternative groups has mainly 
been demonstrated in instances where they are present in stoichiometric 
amounts, a situation that is likely not conducive to the discovery of unknown 
substrates. One notable exception to this was the transfer of a ketone group to 
small molecule substrates by catechol-O-methyltransferase and thiopurine-S-
methyltransferase (213). In addition, this keto-AdoMet was used to identify an 
unknown substrate of TPMT, marking this as one of the few instances where 
AdoMet analogues have been successfully used to identify a novel MTase 
substrate.  
 This chapter describes the synthesis of a novel AdoMet analogue, 
featuring a fluoroketone group. It was hoped that the presence of a 
trifluoromethyl group adjacent to the ketone functionality would allow facile 
chemical modification, as carbonyls adjacent to the CF3-group are known to be 
more electrophilic. In addition to expanding the repertoire of groups transferable 
by Mtases, the inclusion of fluorine would add an additional capacity for 
substrate labeling through 19F NMR. The usability of this analogue with Mtases 
was assessed with commercially available recombinant human thiopurine 
methyltransferase, which is known to promiscuously methylate aromatic thiol 






4.2. Material and Methods 
4.2.1. Chemicals and Reagents 
 S-Adenosyl-L-homocysteine, silver perchlorate, silver p-toluene 
sulfonate, silver trifluoromethanesulfonate, 3-bromo-1,1,1-trifluoroprop-2-one, 
4-nitrobenzenethiol, sodium iodide and potassium iodide were all reagent grade 
from Sigma (Oakville, Canada). Thiopurine-S-methyltransferase (TMPT; E.C. 
2.1.1.67) and adenosylhomocysteine nucleosidase (mTAN; E.C.3.2.2.29) were 
obtained from G Biosciences (St. Louis, USA). Tris(2-carboxyethyl)phospine 
(TCEP) was from Thermo Fisher Scientific (Rockford, USA) and monobasic 
and dibasic potassium phosphate from BioShop (Burlington, Canada). 
4.2.2. Equipment 
4.2.2.1. Chromatography 
 High performance liquid chromatography was performed using a Waters 
(Millford, USA) Chromatography system (Waters 626 pump, 600s controller 
and 2996 photodiode array detector and Millennium 3.20 software). Analytical 
HPLC was performed using a Waters C18 reverse phase column (4 µM, 3.9 × 
150 mm) and preparative scale purifications were carried out using a Supelco 
C18 column (5 µM, 10 × 250 mm). In all cases, 0.1% aqueous TFA and 
acetonitrile were the polar and non-polar mobile phases, respectively.  
4.2.2.2. Spectrophotometry 
Quantification of AdoMet and the AdoMet analogue was performed 
spectrophotometrically, using standard curves generated using known 
concentrations of AdoMet and the reported extinction coefficient of 15, 400 
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M.cm-1 at 260 nm (275). Absorbance measurements required for enzyme 
activity determination were carried out in clear 96-well microplates on a 
SpectraMax M5 microplate reader (Molecular Devices, Downingtown, USA). 
4.2.2.3. Mass spectrometry 
 Prior to analysis, samples were diluted into a 1:1 solution of acetonitrile 
and water containing 0.2% formic acid. Electrospray ionization mass 
spectrometry was performed in positive ion mode, with a QTOF Ultima Global 
mass spectrometer (Micromass (Waters)) and the data processed with MaxEnt 
software (Waters). 
4.2.2.4. Gas chromatography 
 Samples were prepared as solutions in acetone. Gas chromatography was 
performed with an Agilent 5975B Inert series Quadropole GC/MS system 
(Agilent Technologies). Helium was used as the carrier gas for gas 
chromatography with a 30m DB-1 column (Agilent Technologies) and a 
temperature gradient of 30°C – 250°C over 30 minutes. On-line electron impact 
mass spectrometry was performed with an electron energy of 70 eV. 
4.2.2.5. Nuclear Magnetic Resonance 
NMR spectra were acquired using either a 500 or 300 MHz spectrometer 
(Bruker, Milton, ON). Sweep widths were 10.5 ppm and 300 ppm for proton 
and fluorine nuclei, respectively. AdoMet analogues were prepared at 1-2 mg/ 





4.2.3. General Methods 
4.2.3.1. Synthesis of 3-iodo-1,1,1-trifluoroprop-2-one 
 Potassium iodide (335 mg, 2 mmoles) was dissolved in 40 mL of 
distilled methanol. To this solution, 3-bromo-1,1,1-trifluoroprop-2-one (200 µL, 
2 mmoles) was added and the mixture stirred at room temperature, in the dark 
for 8 hours, under an inert (argon) atmosphere. The solvent was then removed 
under vacuum, leaving yellow-brown slurry, to which 30 mL of ddH2O was 
added. This mixture was extracted twice with 30 mL of diethyl ether and the 
organic layer washed successively with ddH2O (2 × 30 mL) followed by 
washing with 30 mL of a saturated brine solution. The organic layer was then 
dried over anhydrous sodium sulphate5. The solvent was removed under 
vacuum to leave 312 mg of an oily, yellow-brown liquid which was confirmed 
by GC-MS to be 3-iodo-1,1,1-trifluoroprop-2-one (75% yield). Further analysis 
by 1H and 19F NMR indicated the compound to exist predominantly as the 
hydrated ketone. 1H-NMR (300 MHz in CDCl3): δ 4.099 (s, 2H; ketone), 3.558 
(s, 2H; hydrate); 19F-NMR: δ -75.3 (CF3- ketone), -84.0 (CF3- hydrate).  >90% 
purity by CG-MS.  
4.2.3.2. Synthesis of S-adenosyl-S-(1,1,1-trifluoropropan-2-one)-L-
methionine (4.1).  
To one equivalent of AdoHcy (50 mg, 0.13 mmoles) dissolved in 4 mL 
of a 1:1 mixture of formic acid/ acetic acid at 0°C under an inert atmosphere, 30 
                                                            
5 Alternatively, the yellow-brown slurry was washed with diethyl ether (3 × 10 
mL) and the organic portion retained. The solvent was then removed under 
vacuum, leaving an oily yellow-brown liquid. 
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equivalents of 3-bromo-1, 1, 1-trifluoroprop-2-one (405 µL, 3.9 mmoles) or 10 
equivalents 3-iodo-1,1,1-trifluoroprop-2-one (155 µL, 1.3 mmoles) were added 
in a drop-wise fashion over 5 minutes. To the resulting light brown mixture was 
added 100 µL of an acetonitrile solution containing one equivalent of silver salt 
(silver perchlorate (AgClO4), silver p-toluenesulfonate (AgOTs) or silver 
trifluoromethanesulfonate (AgTf)). The mixture was stirred at 0°C for 5 
minutes, then allowed to warm to room temperature and stirred in the dark for 
72 hours. The reaction was quenched by the addition of 10 mL of ddH2O and 
the mixture then filtered through a 0.45 µ nylon membrane to remove the 
precipitated silver salt.  After washing with diethyl ether (3 × 15 mL), the 
aqueous layer was retained and lyophilized, leaving a white powder. A portion 
of the crude reaction mixture (10 mg) was dissolved in 0.1% aqueous TFA (800 
µL) and this solution was passed through a 0.2 µm filter. The filtered solution 
was then divided into 100 µL aliquots which were stored at -80 C° or kept on 
Dry Ice prior to fractionation by semi-preparative HPLC using a C18 resin. 
Directly upon thawing, a 100 µL aliquot of the crude reaction product was 
injected onto a C18 column (250 × 100 mm, 5µm) and the desired product was 
obtained using a linear, increasing gradient of acetonitrile (2 – 7% acetonitrile 
over 10 minutes, then 7 – 15% over 8 minutes, at a flow rate of 5 mL/min). 
Fractions were collected in vessels that were kept on dry ice and then 
lyophilized. The concentration of purified analogue was determined from 
extinction coefficient values for AdoMet/ AdoHyc (ε 260 = 15, 400 M




4.2.3.3. Synthesis of the thiopurine methyltransferase product standard 
(1,1,1-trifluoro-3-[(4-nitrophenyl)thio]propane-2-one) (4.3)  
4-Nitro-benzenethiol (87 mg, 0.56 mmoles) was dissolved in 3.5 mL of 
anhydrous tetrahydrofuran (Sigma Aldrich) under an inert (argon) atmosphere. 
Triethylamine (100 µL, 0.72 mmoles) was added and the solution stirred at 
ambient temperature for 10 minutes. 3-Bromo-1, 1, 1-trifluoroprop-2-one (100 
µL, 0.96 mmoles) was then added, and the mixture stirred for an additional 4 
hours. The reaction was quenched by the addition of 4 ml of saturated NH4Cl 
and then washed with ethyl acetate (3 × 15mL). The organic layer was dried 
over MgSO4 and then purified by silica gel chromatography (0-40% ethyl 
acetate in hexane). Fractions containing the desired product were identified by 
thin layer chromatography and these were pooled and the solvent removed 
under vacuum to give 60.5 mg (38%) of a yellow powder. 19F NMR analysis 
indicated the product to be predominantly the hydrated ketone. m.p.: 70 – 74 ºC, 
Rf: 0.35 (Ethyl acetate/ hexane, 2:3).
1H-NMR (300 MHz in CDCl3): δ 8.15 (s, 
1H), 8.13 (s, 1H), 7.56 (s, 1H), 7.53 (s, 1H), 3.58 (s, 1H), 3.45 (s, 1H); 13C-
NMR: δ 147.02, 144.03, 131.15, 126.42, 124.62, 124.43, 29.67; 
19F-NMR: δ: 
79.5 (CF3-ketone), -84.8 (CF3-hydrate). HRMS calculated for [C9H8F3NO4S + 
H+]: 284.020, found 284.003. 
4.2.3.4. TPMT activity assay 
Coupled spectrophotometric assay 
Spectrophotometric assays of TPMT activity were performed by 
monitoring the reduction in absorbance at 411 nm, which corresponds to the 
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disappearance of the 4-nitrobenzenethiol substrate, according to Lee et al. (213). 
Assays were performed in clear 96-well plates (Greiner Bio-One, Monroe, 
USA) and each 100 µL reaction consisted of 200 mM potassium phosphate (pH 
8), 2 mM TCEP, 1µM mTAN, 50 µM 4-nitrobenzenethiol and 50 µM of 
AdoMet and100 µM of 4.2. Reactions were initiated by the addition of the 
enzyme TPMT at various concentrations (0.5 µM, 1.0 µM, 6.0 µM) and 
monitored continuously for 30 minutes. Control reactions contained no enzyme. 
After 30 minutes, the reaction mixtures were subjected to analytical HPLC with 
a Waters µBondapak C18 column (4µm, 3.9 x 150 mm). The polar and non-
polar mobile phases were 0.1% TFA in water and acetonitrile, respectively and 
the products were eluted with the following conditions: 40% acetonitrile for 5 
minutes, then a linear increase to 60% acetonitrile over 15 minutes, a hold at 
60% acetonitrile for 5 minutes and then a return to 45% acetonitrile over 5 
minutes.  
Coupled fluorometric assay 
 Fluorometric assays of TPMT activity were performed with the 
Methyltransferase Fluorometric Assay Kit (Cayman Chemical Company, Ann 
Arbor, USA), according to the manufacturer’s specifications, in black 96-well 
microplates (Corning Life Sciences, Tewksbury, USA). Reactions (200 µL) 
contained 50 µM of AdoMet or 100 µM of AdoMet analogue, 50 µM of 4-





4.2.3.5. Competition assays  
 Fluorometric assays of TPMT catalyzed methylation of 4-
nitrothiobenzene were performed as previously described, each containing 50 
µM of AdoMet in the presence of varying concentrations of fluoroketo-AdoMet. 
  
4.3 Results and Discussion 
4.3.1 Synthesis of S-adenosyl-S-(1,1,1-trifluoropropan-2-one)-L-
methionine (4.1) 
 Attempts at obtaining 4.1 utilizing a synthetic method that was reported 
successful in synthesizing the non-fluorinated parent compound as described by 
Lee et al. (213) did not result in the desired novel fluorinated product. 
Therefore, AgClO4 was utilized to drive the alkylation of the sulfur atom of 
AdoHcy with the 3,3,3-trifluoromethyl-2-propanone group through the 








After 24 hours, analysis of the analytical HPLC and ESI-MS data on the 
reaction mixture indicated the formation of two products having masses of 




495.16 Da and 513.16 Da that eluted at 4.2 minutes and 12.5 minutes 
respectively. These were consistent with the addition of the trifluoroacetone 
group to AdoHcy; the compound of Mw 513.16 being the hydrated ketone form 
(4.2) of the desired analogue (Fig. 4.2B). Together, these products represented ~ 
10% of the total reaction products, with the suspected hydrated ketone form 
predominating (Fig. 4.2A). Comparison of fragment ion mass spectra for this 
product with spectra reported for a methyl-ketone AdoMet (213) derivative 
revealed a similar ion fragmentation pattern (Fig. 4.2C) and final confirmation 
of product identity and structure was obtained with NMR analyses.  
The 19F NMR spectrum for 4.2 (Fig. 4.3A) showed two peaks of roughly 
equal intensity at -86.42 and -86.44 ppm and a minor peak at -77.46 ppm. These 
were in agreement with predicted 19F chemical shifts of the fluorines from the 
hydrated ketone (-80.68) and ketone (-77.47) forms of the desired derivative 
(ACD/ I-Lab NMR predictor). The addition of 1,1,1-trifluoroprop-2-diol to the 
sulfide of SAH generates a chiral sulfonium centre, therefore the peaks at -86.42 
and -86.44 ppm correspond to the –CF3 fluorines from each of the diasteromers. 
This was analogous to 1H spectra for the methylketone AdoMet analogue 
prepared by Lee and coworkers (213), where two methyl group chemical shifts 
were in evidence, corresponding to the stereo-isomers at the chiral sulfonium 
centre. These researchers did not report the presence of a hydrated ketone form 
of their derivative, however, the trifluoromethyl group in the derivative 
described here increases the electrophilicity of the carbonyl carbon, which shifts 







Figure 4.2. Purification of the fluoroketo-AdoMet analogue. A) HPLC chromatogram 
showing the products from the reaction of 3-bromo-1,1,1-trifluoroacteone with AdoHcy, in the 
presence of AgClO4. The product eluting after 4.2 minutes was found to have a mass of 
513.1608, which corresponds to the hydrated ketone form of the desired derivative. (B) 
Formation of S-adenosyl-S-(1,1,1-trifluoropropan-2-diol)-L-methionine (4.2) in aqueous 
conditions. (C) Tandem mass spectra for the product eluting after 4.2 minutes. The structure of 
observed fragment ions are shown. The fragmentation pattern is similar to that of the propan-2-
one AdoMet derivative obtained by Lee and coworkers and is consistent with the proposed 






 Figure 4.3. NMR characterization of the fluoroketo-AdoMet analogue. Top trace: 
19F 
spectrum of the product eluting after 4.2 minutes. The inset zooms in on the peaks at -86.42 and 
-86.44, which correspond to -CF3 fluorines from the two stereo-iosmers of the hydrated ketone 
form of the derivative. The peak at -77.465 is attributed to -CF3 fluorines from the ketone form 
of the derivative; the stereo-isomers were unresolved due to the low intensity of these signals. 




1H-NMR (500 MHz, D2O): δ 8.09-8.06 (m, 2H, aromatic), 5.82 (q, 1H, H1’), 
4.56 (m, 1H, H1’), 4.34 (t, 1H, H3’), 4.29 (m, 1H, H4’), 4.21 (m, 1H), 4.08 (m, 
1H), 3.91-3.72 (m, 2H, H5’), 3.45 (t, 2H, Hλ), 3.35 (t, 1H, Hα), 2.07-1.99 (m, 
2H, Hβ). 19F-NMR: δ -77.46 (ketone), -86.42, -86.44 (hydrate). ESI- HRMS 
(calculated): C17H24N6O7F3S (s-adenosyl-S-(1,1,1-trifluoropropan-2-diol)-L-
methionine); 513.1359 (513.1379), C17H22N6O6F3S (s-adenosyl-S-(1,1,1-
trifluoropropan-2-one)-L-methionine); 495.1290 (495.1274). MSMS: adenine + 
H+; 136.0641 (136.0618), s-ribosylhomocysteine + H+; 250.1033 (250.0744), 
5’-(1,1,1-trifluoropropan-2-one)-thio-5’deoxyadenosine + H+; 394.1144 
(394.0791), 5’(1,1,1-trifluoropropan-2-diol)-thio-5’deoxyadenosine + H+; 
412.1131 (412.0897), s-adenosyl-S-(1,1,1-trifluoropropan-2-one)-L-methionine; 
495.1593 (495.1268). 
 
4.3.2 Optimization of reaction conditions for the synthesis of 4.1 
Obtaining preparative amounts of the desired AdoMet analogue 
presented several challenges. The poor  synthetic yield was compounded by the 
apparent decomposition of the desired product, which occurred in a manner 
similar to that described for AdoMet (279–283). As a result, attempts were 
made to improve the overall product yield and alternative routes to the synthesis 
of the AdoMet analogue were explored. 
4.3.2.1. General conditions 
 In the initial reactions conditions, solid granules of AgClO4 were added 
to a stirring solution of AdoHcy and 3-bromo-1,1,1-trifluoroactone in a mixture 
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of formic acid and acetic acid. It was observed that the silver salt did not readily 
dissolve in this solvent, hence AgClO4 was subsequently added as a solution 
prepared in a minimum volume of acetonitrile. This, in addition to extending the 
reaction time to 72 hours improved the yield to 15-20%. Reactions allowed to 
progress beyond this time suffered from extensive decomposition of both the 
starting material and product (determined by HPLC/ MS analyses).   
4.3.2.2 . Silver salts 
  AdoMet stability is improved by the presence of halide or tosylate 
counterions to the sulfonium centre (284, 285). The reaction was therefore 
performed with silver tosylate (AgOTs) or silver triflate (AgOTf), with a view 
towards improving product stability and consequently, the net yield of viable 
product. The use of AgOTs improved the combined yield of 4.1 and 4.2 to ~ 
20%, with 4.2 as the major product. This reagent also appeared to improve 
product stability prior to HPLC purification. Silver triflate was found to be an 
unsuitable reagent, resulting in a product of molecular weight 527.13 Da, 
consistent with the addition of the fluoroketone group to the sulfone of AdoHcy. 
Increasing the proportionate amount of silver salt did not cause a noticeable 
improvement to product yield, but further complicated product purification due 
to the formation of acetonitrile-silver complexes as well as SAH-silver 
complexes that co-eluted with the desired product. These optimizations 








4.3.2.3. Synthesis of 3-iodo-1,1,1-trifluoroprop-2-one (4.3) and its reaction 
with AdoHcy. 
 The susceptibility of α-haloketones to nucleophilic attack at the α 
position proceeds in the direction I > Br > Cl > F, with iodine containing 
compounds being most susceptible (286). It therefore follows that the use of 3-
iodo-1,1,1-trifluoroprop-2-one would achieve a greater extent of addition of the 
trifluoro-propanone/ propan-2-diol group to AdoHcy, than 3-bromo-1,1,1-
trifluoroprop-2-one. Similar approaches have been used by Coward and others 
to obtain fair to moderate yields of sulfonium salts of 5’ substituted adenosines 
as well as AdoMet derived sulfonium salts through methylation of the 
corresponding sulfide with methyl iodide (287–289).   
 
Scheme 4.1. Optimized conditions for the synthesis of trifluoromethyl ketone 
derivatives of AdoMet. 
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The conversion of 3-bromo-1,1,1-trifluoroprop-2-one was initially 
attempted using conventional Finkelstein reaction conditions6, but conversion 
into 3-iodo-1,1,1-trifluoro propan-2-one by this method did not exceed 35% 
(Figure 4.4). This was not improved by extending the reaction duration, 
increasing temperature or reflux conditions. On the contrary, these alterations 
served to increase the production of undesired side products, which complicated 
chromatographic purification of the target compound.  
Although the Finkelstein reaction is widely believed to be an equilibrium 
process and driven by the formation of insoluble NaBr, high yielding halogen 
transfers have been accomplished using potassium iodide without the 
precipitation of KBr.  Hence, the replacement of bromine with iodine was 
attempted with KI in acetonitrile, ethanol or methanol (Scheme 4.2). It was 
found that KI in methanol resulted in > 90% conversion (by GC/ MS) of the 
bromoketone, with negligible side products, giving the desired iodoketone in 
60-75% yield (Fig. 4.5). The high purity of the obtained 3- iodo-trifluoro-1,1,1-
prop-2-one removed the requirement for purification and the addition of the 
trifluoropropan-2-diol group to AdoHcy using this reagent was attempted 
according to Scheme 4.1. 
                                                            
6 To 335 mg of NaI dissolved in acetone were added 200 µL of 3-bromo-1,1,1-trifluroacetone. 
This mixture was stirred in the dark for a maximum of 24 hours. Precipitated NaBr was 
removed by filtration and the solvent evaporated. Diethyl ether (30 mL) was added to the 
residual yellow-brown liquid and this mixture was washed successively with ddH2O and brine 
then dried over sodium sulfate. The solvent was removed under vacuum to leave a yellow-
brown oily liquid.  
139 
 
Figure 4.5. Analysis of the products from the reaction of 3-bromo-1,1,1-trifluoroprop-2-one with 
KI in methanol. Gas chromatogram of the crude reaction products, which shows greater than 95% 
conversion into 3-iodo-1,1,1-trifluoroprop-2-one (top panel). EI-mass spectrum of 3-iodo-1,1,1-
trifluoroprop-2-one (retention time of 2.864 minutes); the structures of the resultant fragment ions are 
shown (bottom panel). 
Figure 4.4. Attempted synthesis of 3-iodo-1,1,1-trifluoroprop-2-one using conventional 
Finkelstein conditions. The gas chromatogram of the crude reaction product mixture is shown. 
Products of retention time of 2.862 and 3.717 minutes correspond to 3-iodo-1,1,1-trifluoroprop-2-one 
and the starting material 3-bromo-1,1,1-trifluoroprop-2-one, respectively (EI-MS).  
Scheme 4.2. Synthesis of 3-iodo-1,1,1-trifluoropropan-2-one 
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The reaction progress was qualitatively monitored by ESI-MS which indicated 
maximum AdoHcy modification occurring after 3 days. Analytical HPLC of the 
crude reaction products suggested a small improvement in yield, with 20 – 25 % 
conversion of AdoHcy mainly into the hydrated ketone, but it should be stated 
that this yield was achieved using proportionately less amounts of the 
iodoketone. 
4.3.2.4. Attempted synthesis of activated trifluoromethyl ketones  
Activated alkylating agents have been successfully employed in the 
generation of AdoMet analogues in moderate to fair yields ranging between 20 
and 60% (208, 210, 211). In these syntheses, alkyl chains were added to 
AdoHcy after being made more electrophilic by their coupling to mesyl or tosyl 
groups, which have the added benefit of serving as good leaving groups. Hence, 
it was thought that the use of the analogous activated trifluoromethyl propanone 
would result in greater yields of the desired AdoMet analogue.  
Syntheses of triflated or tosylated trifluoromethyl ketones were 
attempted by heating an excess of silver salt (AgOTs or AgTf) with 3-bromo-
1,1,1-trifluoro-prop-2-one to reflux in acetonitrile over 24 hours. Unfortunately, 
although ESI-MS of the crude reaction product mixture suggested the presence 
of the desired compounds, a complex mixture of crude reaction products was 
also evident, which prevented the purification of the target compounds. It is 
likely that the enhanced reactivity of the ketone group due to the neighboring 




4.3.3. Evaluation of the trifluoropropane-2,2-diol AdoMet derivative 
(4.2) as a potential Mtase co-substrate  
4.3.3.1. Thiopurine methyltransferase activity with 4.2. 
As earlier stated, thiopurine methyltransferase promiscuously methylates 
aromatic thiol substrates, which together with its demonstrated transfer of a 
methylketone group to 4-nitrobenzenethiol (213), made it an appropriate 
candidate to assess the potential of 4.2 as a methyltransferase co-substrate. The 
coupled spectrophometric assay for TPMT activity was previously performed in 
a volume of 1 mL (213, 290). However, using the same concentrations of the 
assay components, enzyme catalyzed methylation of 4-nitrothiophenol could be 
detected from assay volumes of 100 µL, making this assay amenable to a 96-




Figure 4.6. Adaptation of the TMPT activity assay to 96-well microplate format. 
Assays were performed in 96-well microplates to a total volume of 100 µL. Data 
points reflect the mean of duplicate experiments. (A) Reaction progress curves at 
different TPMT concentrations (   : 0 µM,     : 0.5 µM,   : 1.0 µM, ×: 6.0 µM). (B) 
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Under assay conditions identical to those used with AdoMet as the co-
substrate, it appeared that the rate of reduction in absorbance in the presence of 
the 4.2 derivative did not exceed that was occurring in the absence of the 
enzyme (Figure 4.7). This could have signified that the trifluoroketone group 
was not transferred to 4-nitrothiophenol, however, the possibility remained that 
a low level of transfer of the fluoroketone group by TPMT was masked by the 




































































































0 µM 0.5 µM 
1.0 µM 6.0 µM 
Figure 4.7. TPMT catalyzed transfer of the trifluoroketone group to 4-
nitrobenzene thiol. Reaction progress curves for fluoroketo-AdoMet utilization by 
TPMT. Assays were performed as earlier described and contained 50 µM of 
fluoroketo-AdoMet and the indicated concentration of TPMT.  
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As well, since the fluoroketo-AdoMet was obtained as a mixture of 
stereoisomers, an inherently low rate of trifluoromethyl ketone transfer would 
be exaggerated by the stereo-selectivity of TMPT, which would reduce the 
effective 4.2 concentration. This effective concentration would also be reduced 
by degradation of the AdoMet analogue (although the stability of the derivative 
in the assay was not directly examined). With this in mind, observation of the 
turnover of 4.2 by TPMT was attempted with the coupled fluorometric assay as 
the increased sensitivity of the fluorescent reporter would enable detection of 
low-level TPMT activity.  
Time-dependent TPMT catalyzed methylation of 4-nitrothiophenol 
utilizing AdoMet itself as the co-substrate, measured by the coupled 
fluorometric assay, mirrored the results obtained using the spectrophotometric 
assays (Figure 4.8A), indicating a linear correlation between the initial rate and 
TPMT concentrations up to 0.5 µM (Figure 4.9). Reaction progress curves for 
parallel reactions carried out with the 4.2 were virtually indistinguishable below 
enzyme concentrations of 1.0 µM, with no noticeable increase in fluorescence 
occurring above the background rate (Figure 4.8B). However, TPMT activity 
with 4.2 was detected by the fluorometric assay at enzyme concentrations of 1.0 
µM and greater and the transfer of the trifluoropropane-diol group was 
confirmed by HPLC analysis of the assay reaction products (Figure 4.8C). In 
addition, the initial rate of the reaction with 4.2 appeared to increase with TPMT 














































Figure 4.8. Modification of 4-nitrobenzenethiol by TPMT monitored by the coupled fluorometric 
assay. Reaction progress curves for TMPT activity at various concentrations in the presence of A) 50µM 
AdoMet and B) 100 µM 4.2. Data points reflect the mean of duplicate experiments. C) HPLC 
chromatograms of the reaction products from TPMT reactions with AdoMet and 4.2. The 
spectrophotometric properties of synthetic standards were used to identify the respective modified 4-










1 µM TPMT & 50 µM AdoMet 
1 µM TPMT & 100 µM 4.2 








As mentioned earlier, 4.2 was obtained as a mixture of stereoisomers 
(approximately 50:50 according to 19F NMR). Therefore, the observed activity 
of TPMT actually represents turnover of the viable stereoisomer, effectively 
reducing the experimentally relevant analogue concentration by half. This 
would mean that TPMT activity in the presence of 100% of the appropriate 
isomer is likely to exceed what was observed here. Even so, in spite of the 
diminished TPMT activity with 4.2 relative to AdoMet, it was still gratifying to 
observe transfer of the trifluoropropane-diol group under the conditions used 
here. Invariably, the  transfer of the alternative groups such as extended alkyl 



























Figure 4.9. Dependence of TMPT activity on enzyme concentration. The initial 
rate of TMPT activity was measured in the presence of 50 µM AdoMet (open 
circles) and 100 µM 4.2 (closed circles). Error bars represent the standard 
deviation of the mean from duplicate experiments. 
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extended reaction times (2 – 24 hours) as well as enzyme and analogue 
concentrations in great excess of what was used in this study (1 – 20 µM and 10 
– 300 µM, respectively) (201–205, 207, 210–212, 291). Quantitative transfer 
has only been demonstrated in the instance of the methylketone AdoMet 
analogue (213). Therefore, while the reduced rate of transfer of the 
trifluoropropane-diol group relative to AdoMet may not be unusual, its transfer 
from the AdoMet analogue synthesized here compares favorably with that 
shown with other AdoMet analogues. 
The physical properties of the trifluoropropan-one/diol, such as its larger 
size and increased hydrophobicity relative to a methyl group, may contribute to 
its reduced rate of transfer by TPMT. These properties may be envisioned to 
bring about steric conflicts or unfavorable interactions within the enzyme active 
site that result in diminished or abolished binding of the AdoMet analogue. This 
is perhaps unlikely, given the wide variety in structures that are transferrable by 
Mtases (Chapter 1), several of which would present, similar if not greater steric 
problems.  
A more fitting explanation seems to be that while the enzyme is able to 
bind the AdoMet derivative, it is unable to efficiently effect the transfer of the 
trifluoromethyl ketone group to the thiol substrate. AdoMet-dependent 
methyltransferases typically accomplish substrate methylation (or other 
modifications) via an SN2 type mechanism (Chapter 1 and (292–294)). In the 
case of the 4.2, the highly electronegative trifluoromethyl group would 
presumably pull electron density away from the α-carbon, thus increasing its 
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susceptibility to nucleophilic attack and this effect that would be augmented by 
the presence of the 2 hydroxyl groups. This was reflected by computational 
calculations of the thermodynamics associated with the alkylation of 
nucleophilc acceptors (Table 4.1).  
 
Table 4.1. Energy of transfer (kJ/ mol) for various groups to 
nucleophilic acceptors (295–297). 
 Nucleophilic Acceptor 
Group 
Transferred    
 -567.05 -586.89 -739.15 
 -671.70 -586.89 -763.67 
 -716.43 -634.41 -819.72 
-702.60 -619.21 -797.06 
-671.79 -587.32 -771.90 
-704.06 -626.89 -808.52 
-522.16 -505.98 -681.79 
-1258.60 -1181.07 -1368.13 
 
Nucleophilic acceptors represent Mtase substrates. Structure drawing and thermochemical 
calculations were peformed in Spartan 10 software (Waveform Inc.), using the default 
protocol for the G3(MP2) thermochemical recipe (288–290). This recipe has been reported 
to reproduce experimental heats of formation for a wide variety of small molecules to within 
6 kJ/mol (mean absolute error). Briefly, the heat of formation for a molecule is calculated 
from two equilibrium geometry calculations (at HF/6-31G* and MP2/6-31G*), a HF/6-31G* 
frequency calculation, a MP2/6-311++G (2df, 2p) energy calculation and a QCISD(T)/6-
31G* energy calculation. The overall reaction energies for a chemical equation are then 
calculated using the equation: ∆E = (Eproduct1 + Eproduct2) – (Ereactant1 + Ereactant2) 
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Surprisingly, these calculations predict the transfer of trifluoromethyl containing 
ketones or germinal diols to be more thermodynamically favored thaN their 
methyl group counterparts. Although this seemingly contradicts experimental 
observations, these calculations did not include the kinetic aspects of the 
reaction, which would contribute significantly to the overall favorability of the 
reaction. 
By the above reasoning, substrate methylation with AdoMet would be 
reduced in the presence of 4.2 as the two compounds would compete for TPMT 
active sites, resulting in fewer available active sites being available for 
productive AdoMet binding due to their occupation by 4.2. Preliminary 
assessments of this hypothesized effect by 4.2 were performed by monitoring 
time-dependent TPMT catalyzed methylation of 4-nitrobenzenethiol in the 
presence of 4.2. As depicted in Figure 4.10, there is a clear reduction in AdoMet 
dependent TPMT activity in the presence of increasing concentrations of 4.2, 
indicating competition between 4.2 and AdoMet for the TMPT active site. This 
finding may also be indicative of the reduced susceptibility of the α-carbon 
from the trifluoroprop-2-one/ diol group to nucleophilic attack by the sulfur 
from 4-nitrothiophenol. It is worth mentioning that irreversible inhibition by 4.2 
cannot be excluded in explaining these observations. Trifluoromethyl ketone 
(TFMK) compounds and their corresponding germinal diols are known 
inhibitors of proteases, phospholipases and esterases, due to the nucleophilic 
attack by an amino acid residue at the TFMK carbonyl carbon, whose 
electronegativity is enhanced by the trifluoromethyl group (277, 278). Although 
149 
 
the derivative obtained here was predominantly as a germinal diol, this would 
be in equilibrium with the corresponding ketone that could then be prone to 
nucleophilic attack from a basic active site residue. Conversely, the geminal diol 
product may cause inhibition by hydrogen bonding to key acidic/ basic residues 




4.4. Conclusions, perspectives and future work 
 A novel analogue of AdoMet featuring a trifluoromethyl group has been 
synthesized. Using the thiopurine methyltransferase as a representative Mtase, 
enzyme catalyzed transfer of this group to a small molecule acceptor was 
demonstrated, which extends the collection of chemical moieties that can be 



























Figure 4.10. Effect of 4.2 on TPMT-catalyzed methylation of 4-nitrothiophenol. 
TMPT activity was monitored with the coupled fluorometric assay. Individual 
reactions included 50 µM AdoMet and varying concentrations of 4.2. Error bars 
represent the standard deviation of the mean of duplicate experiments. 
150 
 
analogue competes with AdoMet for the enzyme, but transfer from the analogue 
occurred to a lesser degree that AdoMet, which was likely the result of chemical 
barriers hindering the transfer of the trifluoropropane diol group to the acceptor.  
The transfer of the trifluoroketone group may be promoted in the 
presence of increased concentrations of the MTase and/or the 
trifluoromethylketone-AdoMet.  This could be particularly useful for further 
studies of the amenability of the modified product to coupling with ketone 
reactive molecules for purposes of substrate labeling. Lee and co-workers made 
use of the reaction between ketones and hydroxylamines to generate an oxime 
from methylketone-modified Mtase substrates and a fluorescent reporter that 
featured a hydroxylamine group (213). As illustrated in Figure 4.11, a similar 
approach could be employed for trifluoroketone modified substrates, however, 
in this instance, the highly electronegative trifluoromethyl group would make 










The increased susceptibility towards conjugative chemistry that is 
imparted by the trifluoromethyl ketone moiety (along with the potential for 
additional substrate labeling through 19F NMR) makes the development of 
AdoMet analogues featuring this group a promising area for continued research. 
The application of a combinatorial-type approach to structure-activity studies 
could prove useful in improving the turnover rate of fluoroketo groups. As 
alluded to earlier, the low rate of transfer of the trifluoromethyl ketone group 
Figure 4.11. Attachment of reporter molecules to trifluoroketone modified Mtase 
substrates. The mechanism of oxime formation from the reaction between the ketone 
group on a modified Mtase substrate and the hydroxylamine group from a 
hydroxylamine derivatized reporter molecule (represented by R; Alexa Fluor 647 for 
example) is shown. The electronegative trifluoromethyl group draws electron density 
away from the carbonyl carbon, making it more susceptible to nucleophilic attack 
from the nitrogen.  
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may derive from the proximity of the trifluoromethyl and ketone functions. 
Mitigation of this effect may be achieved by extending the distance between the 
carbonyl carbon and the sulfonium centre. This could be coupled with α, β- or 
β, γ- unsaturation, which has been shown to aid the transfer of non-native 
groups (207). Alternatively, increasing the number of carbons between the 
carbonyl group and the point of attachment to the thioether may alleviate the 
negative impact on transfer caused by the increased electrophilicity that is 
caused by the trifluoromethyl group while preserving the reactivity of the 
ketone group for substrate labeling.  
The generation of such libraries of AdoMet analogues is presently 
limited by the low synthetic yield as well as product instability. Although the 
use of iodinated alkylating agents was shown here to positively affect yield, 
further improvements may be achieved by revisiting the syntheses of the 
activated alkylating agents. Preliminary attempts at obtaining these agents were 
largely unsuccessful and the harsh conditions of extended reflux may have been 
a causative factor in these failures. However, the advantages afforded by a better 
post-alkylation leaving group that can simultaneously serve as a stabilizing 
counter-ion to the sulfonium ion, in addition to improving synthetic yields make 
this an attractive route towards the synthesis of AdoMet analogues. 
The inherent instability of the AdoMet analogue (in conjunction with 
Mtase stereo-selectivity) limits the apparent rate of transfer of the trifluoroketo 
group by the enzyme. Sulfonium salts are notoriously unstable but their 
decomposition can be greatly slowed by their isolation as a halide or tosylate 
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salt. In this work, the presence of the tosylate anion likely achieves this 
stabilizing effect during synthesis, but since this anion is lost during HPLC 
purification, the analogue becomes vulnerable to decomposition. However, this 
counterion can be reintroduced through ion exchange chromatography. 
Separation of the stereo-isomers would prove to be a difficult undertaking and 
would require additional optimizations of the purification method utilizing 
HPLC columns with reduced particle size or ultra performance liquid 
chromatography (UPLC). 
Future efforts in the development of fluorine and ketone containing 
AdoMet analogues will aid the continued study of Mtases, particularly with 
respect to the identification of novel substrates and functional probing. With 
regards to TSR, the demonstration of the transfer of a fluoroketo-AdoMet would 
be significant as this could eventually lead to TSR mediated RNA and ribosome 
labeling. Such modified ribosomes could be used in the examination of 
ribosome fine structure or the identification of new ribosomal Mtase targets. 
Furthermore, studies of the functional capabilities of these modified ribosomes 










CHAPTER 5: MOLECULAR INTERACTIONS BETWEEN THIOSTREPTON 
AND THE TIPAS RESISTANCE PROTEIN FROM STREPTOMYCES LIVIDANS  
 
5.1. Preface  
 The reaction between thiostrepton and a cysteine residue from TIPAS or 
TIPAL is known to result in irreversible antibiotic binding that results in some 
Streptomyces strains exhibiting thiostrepton resistance. However, evidence also 
suggests the importance of a significant reversible protein-antibiotic interaction 
for biological activity. Several thiopeptides possessing DHA tails of varying 
length are able to covalently bind TIPAL/ TIPAS, while a subset of tailless 
analogues of these thiopeptides (including those of thiostrepton), were able to 
accomplish ptipA induction in vivo (220). It would be expected that the TIP 
protein-thiopeptide interaction is not solely dependent on covalent binding and 
that thiopeptide recognition by TIP proteins would be essential to the eventual 
irreversible protein-antibiotic interaction that leads to thiopeptide resistance. 
Our goal was to explore this type of interaction between thiostrepton and these 
proteins. 
This chapter discusses the direct examination of the non-covalent TIP 
protein-thiopeptide interaction using the TIPAS protein and thiostrepton as the 
model system. In the absence of a structure of the TIPAS-thiostrepton complex, 
molecular modeling was used as a cursory tool for the assessment of this 
binding interaction, based on available NMR data (226). Recombinant 
techniques were used to engineer protein variants of TIPAS lacking the reactive 
residue, and qualitative and quantitative investigations of their binding to 
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thiostrepton and synthesized thiostrepton derivatives lacking the reactive 
molecular component were performed. Additional thiostrepton derivatives were 
synthesized to probe the structural features of thiostrepton important for 
recognition and non-covalent binding by TIPAS.  
 
5.2. Materials and Methods 
5.2.1. Chemicals and reagents 
Dimethyl sulfoxide, dimethyl formamide, acetonitrile and trifluoroacetic 
acid were from Caledon Laboratory Chemicals (Caledon, Canada) and 
triethylamine was from EMD Chemicals (Gibbstown, USA). Thiostrepton 
(Streptomyces azureus; ≥ 90% purity) and MENSA were from Sigma (Oakville, 
Canada). Sodium cyanoborohydride, cyanogen bromide and diethylamine were 
from Sigma-Aldrich. Reagents for PCR and DNA manipulation were as listed in 
Chapter 3 (Section 3.2.1.1.). 
 
5.2.2. Equipment 
5.2.2.1. Protein chromatography 
Protein purifications were carried out with a Waters Chromatography 
system (Waters 626 pump, 600s controller and 2996 photodiode array detector 
and Millennium 3.2 software). Nickel affinity and anion exchange 
chromatography were performed using HisTrap™ HP (1 mL), HiTrap 
Benzamidine FF™ (1 mL) and MonoQ columns; all from GE Healthcare 
(formerly Amersham Biosciences, Uppsala, Sweden).  
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5.2.2.2. Flash chromatography 
Thiostrepton derivatives were purified by Flash chromatography using 
an Isolera Flash Chromatography System (Biotage, Uppsala, Sweden) using 
pre-packed silica columns (Biotage).  
5.2.2.3. Fractionation of peptide digests using high performance liquid 
chromatography  
HPLC purification was performed using a Waters Chromatography 
system (Waters 626 pump, 600s controller and 2996 photodiode array detector 
and Millennium 3.2 software) with a Waters C18 column (5 µM, 3.9 mm × 300 
mm). The polar and non-polar mobile phases were 0.1% aqueous TFA and 
acetonitrile, respectively. 
5.2.2.4. Mass spectrometry 
Protein samples were prepared by first exchanging the buffer for doubly 
distilled water (ddH2O) using a Nanosep centrifugation device (molecular 
weight cut-off of 3000 Da) and the resulting solution was diluted with a mixture 
of acetonitrile and water (1:1) containing 0.2% formic acid. Thiostrepton 
derivatives were initially dissolved in acetonitrile, then diluted with a mixture of 
acetonitrile and water (1:1) containing 0.2% formic acid. Mass spectrometry 
was performed utilizing a Micromass Q-TOF Ultima Global mass spectrometer 






5.2.2.5. Circular dichroism 
 Spectra were acquired with a Jasco J715 spectropolarimeter, in the low 
UV region (190 – 250 nm), with a band width of 1 nm, at a scanning speed of 
100 nm/ min. Spectra from 15 scans were averaged. Samples were prepared at 
0.1 mg/ mL in a buffer comprised of 20 mM Tris pH 7.5, 5 mM DTT, 50 mM 
NaCl, 5 mM MgCl2, 1 mM EDTA and 10% glycerol (v/v)). 
5.2.2.6. Fluorescence spectroscopy 
Fluorescence measurements were carried out in black 96 well 
microplates (Corning Life Sciences, Tewksbury, USA) using a SpectraMax M5 
(Molecular Devices, Dowington, USA) calibrated to an internal standard. 
5.2.2.7. Nuclear magnetic resonance 
Thiostrepton derivatives (2 – 4 mg) were dissolved in 600 – 700 µL of a 
mixture of deuterated chloroform and methanol (4:1). NMR spectra were 
acquired using either Bruker 300 MHz or 500 MHz spectrometers and chemical 
shifts are reported in ppm, relative to the solvent peaks (CDCl3; 7.24 ppm). 
5.2.2.8. Isothermal titration calorimetry  
ITC was performed using an ITC200 (Microcal, now GE Healthcare, 
Piscataway, USA) and the data analyzed using Origin (5.0) software. 
5.2.2.9. Polymerase chain reactions  
 PCR reactions were performed with a Techne TC-512 thermal cycler 





5.2.3. General methods 
5.2.3.1. DNA manipulation 
DNA manipulation and cloning were performed in accordance with 
standard protocols provided by Sambrook et al. (264). 
5.2.3.2. Electrophoresis 
Protein and DNA electrophoresis were performed as described in 
Chapter 3 (Section 3.2.3.1.). 
5.2.3.3. Protein characterization 
Protein mass spectrometry was performed as described in Section 
3.2.3.2. Protein quantification was performed as described in Section 3.2.3.3. 
5.2.3.4. Expression, purification and characterization of TIP proteins 
The DNA sequence encoding TIPAS as well as a sequence encoding the 
C-terminal 90 amino acids of TIPAS were amplified from Streptomyces lividans 
2K4 genomic DNA (generously supplied by Professor Gerard Wright, 
McMaster University) using PCR techniques (Table 1). Primers were designed 
to introduce restriction sites for Nde1 and BamH1 at the 5’ and 3’ end of these 
sequences, respectively. After visualization of the ethidium bromide stained 
agarose gels, the desired amplicons were purified, and then doubly digested 
with Nde1 and BamH1. The digested DNA was then inserted into the pET28a 
plasmid doubly digested with the same restriction enzymes, using T4 DNA 
ligase (Fermentas), generating plasmids bearing the coding region for TIPAS or 
TIPASt. Ligation reactions were typically conducted in a volume of 20 µL with 
a 3:1 ratio of vector to insert DNA and 1 unit of ligase at 10-12°C, overnight. A 
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10 µL portion of this ligation reaction was then used to transform chemically 
competent E. coil DH5α cells, which were then spread (100 µL) on to nutrient 
agar plates containing kanamycin (30 µg/ mL) and incubated overnight at 37 °C. 
Single colonies were then selected and cultured overnight at 37 °C in 2 mL of 
Luria Bertani broth containing kanamycin (30 µg/ mL) and the plasmid 
harvested using the Plasmid Miniprep Kit (Qiagen, Toronto, Canada). The 
presence of the TIPAS gene/ coding region for TIPASt was confirmed by DNA 
sequencing at the Mobix Lab (McMaster University, Hamilton, Canada) (or 
protein analysis using SDS-PAGE after induction by addition of 1 mM IPTG), 
after which these plasmids were used to transform E. coli BL21 cells.  
E. coli BL21 transformed with plasmids bearing the coding region for 
TIPAS or TIPASt were grown in 1 L of Luria-Bertani broth containing 
kanamycin (30 µg/ ml) at 37 ºC to an optical density of 0.6-0.8 (600 nm). 
Protein expression was induced by the addition of 1 mM IPTG and the culture 
incubated at 37 ºC for an additional 3-5 hours with shaking. Cells were then 
pelleted by centrifugation (8000 × g for 20 minutes at 4 ºC) and then 
resuspended in lysis/ loading buffer comprised of 50 mM Tris pH 7.5, 500 mM 
NaCl, 5 mM MgCl2, 20 mM imidazole and 10% glycerol (v/v). Cell disruption 
was performed as described in Chapter 3 and cellular debris were removed by 
centrifugation (48,300 × g for 20 minutes at 4 ºC) and the crude lysate 
containing the soluble proteins was directly introduced onto a 1 mL nickel 
affinity column (GE Healthcare), pre-equlibrated with lysis/ loading buffer. 
Non-binding proteins were eluted with lysis/ loading buffer and the 
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hexahistidine-tagged TIP proteins were eluted with a buffer containing 50 mM 
Tris pH 7.5, 1 M NaCl, 5 mM MgCl2, 500 mM imidazole and 10% glycerol 
(v/v), upon which EDTA was immediately added to the collected fractions at 
final concentration of 2 mM. The protein solution was then dialyzed twice, for 3 
hours against 500 mL of fresh storage buffer (20 mM Tris pH 7.5, 5 mM DTT, 
50 mM NaCl, 5 mM MgCl2, 1 mM EDTA and 10% glycerol (v/v)) and then 
overnight against 1L of fresh storage buffer. To remove the N-terminal hexa-
histidine tag, CaCl2 was added to protein solutions at a final concentration of 2.5 
mM and solutions were incubated with thrombin (GE Healthcare; 1U/100 µg of 
protein) overnight at 4 ºC. Tag-free proteins were obtained after injection onto a 
nickel affinity column attached in series to a benzamidine column (GE 
Healthcare) and elution with loading/ lysis buffer. EDTA was immediately 
added to a final concentration of 2 mM to the collected fractions and the protein 
solution was dialyzed against storage buffer overnight. The solution was divided 
into aliquoted into 200 µL fractions, frozen with liquid nitrogen and stored at -
80ºC for future use. Protein yields were typically 30-50 mg from 3 – 5 g of 
pelleted cells. Point mutations (C207A, C214A, and C214S) were introduced 
into TIPAS by PCR driven overlap and extension (Table 5.1) and the mutants 










Amino acid sequence of recombinant TIPAS; C207 and C214 are underlined. 
G  S  H  M  G  I  N  L  T  P  E  E  K  F  E  V  F  G  D  F  D  P  D  Q  Y  E  E  E  
V  R  E  R  W  G  N  T  D  A  Y  R  Q  S  K  E  K  T  A  S  Y  T  K  E  D  W  Q  
R  I  Q  D  E  A  D  E  L  T  R  R  F  V  A  L  M  D  A  G  E  P  A  D  S  E  G  A  
M  D  A  A  E  D  H  R  Q  G  I  A  R  N  H  Y  D  C  G  Y  E  M  H  T  C  L  G  
E  M  Y  V  S  D  E  R  F  T  R  N  I  D  A  A  K  P  G  L  A  A  Y  M  R  D  A  I  
L  A  N  A  V  R  H  T  P 
 
 
Amino acid sequence of TIPASt 
G  S  H  M  Q  D  E  A  D  E  L  T  R  R  F  V  A  L  M  D  A  G  E  P  A  D  S  
E  G  A  M  D  A  A  E  D  H  R  Q  G   I  A  R  N  H  Y  D  C  G  Y  E  M  H  T  
C  L  G  E  M  Y  V  S  D  E  R  F  T  R  N  I  D  A  A  K  P  G  L  A  A  Y  M  
R  D  A  I  L  A  N  A  V  R  H  T  P 
 
Table 5.1. PCR primers used for TIP protein expression and point mutant 
generation 
 Forward Reverse 
TIPAS GCCATATGGGAATCAACCTCACCCCGGAGG GCGGGATCCTTATCAGGGGGTGTGCC 
TIPASt GCCATATGCAGGACGAGGCCGACGAGCTC GCGGGATCCTTATCAGGGGGTGTGCC 
Point Mutants 
C207A CACTACGACGCGGGGTACGAGATGCACACCTGCCT TCGTACCCCGCGTCGTAGTGGTTGCGGGCGATGCC 
C214A CACACCGCGCTGGGCGAGATG CTCGCCCAGCGCGGTGTGCATC 













Table 5.2. PCR conditions for amplification of the 
coding sequence for TIPAS and TIPASt from S. 
lividans genomic DNA 
 Minutes Temperature ( ºC) 
Initial denaturation 5 95 
Hot  start 
10 cycles   
Denaturation 1 95 
Annealing 1 60 
Extension  1.5 72 
Final Extension 10 72 
Reactions were carried out in a total volume of 50 µL 
and contained 1 unit of pfu polymerase, 2.5 mM of 

















5.2.3.5. Ion exchange chromatography 
Protein samples were dialyzed overnight against a buffer containing 50 
mM Tris (pH 7.5) and 5 mM DTT (for small volume samples, the buffer was 
replaced using a NanoSep centrifugation device). The protein solutions were 
then applied to a MonoQ anion exchange column, equilibrated with the same 





Table 5.3. PCR conditions to generate full length 
TIPAS mutant genes. 
 Minutes Temperature ( ºC) 
Initial denaturation 5 95 
Hot  start 
10 cycles   
Denaturation 2 95 
Annealing 1 
60 – 50 (reduce by 1º 
every cycle) 
Extension 2.5 72 
PAUSE – ADD T7 
PRIMERS 
5 72 
25 cycles   
Denaturation 2 95 
Annealing 1 50 
Extension 2.5 72 
Final Extension 10 72 
Reactions were carried out in a total volume of 50 µL and 
contained 1 unit of pfu polymerase, 2.5 mM of dNTPs, 
equal concentrations of 5’ and 3’ gene fragments with the 
total of DNA not exceeding 100 ng and 10% DMSO 
(v/v). 5’and 3’ fragments were generated from the TIPAS 
gene using standard PCR conditions: 25 cycles, 
Denaturation: 95ºC for 2 minutes; annealing: 50ºC for 1 
minute; extension: 72ºC for 1.5 minutes 
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5.2.3.6. Reaction of TIP proteins with thiostrepton 
TIPAS or its variants were reacted with thiostrepton according to the 
method described in Chiu et al. (225). Sodium cyanoborohydride was added to 
protein solutions (3.5 equivalents) and this mixture was left standing for 5 -10 
minutes at room temperature. After the deactivation of excess sodium 
cyanoborohydride by the addition of 2 volumes of acetone, thiostrepton 
(prepared as a solution in DMSO) was added (5 equivalents) and this mixture 
was placed in a sealed vessel on a platform shaker for 60 minutes at room 
temperature. After incubation, the reaction mixture was passed through a 0.2 
micron cellulose acetate filter to remove precipitated thiostrepton and washed 
(and the buffer exchanged to ddH2O for purposed of ESI-MS analysis) using a 
NanoSep centrifugal device (molecular weight cut-off: 3000 Da; Pall Life 
Sciences) to remove excess DMSO and unreacted antibiotic. 
5.2.3.7. Cyanogen bromide digestion of TIP proteins & protein-thiostrepton 
complexes 
 Approximately 1-2 mg of unbound protein or protein-thiostrepton 
complex was precipitated using trichloroacetic acid7. The dried precipitate was 
dissolved in 800 µl of degassed8 87.5 % formic acid. Cyanogen bromide, 
                                                            
7One volume of TCA was added to 4 volumes of protein, and this solution was 
incubated at 4°C for 10 minutes. Precipitated protein was then pelleted by 
centrifugation and washed 3 times with cold acetone. After the final wash, the 
supernatant was decanted and the pellet heat-dried. 
8 Cleavage efficiency was considerably reduced without degassing. 
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prepared as a 1 mL solution in degassed acetonitrile9, was added to a final 
concentration that was 200 M in excess of that of methionine (298) and the 
mixture incubated in the dark, at room temperature for 24 hours. The reaction 
was quenched by the addition of 5 volumes of ddH2O, and then lyophilized. 
5.2.3.8. Synthesis of thiostrepton derivatives 
5.2.3.8.1. Truncated derivatives. 
Truncated thiostrepton derivatives were prepared according to previous 
methodologies (90, 239).  
5.1. Diethylamine (5 ml) was added to a solution of thiostrepton (0.3 mmoles/ 
500 mg in 25 ml of chloroform), which was stirring at 0°C. The mixture was 
allowed to warm to room temperature, and stirred for an additional 4 hours. The 
volatiles were coevaporated with toluene and the residue purified by silica gel 
chromatography (2-5% CH3OH in CHCl3.).  
70% yield, white powder, m.p.: 230 – 245 ºC, Rf: 0.34 (CH3Cl/MeOH 9:1). 
1H 
NMR (300 MHz, CDCl3/ CD3OD 4:1) 9.7 (s, 1H), 8.64 (d,  J = 9.0, 1H), 8.14 
(s, 1H), 8.13 (s, 1H), 8.03 (s, 1H), 7.86 (s, 1H), 7.42 (s, 1H), 7.16 (s, 1H), 6.95 
(d, J = 8.2, 1H), 6.92 (d, J = 8.2, 1H), 6.73 (d,  J = 9.9, 1H), 6.49 (d,  J = 1.5. 
1H), 6.32 - 6.16 (m, 2H), 6.07 (q,  J = 7, 1H), 5.69 (d,  J = 1.6, 1H), 5.67-5.56 
(m, 2H), 5.49 (m, 1H), 5.27-5.13 (m, 3H), 4.83 (dd,  J = 9.3, 12.9, 1H), 4.68 - 
4.51 (m, 1H), 4.37 - 4.22 (m, 2H), 3.72 - 3.61 (m, 2H), 3.56 - 3.44 (m, 2H), 3.02 
(dd, J = 11.71, 12.78, 1H), 2.15 (t, J = 12.9, 1H),  1.85 - 1.72 (m, 1H), 1.56 (d, J 
= 6.5, 3H), 1.46 (d, J = 7.0, 3H), 1.28 (d, J = 6.5, 3H), 1.23 (d, J = 6.5, 3H), 
                                                            
9 This was performed in the fumehood as CNBr is a highly toxic carcinogen. 
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1.15 (d, J = 6.4, 4H) , 1.12 - 0.98 (m, 8H), 0.85 (d, J = 6.5, 3H), 0.74 (t, J = 7.1, 
4H), 0.66 (d, J = 6.0, 3H). HRMS calculated for [ C69H82N18O17S5+2H
+] 
1596.4865, found (ESI) 1596.4883. 
5.2. Diethylamine (4.5 ml) was added to a stirring mixture of 1 in chloroform 
(0.062 mmoles /100 mg in 5 ml CHCl3), at 0°C. The mixture was allowed to 
warm to room temperature and stirred for an additional 18 hours. After 
coevaporation of the volatiles with toluene, the crude mixture was purified by 
silica gel chromatography (2-5 % CH3OH in CHCl3.).  
40% yield, white powder, m.p.: 230 – 245 ºC, Rf: 0.29 (CH3Cl/MeOH 9:1).
 1H 
NMR (300 MHz, CDCl3/ CD3OD 4:1) 9.73 (s, 1H), 8.64 (d, J = 7.6, 1H), 8.14 
(s, 1H), 8.11 (s,1H), 8.02 (s, 1H), 7.87 (s, 1H), 7.42 (s, 1H), 7.16 (s, 1H), 7.03 – 
6.89 (m, 2H), 6.73 (d, J = 9.1, 1H), 6.40 – 6.17 (m, 2H), 6.15 – 6.02 (m, 1H), 
5.77 – 5.67 (m, 1H), 5.67-5.59 (m, 2H), 5.31-5.10 (m, 3H), 4.95-4.75 (m, 1H), 
4.68 – 4.51 (m, 1H), 4.41 – 4.17 (m, 3H), 3.72 – 3.63 (m, 2H), 3.55 – 3.45 (m, 
2H), 3.08 – 2.96 (m, 1H), 2.93 – 2.67 (m, 2H), 2.16 (t, J = 12.8, 1H), 1.86 – 
1.73 (m, 1H), 1.57 (d, J = 5.3, 3H),  1.46 (d, J = 5.7, 3H),  1.35 – 1.20 (m, 7H), 
1.20 – 1.12 (m, 5H), 1.11 – 1.00 (m, 8H), 0.85 (d, J = 6.4, 3H), 0.74 (t, J = 6.4, 
4H), 0.70 – 0.60 (m, 3H). HRMS calculated for [ C66H79N17O16S5+2H
+] 
1527.4651, found (ESI) 1527.4644 
The spectroscopic and physical properties of synthesized 5.1 and 5.2 were 





5.2.3.8.2. Michael adducts 
Michael adducts of thiostrepton were prepared according to the 
procedures described in Chapter 2 (246). To a stirring mixture of thiostrepton or 
5.1 under an inert atmosphere at room temperature (0.03 mmoles/ 50 mg in 1.5 
ml of dimethylformamide), were added triethylamine (0.3 mmoles; 42 µl), 
followed by MENSA (0.03 mmoles; prepared as a 150 mM stock solution in 
ddH2O). The mixture was cooled to 4 °C and stirred for an additional 18 hours. 
The solvent was removed under vacuum and the residual orange powder 
purified by silica gel chromatography (7 – 60 % CH3OH in CHCl3). 
5.3: 50% yield, white powder, m.p.: 240 – 250 ºC, Rf: 0.54 (CH3Cl/MeOH 7:3). 
1H NMR (300 MHz, CDCl3/ CD3OD 4:1) 
1H NMR (300 MHz, CDCl3/ CD3OD 
4:1) 9.74 (s, 1H), 8.64 (d, J = 9.1, 1H), 8.22 – 8.09 (m, 2H), 8.03 (s, 1H), 7.87 
(s, 1H), 7.42 (s, 1H), 7.17 (s, 1H), 7.05 – 6.89 (m, 2H), 6.73 (d, J = 10.1, 1H), 
6.33 – 6.15 (m, 2H), 6.07 (q, J = 7.0, 1H), 5.76 – 5.67 (m, 1H), 5.61 – 5.57 (m, 
2H), 5.57 – 5.47 (m, 1H), 5.29 – 5.09 (m, 3H), 4.82 (dd, J = 9.2, 12.72, 1H), 
4.68 – 4.51 (m, 1H), 4.32 – 4.23 (m, 2H), 3.71 – 3.62 (m, 2H), 3.52 – 3.45 (m, 
2H), 3.07 – 3.00 (m, 1H), 2.82 (d, J = 4.4, 1H), 2.81 – 2.71 (m, 1H), 2.15 (t, J = 
13.0, 1H), 1.89 – 1.84 (m, 1H), 1.83 – 1.72 (m, 1H), 1.57 (d, J = 6.5, 3H),  1.46 
(d, J = 7.0, 3H), 1.29 (d, J = 5.7, 3H), 1.23 (d, J = 6.7, 3H),  1.14 (d, J = 6.4, 
4H), 1.10 (s, 3H), 1.06 – 0.99 (m, 6H), 0.85 (d, J = 6.9, 3H), 0.74 (t, J = 7.0, 
4H), 0.66 (d, J = 6.6, 3H). HRMS calculated for [ C74H92N19O21S7+2H
+] 
1807.4832, found (ESI) 1807.4838 
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5.4. 20% yield, white powder, m.p.: 240 – 250 ºC, Rf: 0.61 (CH3Cl/MeOH 7:3). 
1H NMR (300 MHz, CDCl3/ CD3OD 4:1) 9.73 (s, 1H), 8.65 (d, J = 8.0, 1H), 
8.22 – 8.08 (m, 2H), 8.02 (s, 1H), 7.84 (s, 1H), 7.42 (s, 1H), 7.16 (s, 1H), 7.02 – 
6.91 (m, 2H), 6.73 (d, J = 9.99, 1H), 6.47 (d, J = 4.2, 1H),  6.31 – 6.15 (m, 2H), 
6.08 (q, J = 7.0, 1H), 5.73 – 5.57 (m, 2H), 5.53 – 5.47 (m, 1H), 5.25 – 5.11 (m, 
2H), 4.90 – 4.77 (m, 1H), 4.67 – 4.54 (m, 1H), 4.37 – 4.21 (m, 2H), 3.70 -3.62 
(m, 2H), 3.53 – 3.46 (m, 2H), 2.83 (d, J = 4.4, 2H), 2.78 – 2.72 (m, 2H), 2.25 – 
2.10 (m, 1H), 1.93 – 1.83 (m, 1H), 1.81 – 1.74 (m, 1H), 1.57 (d, J = 6.52, 3H), 
1.46 (d, J = 7.0, 3H), 1.29 (d, J = 5.7, 3H), 1.23 (d, J = 6.7, 4H), 1.17 (d, J = 5.8, 
4H), 1.14 – 1.10 (s, 4H), 1.09 – 1.01 (m, 10H), 0.92 – 0.82 (m, 5H), 0.81 – 0.66 
(m,7H). HRMS calculated for [ C71H88N18O20S7 + H
+] 1737.4600, found (ESI) 
1737.4546.  
5.2.3.9. Fluorescence quenching of TIPAS  
Protein-antibiotic reactions were performed as described in Section 
5.2.3.2, with 10 µM of protein and varying amounts of thiostrepton or its 
truncated derivatives. Fluorescence measurements were carried out on 200 µl of 
the filtered and washed reaction using an excitation wavelength of 278 nm and 
emission at 346 nm. 
5.2.3.10. Isothermal titration calorimetry 
 Prior to ITC experiments, protein to be used was first dialyzed overnight 
against a buffer comprised of 20 mM Tris pH 7.5, 10% glycerol (v/v) and 5 mM 
2-mercaptoethanol. The dialysate was used to prepare working solutions of 
protein and the buffer was used to prepare thiostrepton analogues at 7 µM and 
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100 µM, both containing DMSO at a final concentration of 15% (v/v). 
Titrations were performed at 25°C and consisted of 16 or 17 injections of 2.0 µL 
or 2.2 µL of antibiotic solution into a sample cell containing protein solution. 
The heat of dilution/ mixing was obtained from injections of the respective 
antibiotic solutions into buffer containing no protein (with DMSO present at 
15% v/v)). After subtraction of the heats of dilution, titration curves were 
analyzed using Origin software and the data fitted using the model for one set of 
binding sites (Please refer to Appendix 4 for curve fitting methodologies) 
5.2.3.11. Molecular modeling 
 Protein Data Bank (PDB) files of TIPAS and thiostrepton were 
individually imported into Molegro Virtual Docker v. 5.0 (Molegro, Aarhus, 
Denmark). TIPAS was designated as the protein/ receptor and thiostrepton as 
the ligand. Both structures were edited to include bonds missing from the PDB 
file, correct improper bonds, add explicit hydrogen atoms and assign missing 
charges. As well, the flexible bonds in thiostrepton were allowed their full range 
of rotation. The thiostrepton binding site (cavity) was defined as a 16Å region 
that encompassed the binding site proposed by Kahmann et al.(226). Docking 
was constrained to the designated cavity and the entire simulation consisted of 
15 runs of 1500 iterations each, using the MolDock SE heuristic search 
algorithm and MolDock scoring function (299). The poses exhibiting the 20 






5.3. Results and Discussion 
5.3.1. Modeling the TIPAS-thiostrepton interaction  
The binding of thiostrepton to its proposed TIPAS binding site was 
initially examined in silico to ascertain the possibility that such binding would 
allow for positions of the thiostrepton tail that would facilitate Michael addition 
with C214, the reactive cysteine found in the TIP proteins. Binding simulations 
were carefully designed so as not to introduce bias into the results; structural 
editing was limited to bond corrections and inclusion of hydrogen atoms and the 
rotatable bonds in thiostrepton were allowed their full degree of freedom. Also, 









A sample of the docking results is presented in Figure 5.2. Of the top 20 
poses returned by the docking simulation, six of these depicted the core of the 
thiostrepton molecule embedded in the hydrophobic cleft and the DHA tail in 
proximity to the C214 protein residue (Figure. 5.2A). Little deviation of the 
position of the thiostrepton core was seen among these poses, an observation 
Hydrophobic cleft forming 
the proposed binding site 
Figure 5.1. Proposed thiostrepton binding site. The NMR derived structure for 
TIPAS (PDB: 1N9Y) was imported into UCSF Chimera v.1.5.2 and mapped with a 
hydrophobic surface; orange indicates greater hydrophobicity. 
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that was consistent across the full set of results (Figure. 5.2A). However, 
variation was seen in the position of the thiostrepton tail among these top poses 
(Figure. 5.2B), which could be expected due to the inherent flexibility of the tail 
(85). Nevertheless, in all cases at least one of the tail DHA residues was 
positioned such that Michael addition between the DHA olefin and C214 was 
possible, offering some theoretical support for the experimentally determined 
covalent antibiotic-protein interaction (Figure. 5.3).  
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Figure 5.2. Modeling TIPAS-thiostrepton binding. (A) The 
top left panel shows 6 outcomes of the docking of thiostrepton 
on TIPAS (red ribbons) that resulted in the DHA tail positioned 
within bonding distance of C214. Top Right panel shows an 
overlay of the 6 thiostrepton confirmations. (B) Orientations of 
the bis-DHA thiostrepton relative to C214. 
Figure 5.3. The binding of 
thiostrepton to TIPAS. (Top) 
Thiostrepton (space-filling) was 
docked into the hydrophobic cleft on 
TIPAS (pose 1); (Bottom) 90° x-axis 
rotation of pose 1 with TIPAS 
rendered as green ribbons. Images 
were generated using UCSF 
Chimera, after creating a PDB file of 





5.3.2. Interaction of TIPAS and its variants with thiostrepton 
The available NMR structure for TIPAS excludes the N-terminal 54 
amino acids of the protein, which could not be positioned by the authors of the 
study due to flexibility of this region of the protein (226). With the view 
towards future endeavors at obtaining the crystal structure of TIPAS or its 
complex suitable for X-ray diffraction, a truncated variant of the protein lacking 
these N-terminal amino acids (TIPASt) was generated. It was found that while 
the native protein became virtually 100% covalently bound to thiostrepton at a 
1:1 stoichiometry, TIPASt was unreactive by comparison, with the majority of 
this protein remaining unbound (Figure 5.4A). Mass spectrometric analysis of 
the reaction products of the TIPASt-thiostrepton reaction also indicated the 
formation of complexes with a 2:1 stoichiometry of antibiotic to protein in 
addition to 1:1 complexes (Figure 5.4B). These bis-thiostrepton protein 
complexes did not occur with the native TIPAS and their occurrence with 
TIPASt was immediately suggestive of a conformational difference in this 
protein that resulted in the exposure of a second site for covalent attachment to 
thiostrepton. The likely candidate for this second site of attachment would be 
C207, although, the addition of thiostrepton to this site has not been reported in 
the literature. 
Evidence for the suspected structural divergence of TIPASt from TIPAS 
was obtained from comparative CD spectra for these proteins, shown in Figure 
5.4C. The spectrum for TIPASt indicates the loss of gross secondary and tertiary 
structural features for TIPASt with respect to TIPAS which may signify that this 








Figure 5.4. Purication and characterization of TIP-thiostrepton complexes. (A) 
Anion exchange chromatography of the TIPAS-thiostrepton reaction. The 
chromatograph indicates greater than 95% complex formation. (B) Deconvoluted mass 
spectra of the complexes formed between thiostrepton and TIPAS (the molecular 
weight of TIPAS is 16844 Da) and TIPASt. The spectrum of the TIPASt reaction 
shows the presence of mono- (12092.000 Da) and di- (13756.500) thiostrepton-protein 
complexes. (C) Far UV circular dichroism spectra for TIPAS (solid line) and TIPASt 
(dashed line). Measurements were performed on 0.75 mM protein in a buffer comprised 







Such a structural change could lead to the exposure of a second potential site for 
covalent antibiotic attachment. Due to these structural divergences, subsequent 
studies of the protein-antibiotic interaction were carried out using only the full 
length TIPAS or its point mutants. 
The TIPASt variant encompasses the region of TIPAS proposed to 
construct the thiostrepton binding site and the poor (covalent) reactivity of this 
synthetic construct with thiostrepton was attributed to its adoption of a structure 
different to that in the native, full length protein. This is in agreement with the 
hypothesis that a significant non-covalent interaction between protein and 
antibiotic must precede covalent bond formation; the structural elements 
facilitating this non-covalent interaction are lost in the altered structure of 
TIPASt, hence covalent bond formation is reduced. In order to examine this 
non-covalent component to antibiotic binding, the elimination of covalent 
protein-antibiotic binding was attempted through the generation of mutants of 
TIPAS in which the reactive cysteine (C214) was replaced with an alanine or a 
serine. At the same time, a C207A point mutant was made in order to rule out 
covalent binding at this site in the native protein. As expected, the formation of 
covalent complexes with the C207A mutant was unperturbed, but unexpectedly, 
the C214A and C214S were virtually 100% covalently bound by thiostrepton 
under the same reaction conditions as the native protein (Figure.5.5).  
Covalent complex formation between thiostrepton and C214S could be 
explained by a Michael addition occurring with the oxygen from the serine 
hydroxyl, but this does not account for covalent complex formation with the 
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C214A mutant, where no Michael acceptor is presented at the 214 position. This 
implies that these complexes resulted from the covalent attachment of 
thiostrepton to an alternate amino acid residue. Furthermore, the occurrence of 
these complexes lends credence to the notion of a significant non-covalent 
interaction occurring between antibiotic and protein that sufficiently 
immobilizes the antibiotic, thereby allowing for the reorientation of the tail of 




Figure 5.5. Deconvoluted mass spectra of thiostrepton complexes with TIPAS 
mutants. Masses at 16812.500 Da and 16828.500 Da correspond to the unbound 
C214A and C214S variants, respectively.  
 
 
5.3.3. Mapping the site of covalent addition of thiostrepton by point 
mutation studies on TIPAS 
 The second cysteine residue (C207) in TIPAS is the most likely point of 
covalent attachment in the thiostrepton complexes with TIPAS mutants. Support 
for this was sought by peptide mapping studies on peptide fragments generated 
by digestion of the covalent complexes of these mutants with thiostrepton. 
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TIPAS features cleavage sites for several proteases and chemicals, but cyanogen 
bromide, which cleaves at methionines, was chosen as the cleavage agent since 
one of the 6 methionine residues in the TIPAS primary sequence is conveniently 








 HPLC analysis of the products from cyanogen bromide cleavage of 
unbound TIPAS mutants yielded 7 products as predicted (Figure. 5.7) and 
ensuing mass spectrometry for each of these identified them individually as the 
expected peptide fragments, with the exception of the product of mass 2450.124 
Da (designated D). The mass of this product is approximately 48 Da higher than 
what was expected for this peptide (Table 5.4). The increased molecular weight 
is attributed to the reaction of cyanogen bromide with cysteine (300, 301). In 
this case C207 is oxidized to cysteic acid, which was confirmed by tandem mass 
spectrometry (Figure 5.8). This peptide D was absent from the chromatograms 
of digests of TIPAS mutant complexes, while a new product eluting in a higher 
percentage of acetonitrile was detected (peptide D1). The mass determined for 
this product was consistent with the addition of thiostrepton to peptide D. The 
14.811 Da difference between the observed and predicted molecular weight of 
peptide D bound with thiostrepton is due to a reaction between CNBr and 
thiostrepton that increases the mass of thiostrepton by this amount. Cyanogen 
Figure 5.6. Cyanogen bromide cleavage sites in TIPAS. The schematic depicts 
the TIPAS sequence in the N to C-terminus direction. The masses of the peptides 
expected from cleavage are shown (after conversion of methionine to homoserine 
lactone). C207 is found in the peptide of mass 2402.009; while the 214 position falls 
within the peptide of mass 725.334 (C214S) 709.339(C214A). 
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bromide is also known to engage reactions with amines (302) and its reaction 
with thiostrepton probably involves a primary or secondary amine from 
thiostrepton, or the amine from the dehydropiperidine core of the molecule. In 
addition, the peptide containing C214 (peptide C) was present in 
chromatograms of digests from both variants and no other product with a mass 
corresponding to the addition of thiostrepton to any of the remaining peptides 
was observed. 
These results show that thiostrepton addition occurs to a residue within 
peptide D. The serendipitous oxidation of cysteine to cysteic acid by CNBr that 
occurred during digests of unbound TIPAS variants enabled the conformation of 
C207 as the reactive residue. Thiostrepton binding to a different residue would 
have resulted in a mass for peptide D1 48 Da higher than what was observed, 
due to the formation of cysteic acid. Hence, in the complexes with TIPAS 
variants, the Michael addition between with thiostrepton with C207 renders the 
thiol unavailable for reaction with CNBr.  
A review of the interaction between TIPAS and thiostrepton modeled in 
Figure 5.3 shows C207 to be in a less favorable position for a Michael addition 
with the tail DHA from thiostrepton. Therefore, the unprecedented finding of 
covalent addition to C207 is indicative of a significant non-covalent interaction 
occurring between the protein and antibiotic, supporting the hypothesis that this 
interaction sufficiently immobilizes the core of the thiostrepton molecule on the 
protein, allowing for the repositioning of the flexible tail region that enables 










Unbound Thiostrepton complex 
C214A C214S C214A C214S 
A: 1-4 382.160 382.196 382.198 382.203 382.191 
B: 73-84 1100.426 1100.543 1100.484 1100.494 1100.461 




709.391 725.402 709.410 725.390 
C + Thiostrepton 2374.219/2390.214 
(C214A)/ (C214S) 
- - - - 
D‡: 85-105 2402.009 2450.124 2450.109 - - 
D + Thiostrepton  4066.889 - - 4081.700 4081.784 
E:135-147 1432.790 1432.836 1432.854 1432.884 1432.888 
F: 113-134 2439.218 2439.388 2439.356 2439.382 2439.388 
G: 5-72 8155.880 8160.500 8160.500 8160.500 8160.500 
†Predicted peptide mass was calculated with methionines as homoserine lactone. Observed Mr 
values were deconvoluted from the multiply charged molecular ions detected by ESI-MS.   
 
 
Figure 5.7. Analysis of the cleavage products from cyanogen bromide digestion of 
thiostrepton complexes with TIPAS mutants. (A) HPLC chromatograms of the 
products from CNBr digestion of thiostrepton complexes with the C214A variant (left 
panel) and the C214S variant (right panel). The bottom trace of each panel shows the 
products from the digestion of the unbound protein. B) ESI-mass spectra of peptide D 
and peptide D1. Spectra for peptide D show doubly and triply charged molecular ions 
of the peptide, with cysteine oxidized to cysteic acid (Mw: 2450.103 Da). Quadruply 
and triply charged molecular ions in the spectra from peptide D1 derive from a Mw of 
4080.71 Da, which coincides with the addition of thiostrepton to C207 in peptide D 
(before cysteine oxidation by cyanogen bromide).
B) 
A) 

















































































































































































































































































5.3.4. Qualitative evaluation of the non-covalent binding of thiostrepton to 
TIPAS 
Several amino acid residues present in the primary sequence of TIPAS 
contribute to the intrinsic fluorescence of the protein, many of which line the 
proposed thiostrepton binding site (Figure. 5.9A). During NMR analyses of 
TIPAS (226) chemical shift changes in response to antibiotic binding were 
observed that were consistent with significant conformational changes in the 
protein structure. Since the fluorescent properties of amino acids in a protein are 
known to be sensitive to local environmental changes that accompany global 
conformational changes, it was thought that the changes in intrinsic TIPAS 
fluorescence that would presumably occur upon antibiotic binding would 
provide an expedient, qualitative, dual monitor of the general location of the 











Figure 5.9. Fluorescent residues in TIPAS. (A) TIPAS docked with thiostrepton. 
Tyrosines are shown in magenta and tryptophans in yellow. The reported TIPAS 
crystal structure only shows the position of one tryptophan. (B) Excitation (red) and 
emission (blue) fluorescence maxima for TIPAS.
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In order to properly investigate the non-covalent interaction of 
thiostrepton with TIPAS, the covalent interaction had to first be removed or 
prevented. The intrinsic protein fluorescence of TIPAS was therefore measured 
in the presence of thiostrepton derivatives 5.1 and 5.2 (Figure. 5.10). These 
derivatives, particularly 5.2, lacked the reactive tail DHA and would thus be 
unable to form a covalent bond with TIPAS. In addition, the intrinsic 
fluorescence of TIPAS and its C214S mutant were measured in the presence of 




The results of these experiments are presented in Figure. 5.11. As expected, the 
intrinsic fluorescence of TIPAS or its C214S mutant decreased in the presence 
of increasing concentrations of thiostrepton, with fluorescence approaching zero 
at the highest concentrations of antibiotic. These observations are consistent 
with the proposed antibiotic binding site on the protein, since the occupation of 
this site by thiostrepton would bring about decreased fluorescence.  
 
5.1 5.2 











This trend was also evident in the presence of the thiostrepton derivatives. The 
reduction of intrinsic TIPAS fluorescence caused by 5.1 mirrored that caused by 
thiostrepton, but it was subsequently found that 5.1 does indeed form a covalent 
complex with TIPAS (Figure 5.12). While this complexation occurs to a lesser 
extent than with thiostrepton, its formation likely contributed to the observed 
reductions in fluorescence. Unlike thiostrepton and derivative 5.1, derivative 5.2 
did not form a covalent complex with thiostrepton. The observed reduction in 
TIPAS fluorescence in the presence of this compound is therefore solely 
attributed to the non-covalent interaction with the protein. 
A) B) 
C) D) 
Figure 5.11. Effect of thiostrepton binding on TIPAS fluorescence. A) TIPAS & 
thiostrepton; B) TIPAS & 5.1; (C) TIPAS (C214S) & thiostrepton; D) TIPAS and 5.2. 
Reactions of TIPAS proteins were performed as described using 10 µM of protein and 
varying concentrations of thiostrepton derivatives. Fluorescence readings were 







These observations reinforce the proposition of a significant protein-
antibiotic non-covalent interaction. In the case of 5.1, the DHA in its truncated 
tail is likely not to be initially presented in a position that would be favorable 
towards Michael addition with C214. However, as with the TIPAS mutants, the 
non-covalent binding allows for reorientation of the tail in this derivative to a 
more amenable position.  
5.3.5. Non-covalent binding affinity of thiostrepton to TIPAS 
 The non-covalent binding of thiostrepton to TIPAS was quantified using 
isothermal titration calorimetry. In this approach, the absence of any covalent 
bond formation was absolutely crucial. Heat evolved from the formation of such 
bonds would interfere with that of the non-covalent interaction, which would 
ultimately result in incorrect values for the binding constants. This precluded 
titrations of thiostrepton into TIPAS. Although titrations of thiostrepton into a 
TIPAS variant (a double mutant with C207 and C214 replaced) could have 
Figure 5.12. TIPAS reaction with 5.1. Deconvoluted ESI mass spectrum of the crude 
product mixture from the reaction of TIPAS with 5.1, which indicates substantial 
covalent complexation (unbound TIPAS at 16841.500 and TIPAS covalently bound 
with 5.1 at 18437.500). 
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circumvented this problem of unwanted covalent bond formation, the aqueous 
insolubility of thiostrepton made such experiments impractical. Proportions of 
DMSO in excess of 25% (v/v) would be required to achieve concentrations of 
thiostrepton that would produce measurable results with acceptable signal to 
noise ratios. However, at these proportions of DMSO, the accompanying heats 
from dilution and mixing would eclipse those from the interaction under study.  
Thiostrepton derivatives were turned to once again, in the quantification 
of the affinity of the non-covalent protein-antibiotic interaction. The truncated 
derivatives 5.1 and 5.2 exhibited better aqueous solubility that thiostrepton, 
making them suitable for ITC experiments. As earlier mentioned, derivative 5.1 
was found to covalently bind TIPAS, hence, titrations with this derivative were 
performed using the C214A variant of TIPAS. Unlike native thiostrepton, this 
derivative did not covalently bind to this TIPAS variant, most likely because its 
Michael acceptor is outside the distance range for bonding with C207. 
Additional derivatives, 5.3 and 5.4, were prepared to probe the structural 
determinants of the non-covalent interaction (Figure 5.13). Derivative 5.3 (also 
featured in Chapter 2) was used to determine the contribution of the tail region 
of thiostrepton to non-covalent binding. The MENSA appendage would also 
block the reactive olefin, thus preventing covalent binding to this analogue. The 
synthesis of derivative 5.4 was unexpected as a Michael adduct of 5.1 with the 
appendage on the tail DHA was initially sought. Here, however, a novel 
derivative featuring a modification to the DHA on a thiostrepton macrocycle 




















Figure 5.14. Site of thiol Michael Addition in 5.4. The olefin region of proton 
spectra for thiostrepton, 5.1 and 5.4. is shown, with integrals indicated below 
spectra. Chemical shifts for DHA2 protons are present in the spectra for 5.4, which 
indicates that this was not the site of thiol addition. Although the individual peaks 
for the DHA1 protons are obscured, integration of the region where they would be 
located indicates the absence of the DHA1 protons that are present in thiostrepton 
(and 5.1). 
5.3 5.4
Figure 5.13. Structures of Michael derivatives of thiostrepton. 
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A similar derivative of 5.1 has been prepared by Schoof et al. (239), however, in 
their synthesis, these researchers employed buffered conditions and used less 
basic conditions than were used here. Therefore, the higher pH used here likely 
increases the indiscriminate reactivity of MENSA hence producing isolatable 
yields of internally modified olefin. In any case, the opportune generation of this 
derivative enabled probing of the contribution from the thiostrepton macrocyles 
to non-covalent binding. None of the derivatives used in the ITC experiments 
formed covalent complexes with TIPAS during the time span of the ITC 
experiment (confirmed by ESI-MS immediately after completion of the 
titration). 
The results of ITC titrations are presented in Figure 5.15. All derivatives 
were determined to bind TIPAS proteins at a 1:1 stoichiometry. Derivatives 5.2, 
5.3 and 5.4 bound TIPAS with dissociation constants of 5.38 ± 0.03 µM, 0.19 ± 
0.01 µM and 12.95 ± 0.01 µM, respectively and 5.1 bound the C214A mutant 
with a dissociation constant of 0.21 ± 0.002 µM, confirming a significant non-
covalent interaction between thiostrepton and TIPAS.  The finding of a low 
micromolar binding affinity for derivative 5.2 indicates that the thiostrepton 
macrocycles are the major contributors to this interaction. Fittingly, derivative 
5.4 displayed the weakest affinity for TIPAS, in spite of possessing a tail region. 
This is explained by the added presence of the MENSA appendage on the core 
of the thiostrepton molecule disrupting the predominantly hydrophobic, non-
covalent interactions between the thiostrepton and TIPAS, resulting in its 
diminished binding affinity, particularly in comparison to 5.2. Meanwhile, the 
187 
 
dissociation constants for derivatives 5.1 and 5.3 were approximately 30-fold 
less than that of 5.2. Since both these derivatives possess DHA tails, these 
results indicate that the affinity of this non-covalent interaction is enhanced by 





















Figure 5.15. Isothermal titration calorimetry of TIPAS with thiostrepton 
derivatives.  Top panels show heats of injection and bottom panels show the 
binding isotherm for sequential injections of 5.1 (A); 5.3 (C) and 5.4 (D) into 
TIPAS and 5.2 into the C214A variant of TIPAS (B). 
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5.3.6. X-ray crystallography of TIPAS & the TIPAS-thiostrepton complex 
 Prior to performing crystallography experiments, samples of TIPAS or 
the TIPAS-thiostrepton complex were first subjected to an additional level of 
purification by anion exchange chromatography to ensure a sample purity 
greater than 95% and then concentrated to 8-10 mg/mL. Suitable conditions for 
crystal growth were first sought with the Hampton Crystal Screen Cryo, using 
the sitting drop method. To the main reservoir of individual wells of a 96-well 
sitting drop plate was added 100 µL of crystallization cocktail, while 1 µL of 
protein solution and 1 µL of the same crystallization cocktail were added to the 
sample reservoir and mixed. The wells were sealed, and left undisturbed at 
ambient temperature. The progress of crystal growth was monitored weekly. 
This initial screen proved to be largely unsuccessful, resulting mainly in protein 
precipitation or aggregation.  
 
 
Figure 5.16. Schematic of an individual well from a 96-well sitting drop 
plate. 
 
 Continual screening for suitable conditions by this approach would have 









was supplied to the Hauptman Woodward Research Institute for the 
simultaneous screening of 1536 different conditions, by the vapor diffusion 
under oil technique (303). This high-throughput approach was used to identify 
conditions that could be further optimized, from a large collection of cocktails 
that simultaneously screened the effects of salts, pH, buffers and aids such as 
PEG. Crystal growth was tracked on a weekly basis and by week 3, several 
potential “hits” (wells containing observable crystalline material) were 
identified, along with several wells containing precipitated protein. After an 
additional two weeks, the corresponding wells were imaged under UV light to 














0.1 M HEPES (pH 
7.5), 3.74 M NH4Cl  
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0.1 M HEPES (pH 
7.5), 3.46 M K2PO4  
3 
 
0.075 M Na-HEPES 







0.2 M K2SO4 (pH  




1.6 M Sodium 
citrate tribasic 
dihydrate (pH 6.5)  
Figure 5.17. High throughput screening of crystal growth conditions for 
TIPAS. Images of 5 wells containing suspected protein crystals are shown 
viewed under polarized (top panels) and UV light (bottom panels) after 5 weeks 
of growth. Wells exhibiting fluorescence under UV light (boxed in yellow) 
contain protein (micro)crystals. 
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The UV absorbance by the several tyrosines and tryptophans in TIPAS enabled 
quick confirmation of the presence of protein crystals produced by the cocktails 
indicated in Figure 5.17 and additional optimization of cocktail 2 was 
performed.  
 The conditions of cocktail 2 were varied with respect to K2PO4 
concentration (2.0 M, 2.5 M and 3.0 M) and pH (7.5, 8.0, 8.3), generating 9 
unique conditions that were used in sitting drop crystallization trials for TIPAS 
and the TIPAS-thiostrepton complex. After 4 weeks, crystal growth was seen in 
the cocktails containing 0.1M HEPES at pH 8 with 2.0 M K2PO4 for TIPAS and 
0.1 M HEPES at pH 8.3 with 2.0 M K2PO4 for the TIPAS-thiostrepton complex 







Figure 5.18. Optimized conditions for crystal growth of TIPAS and the 
TIPAS-thiostrepton complex. Images for TIPAS (left) and the TIPAS-
thiosterpton complex (right) were taken under polarized light.  
191 
 
While this was an improvement with respect to the clumped micro-crystals 
obtained from the high throughput screen, these crystals were not of a sufficient 
size or quality suitable for X-ray diffraction experiments, hence an additive 
screen was next attempted to improve crystal quality. In this approach, minute 
amounts of a small molecule were added to the crystallization cocktail in an 
effort to aid the crystallization process. Thirty-one such additives (Appendix 8) 
were tested for each of the optimized conditions that yielded needles, but, 
unfortunately, crystal quality was not improved. 
 
5.4. Conclusions, Perspectives and Future work 
 A high affinity non-covalent interaction between TIPAS and thiostrepton 
has been demonstrated and the underlying molecular and structural determinants 
for this interaction have been determined. The results are in support of the 
thiostrepton binding site on TIPAS that has been previously proposed and they 
further show that the interaction is governed predominantly by the hydrophobic 
interactions that occur between the thiostrepton macrocycles and the amino acid 
residues that form the binding site. Although the bis-DHA tail primarily serves 
to supply the olefin that participates in a Michael addition with the thiol from 
C214, the results presented here show it also enhances the non-covalent binding 
affinity of TIPAS for thiostrepton. Together, these findings are consistent with a 
binding mechanism in which the non-covalent interaction necessarily precedes 
the covalent binding of thiostrepton, which allows for the presentation of the tail 
region in the proper orientation that leads to covalent binding with the protein.  
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 Although the results of this study provide a model for TIP mediated 
thiopeptide resistance, a broader understanding could be gained from the 
detailed study of the structural determinants for the binding of additional 
thiopeptides antibiotics that are susceptible to TIP mediated resistance. This 
would be aided by the solution of structures for the TIPAS-thiostrepton/ 
thiopeptide complex, possibly in future by NMR studies.  
Complete structures for the complex remain elusive and the attempts at 
crystallization of the TIPAS or the TIPAS-thiostrepton complex in this work 
were unsuccessful. However, many potential areas for modification remain. A 
higher initial protein concentration can be used since the final protein 
concentration was reduced to half by the addition of an equal volume of 
crystallization cocktail. Alternatively, the ratio of protein to crystallization 
cocktail in the drop can be increased. As well, additional additives such as PEG 
or ionic salts may be more rigorously investigated for their effects on protein 
crystallization and initial trials using these approaches have offered promising 
results. Finally, an alternative method of crystallization such as hanging drop 
can be attempted, which will allow for the use of a larger sample volume that 
can positively affect the outcome. On the other hand, structures of the complex 
may be sought through NMR spectroscopy. 
As earlier mentioned, TIP mediated resistance occurs against a broad 
range of thiopeptides and it is likely that the mechanism of antibiotic binding 
described above extends across this group. TIP genes and their products have 
been identified in several Streptomyces, which importantly are not 
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manufacturers of thiopeptides or their corresponding resistance enzymes. 
Therefore, the findings presented have contributed to the understanding of drug 
resistance in this microbial class and may have implications in the design of 
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APPENDIX 1: NMR Spectra for thiostrepton derivatives  




Figure A1.1. Full proton spectra for thiostrepton and the Michael adducts 
used in antibacterial activity testing. The structure of the tail region is shown. 
As discussed in Chapter 2, compounds 3 and 4 were obtained as separate HPLC 
fractions, however, the stereochemistry at the chiral center that is created by 
Michael addition is unknown (this is also the case with compound 2). Compound 


















Figure A1.3. Full TOCSY spectra for Michael adducts of thiostrepton with 
MENSA. The compounds were resolved during HPLC purification, but represent a 




Figure A1.4. Full TOCSY spectra for Michael adducts of thiostrepton with 
captopril. As with the 2-mercaptoethanesulfonic acid adducts, the compounds are a 







Figure A1.5. Full proton spectra for thiostrepton derivatives used in binding 






APPENDIX 2: Cell free assays of  inhibition of protein translation 
by thiostrepton and its Michael adducts. 
 
Figure A2.1. Optimization of the assay for the inhibition of in vitro translation. (A) 
Dynamic range of light output by luciferase. Luminescence was recorded for 50 µL 
samples of luciferase at various concentrations in phosphate buffer. The plot indicates a 
linear relationship for luminescence values between 1.0 × 103 and 1.5 × 106 RLU, with 
luciferase concentration. (B) Time course for luciferase production/ light output from in 
vitro translation. Translation reactions were performed using 700-800 ng of pBESTluc. 
DMSO was included to a final concentration of 1% (assay volume of 25µl). 
Uninhibited luciferase production/ light output increases linearly with time, up to 75 
minutes. After this maximum time interval, RLU remains within the linear range. (C) 
Luciferase (20 ng in phosphate buffer) was incubated with various concentrations of 
thiostrepton and the light output measured. The final DMSO concentration was 50% 
v/v (50 µL assay volume). Noticeable reductions in light output were observed at 
thiostrepton concentrations exceeding 0.04 mg/ mL (24.02 µM). In all cases, error bars 
































































Empirical formula   C24H26O6Cu 
Formula weight    473.99 g/mol 
Temperature    200(2) K 
Wavelength    0.71073 A 
Crystal system, space group  Monoclinic, P21/n 
Unit cell dimensions                         a = 8.0504(4) Å, b = 7.4273(4) Å, c = 18.4665(10) Å 
α = 90 °, β = 100.3470(10) °, γ = 90 ° 
Volume     1086.21(10) Å3 
Z, Calculated density   2, 1.449 g/cm3 
Absorption coefficient   1.043 mm-1 
F(000)     494 
Crystal size    0.54 x 0.13 x 0.05 mm 
Theta range for data collection  2.96 to 27.99 ° 
Limiting indices    -10<=h<=10, -9<=k<=9, -24<=l<=24 
Reflections collected / unique  12425 / 2626 [R(int) = 0.0210] 
Completeness to theta = 27.99  99.8 % 
Absorption correction   Empirical 
Max. and min. transmission  0.9497 and 0.6027 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  2626 / 0 / 142 
Goodness-of-fit on F2   1.256 
Final R indices [I>2 σ (I)]   R1 = 0.0320, wR2 = 0.0827 
R indices (all data)   R1 = 0.0372, wR2 = 0.0854 





Table A3.1. Atomic coordinates ( x 104) and 
equivalent isotropic displacement parameters 
(Å2 x 103) for C24H26O6Cu. 
 x y z U(eq) 
Cu(1) 5000 5000 5000 26(1) 
O(1) 7359(2) 5734(2) 5174(1) 30(1) 
O(2) 4850(2) 5208(2) 6022(1) 32(1) 
O(3) 5674(2) 1740(2) 5154(1) 35(1) 
C(1) 3032(3) 6019(4) 7919(1) 53(1) 
C(2) 4030(3) 6769(4) 8528(1) 45(1) 
C(3) 5675(3) 7228(3) 8504(1) 42(1) 
C(4) 6318(3) 6977(3) 7862(1) 37(1) 
C(5) 5318(2) 6246(3) 7236(1) 28(1) 
C(6) 3671(3) 5753(4) 7278(1) 41(1) 
C(7) 5906(2) 5998(3) 6518(1) 27(1) 
C(8) 7491(2) 6614(3) 6420(1) 31(1) 
C(9) 8137(2) 6412(3) 5770(1) 28(1) 
C(10) 9918(3) 7030(3) 5753(1) 39(1) 
C(11) 6338(3) 563(3) 4668(1) 36(1) 
C(12) 4991(3) 741(3) 5694(1) 36(1) 
U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
Table A3.2. Hydrogen coordinates ( x 104) 
and equivalent isotropic displacement 
parameters (Å2 x 103) for C24H26O6Cu 
 x y z U(eq) 
H(1A) 1902 5683 7938 64 
H(2A) 3584 6969 8964 55 
H(3A) 6373 7718 8928 50 
H(4A) 7453 7306 7850 45 
H(6A) 2975 5228 6862 50 
H(8A) 8176 7210 6821 37 
H(10A) 10181 6816 5262 58 
H(10B) 10711 6357 6120 58 
H(10C) 10016 8319 5867 58 
H(11A) 7305 -115 4948 54 
H(11B) 6755 1279 4286 54 
H(12A) 4488 1582 6010 54 
H(12B) 5908 71 6010 54 
U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
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Table A3.3. Bond lengths [Å] and 















































Symmetry transformations used to generate 
equivalent atoms: 






APPENDIX 4: ITC Supplement – Curve fitting and data 
processing (adapted from ITC Data Analysis in Origin. Tutorial 
Guide. Version 7.0. MicroCal, LLC) 
 
A4.1. Volume correction 
Before the first injection, the macromolecule (receptor; M) will be 
present at an initial bulk concentration, M , while the ligand (X) will be at zero 
concentration within the cell. The cell volume is V0, the size of the ith injection 
is ΔVi and the total liquid injected at any point is ΔV (sum of all individual 
injections). Only changes (in heat) occurring the liquid in V0 are detected, 
however, liquid of a volume equal to that of ΔV, is displaced from the cell is 
each injection of ligand, effectively altering the concentration of macromolecule 
within the cell (the same number of moles of macromolecule becomes 
distributed throughout a volume of V0 + ΔV). The law of mass conservation will 
hold that: 
 
M V M V
1
2



















A4.2. Model for one set of sites 
Terms: 
K = binding constant 
N = number of sites 
V0 = cell volume 
M  = Initial bulk volume 
Mt & [M] = bulk and free concentration of macrocolecule (receptor) in V0 
Xt & [X] = bulk an free concentration of ligand 










  (1) 
 
X X nΘM  (2) 
 
Combining (1) and (2) gives 1 0 (3) 
 
The total heat content Q, of at cell at a given fractional saturation Θ is described 
by  
 
Q nΘM ΔV  (4) 
 
 
where ΔH is the heat released per mole of ligand bound. Solving the quadratic 
equation (3) for Θ and substituting the solution into equation (4) gives the 
following expression for Q: 
Q 1 1  (5) 
Therefore, Q can be calculated for any combination of n, K and ΔH at the end of 
the ith injection and designated Q(i). However, since the ITC experiment in 
concerned with the change in heat content from the i – 1 injection to the ith 
injection, equation (5) is only applicable to the volume contained in V0. Hence, 
the correct expression for this change in heat (ΔQ), after correction for the 
displaced volume is:  
ΔQ i Q i Q i 1  (6) 
Fitting of the experimental data commences with initial guesses for n, K and ΔH 
by Origin, the calculation of ΔQ for each injection and a comparison of this with 
what is experimentally measured, then the improvement of the initial values by 
Marquardt methods and continued iteration of this procedure until the fit no 







A4.3. Sample Calculations 
Table A4.1. Parameters of AdoMet binding to TSR 










1 2.08 0.052 9010 536 -4028 148.2 4.35 
2 1.91 0.048 9560 538 -4149 150 4.06 
3 2.11 0.045 9260 502 -3707 119.8 5.50 
 N K ΔH 
 High Low High Low Low High 
1 2.13 2.03 9546 8474 -3879.80 -4176.20 
2 1.96 1.86 10098 9022 -3999.00 -4299.00 
3 2.16 2.07 9762 8758 -3587.20 -3826.80 
  Mean N  2.03  Std Dev N 0.11 







 Mean Δ H -3.96×10
3
 Std Dev Δ H 255.47 
  Mean Δ S  4.64  Std Dev Δ S 0.76 
 
Experimental details are given in Chapter 3. Prism software defines ligand 
binding by the parameter “K”; the inverse of this parameter, 1/K is the 
dissociation constant (Kd). The table shows the values obtained from three 
individual replicates, after non-linear curve fitting of the integrated heats per 
injection, using the model for one set of sites. The error associated with each 
parameter from a replicate was used to generate high (+ error) and low (-error) 
values. The mean and standard deviation of all high and low values were 












Table A4.2. Parameters for AdoMet binding to TSR mutants 
N129A 


































 -19.55 ±0.64 
 
N129D 




































 -86.75 ±7.00 
 
R135A 


































 -233 ±39.60 
 
R135K 




















 ±343.4 -14.1 



































 ±563.5 -9.49 







 ±1244.89 -10.95 ±2.058 
 
R165K 




















 ±326.7 -4.87 







 ±336.64 -4.07 ±1.13 
 
 
Table A4.3. Parameters for the binding of thiostrepton analogues to TIP-AS (or its 
C214A variant) 
C214A + 5.1 































 ±757.7 -63.3 







 ±929.16 -64.8 ±3.04 
 
TIP-AS + 5.4 
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TIP-AS + 5.2 



















































 -187.3 ±7.09 
 
TIP-AS + 5.3 
































































APPENDIX 5: Fluorometric enzyme assay supplement & enzyme 
kinetics for AdoMet  
A5.1. General considerations. 
 In was essential to maintain an RNAse free environment while 
performing TSR assays. Therefore, RNAse free (certified by the manufacturer, 
Corning Life Sciences, Tewksbury, USA) microfuge tubes and pipette tubes 
were used. 96-well microplates were supplied RNAse free in sealed packages 
and were not re-used. When necessary, buffers or solutions were prepared using 
autoclaved MilliQ grade water. In addition, all working surfaces were wiped 
down with an RNAse decontaminating solution (“RNAse away”, Sigma-
Aldrich). 
 Each fluorometric assay kit was supplied with sufficient reagents for 96 
assays and these kits were quality tested by the manufacturer (Cayman 
Scientific Company, Ann Arbor, USA) on an individual basis. Therefore, 
reagents from different kits were not used together, particularly for kinetic 
measurements of enzyme activity otherwise introduction of an immeasurable 
variability and inconsistency could result. As well, assays were preformed in a 
timely fashion and the fluorometric reagent was added last to avoid variability 
and minimize background due to the decomposition of this reagent.  
 
A5.2. Principle of the Mtase assay 
 Several commercial kits that monitor methyltransferase activity through 
non-radiometric means are currently available. In these kits, Mtase activity is 
assayed by monitoring the production of S-adenosylhomocysteine (266, 304–
307). AdoHcy can be directly detected through immunogenic means, or its 
formation during the Mtase catalyzed reaction is coupled to successive 
enzymatic reactions that convert the AdoHcy produced into a more easily 
















The kit offered by the Cayman Chemical Company was selected to 
monitor TSR activity and determine to the kinetic parameters for AdoMet 
utilization by TSR, as well as for substrate utilization studies of an AdoMet 
analogue by TPMT. The principle of the assay is shown schematically in Figure 
A5.2 and it extends the spectrophotometric Mtase assay described in (266), by 
further converting hypoxoxanthine to urate with a concomitant production of 
hydrogen peroxide. Subsequent oxidation of the 10-Acetyl-3,7-
dihydroxyphenoxazine by the hydrogen peroxide that is produced results in the 
formation of the fluorophore resorufin. Therefore, the amount of resorufin 
produced is directly correlated with the AdoHyc produced. Since AdoHyc 
production is sthoichiometerically related to the amount of AdoMet initially 
present, fluorescence output can thus be directly correlated with (initial) 
AdoMet concentration. The required amounts of the individual assay reagents 
are predetermined and are supplied as individual vials and the assay is 
performed by mixing the reagents according to the manufacturer’s instructions. 
An added benefit of the assay is its continuous format, which avoids variability 
from reaction quenching or washing steps that are necessary in other assays. As 
well, AdoMet can be added separately, which allows for the determination of 




















Generation of fluorophore 
ATP Luminescent detection 
(307) 
























A5.3. Sample calculation and data processing for the determination of 
kinetic parameters for AdoMet turnover by TSR (and mutants).  
 Quantification of AdoHcy was necessary for subsequent determinations 
of enzyme kinetic parameters (Vmax, kcat). In order to quantify the amount of 
AdoHcy generated during kinetic enzyme assays, a standard curve correlating 
the observed change in fluorescence with the concentration of AdoHcy was 
generated. Reactions were set up containing known amounts of AdoHcy, but 
lacking enzyme (Mtase) and were performed in an identical manner to reactions 
where enzyme was present. Figure A5.1 shows the ranges over which the 
relationship is linear and the equation describing this linear correlation : 




y 524.74x 0.8715, was used to convert the observed rate (ΔRFU/ second) 
from the assays containing Mtase to number of moles of AdoHcy (i.e. number 




Table A5.1. AdoHcy Standard Curve 
µmoles of 
AdoHcy 
ΔRFU/ second ΔRFU/ second 
Mean ΔRFU/ 
second 
0.16 46.819 46.185 46.502 
0.08 40.896 40.262 40.579 
0.04 21.722 21.088 21.405 
0.02 9.765 9.131 9.448 
0.01 4.148 3.514 3.831 
0.005 2.032 1.398 1.715 
0.0025 1.178 0.544 0.861 

















Number of µmoles of AdoHcy













































Figure A5.4. Dependence of initial rate of the K221A variant of TSR on [AdoMet]. 
The rate of AdoHcy formation in the absence of Mtase at each AdoMet (×) concentration 
was obtained from assays containing no Mtase. Assays for the determination of this 
background rate were performed simultaneously with the assays containing Mtase (i.e. in 
the same 96-well plate, using the same reagent stock, at the same time).  
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Table A5.2. Sample calculations for the conversion of  (ΔRFU/ second) to (Δ[AdoHcy]/ 
second) 




1 46.998 26.491 11.935 5.493 2.758 1.316 0.232 
2 48.123 26.6 11.943 5.507 2.809 1.348 0.258 




1 46.766 26.259 11.703 5.261 2.526 1.084 0 
2 47.865 26.342 11.685 5.249 2.551 1.09 0 





1 13.266 10.208 6.69 2.877 1.562 0.711 0 
2 14.365 10.291 6.672 2.865 1.587 0.717 0 




1 0.1497 0.1173 0.0801 0.0397 0.0258 0.0168 0 
2 0.1613 0.1182 0.0799 0.0396 0.026 0.0168 0 
3 0.1532 0.127 0.0807 0.0407 0.0253 0.0168 0 
The raw data set for the K221A variant is used as an example. * : The observed rate at 0 µM AdoMet was subtracted 
from each value. †: The rate of Mtase free AdoHcy formation for each concentration of AdoMet (Figure A5.2) was 
subtracted from the rates corrected for assay background. ‡ After correcting for uncatalyzed AdoHcy formation, the 
following transformation was performed to obtain ΔAdoHcy (µmoles) /second: 
    .
.  ; where 180 is 








Table A5.3. Raw data used for the generation of Michaelis-Menten plots and 
the determination of enzyme kinetic parameters 
[AdoMet] (µM) 0.5 0.2 0.08 0.032 0.0128 0.00512 0 
TSR 
1 0.334 0.199 0.1 0.067 0.053 0.045 0 
2 0.292 0.18 0.093 0.069 0.054 0.046 0 
3 0.278 0.197 0.103 0.076 0.055 0.044 0 
E220Q 
1 0.283 0.276 0.15 0.076 0.053 0.043 0 
2 0.291 0.252 0.123 0.068 0.052 0.043 0 
3 0.383 0.291 0.15 0.075 0.065 0.045 0 
K221A 
1 0.15 0.117 0.08 0.04 0.026 0.017 0 
2 0.161 0.118 0.08 0.04 0.026 0.017 0 
3 0.153 0.127 0.081 0.041 0.025 0.017 0 
R165A 
1 0.261 0.132 0.084 0.04 0.034 0.023 0 
2 0.158 0.112 0.076 0.043 0.034 0.023 0 
3 0.187 0.127 0.084 0.04 0.032 0.025 0 
The rates of AdoHcy formation (nmoles/ second) at various concentrations of AdoMet are shown, after corrections 
for assay background and the background rate of AdoHcy formation (background rates of AdoHyc formation were 
determined in parallel the rate in the presence of Mtase. The background values shown in Figure A5.2 are applicable 
to the data sets for K221A and R165A. Separate background rates were used for TSR and E220Q). Values in red 
were excluded from non-linear curve fitting according to: Rate V AdoMet K AdoMet  
 
Km(AdoMet):104.20 µM 
Vmax: 1.857 × 10







According to the Michaelis-Menten model: , therefore,   
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APPENDIX 6: Comparison of TSR and NHR 
 
 NHR MTEPAIITNASDPAVQRIIDVTKHSRASIKTTLIEDTEPLMECIRAGVQFIEVYGSSGTP 
  TSR MTELDTIANPSDPAVQRIIDVTKPSRSNIKTTLIEDVEPLMHSIAAGVEFIEVYGSDSSP 
  ***   *:* ************* **:.********.****..* ***:*******..:* 
 
 NHR LDPALLDLCRQREIPVRLIDVSIVNQLFKAERKAKVFGIARVPRPARLADIAERGGDVVV 
 TSR FPSELLDLCGRQNIPVRLIDSSIVNQLFKGERKAKTFGIARVPRPARFGDIASRRGDVVV 
  ***** :::******* ********.*****.***********:.***.* ***** 
 
 NHR LDGVKIVGNIGAIVRTSLALGAAGIVLVDSDLATIADRRLLRASRGYVFSLPVVLADREE 
 TSR LDGVKIVGNIGAIVRTSLALGASGIILVDSDITSIADRRLQRASRGYVFSLPVVLSGREE 
  **********************:**:*****:::****** **************: *** 
 
 NHR AVSFLRDNDIALMVLDTDGDLGVKDLGDRADRMALVFGSEKGGPSGLFQEASAGTVSIPM 
 TSR AIAFIRDSGMQLMTLKADGDISVKELGDNPDRLALLFGSEKGGPSDLFEEASSASVSIPM 
  *::*:**. : **.*.:***:.**:***. **:**:********* **:***:.:***** 
 
 NHR LSSTESLNVSVSVGIALHERSARNFAVRRAAAQA 
 TSR  MSQTESLNVSVSLGIALHERIDRNLAANR----- 




Figure A6.1. Sequence alignment of NHR (nosiheptide resistance methyltransferase) and TSR 
(thiostrepton resistance methyltransferase). Alignment was performed using CLUSTAL Omega. α-helical 
regions are shaded purple and β-sheets are in blue. The two enzymes share 73% sequence identity and 82.1% 
sequence similarity. Accession numbers are P52391 and P18644 for NHR and TSR, respectively 
Figure A6.2 A) Stereoview of superimposed structures for TSR (green) and the nosiheptide 
resistance methyltransferase (purple). (B) Superimposed structures of AdoMet, as positioned in the 
binding pockets of the individual subunits of TSR (white) and the nosiheptide resistance 
methyltransferase (magenta). Structures were generated from PDB structure files (TSR: 3GYQ; NHR 





APPENDIX 7: Confirmation of mutant identity. 
The DNA sequence of the gene encoding region from plasmids bearing mutated TSR and TIP-
AS genes shown (translated sequence is shown below in upper case). Mutated codons are 




 M  T  E  L  D  T  I  A  N  P  S  D  P  A  V  Q  R  I  I  D  
gtcaccaagccgtcgcgatccaacataaagacaacgttgatcgaggacgtcgagcccctc 
 V  T  K  P  S  R  S  N  I  K  T  T  L  I  E  D  V  E  P  L  
atgcacagcatcgcggccggggtggagttcatcgaggtctacggcagcgacagcagtcct 
 M  H  S  I  A  A  G  V  E  F  I  E  V  Y  G  S  D  S  S  P  
tttccatctgagttgctggatctgtgcgggcggcagaacataccggtccgcctcatcgac 
 F  P  S  E  L  L  D  L  C  G  R  Q  N  I  P  V  R  L  I  D  
tcctcgatcgtcaaccagttgttcaagggggagcggaaggccaagacattcggcatcgcc 
 S  S  I  V  N  Q  L  F  K  G  E  R  K  A  K  T  F  G  I  A  
cgcgtccctcgcccggccaggttcggcgatatcgcgagccggcgtggggacgtcgtcgtt 
 R  V  P  R  P  A  R  F  G  D  I  A  S  R  R  G  D  V  V  V  
ctcgacggggtgaagatcgtcggggcgatcggcgcgatagtacgcacgtcgctcgcgctc 
 L  D  G  V  K  I  V  G  A  I  G  A  I  V  R  T  S  L  A  L  
ggagcgtcggggatcatcctggtcgacagtgacatcaccagcatcgcggaccggcgtctc 
 G  A  S  G  I  I  L  V  D  S  D  I  T  S  I  A  D  R  R  L  
caaagggccagccgaggttacgtcttctcccttcccgtcgttctctccggtcgcgaggag 
 Q  R  A  S  R  G  Y  V  F  S  L  P  V  V  L  S  G  R  E  E  
gccatcgccttcattcgggacagcggtatgcagctgatgacgctcaaggcggatggcgac 
 A  I  A  F  I  R  D  S  G  M  Q  L  M  T  L  K  A  D  G  D  
atttccgtgaaggaactcggggacaatccggatcggctggccttgctgttcggcagcgaa 
 I  S  V  K  E  L  G  D  N  P  D  R  L  A  L  L  F  G  S  E  
aagggtgggccttccgacctgntcgaggaggcgtcttccgcctcggtttccatccccatg 
 K  G  G  P  S  D  L  X  E  E  A  S  S  A  S  V  S  I  P  M  
atgagccagaccgagtctctcaacgtttccgtttccctcnggatcgcgctgcncgagagg 
 M  S  Q  T  E  S  L  N  V  S  V  S  L  X  I  A  L  X  E  R  
atcgacaggaatctcgcggccaaccga 




 M  T  E  L  D  T  I  A  N  P  S  D  P  A  V  Q  R  I  I  D  
gtcaccaagccgtcgcgatccaacataaagacaacgttgatcgaggacgtcgagcccctc 
 V  T  K  P  S  R  S  N  I  K  T  T  L  I  E  D  V  E  P  L  
atgcacagcatcgcggccggggtggagttcatcgaggtctacggcagcgacagcagtcct 
 M  H  S  I  A  A  G  V  E  F  I  E  V  Y  G  S  D  S  S  P  
tttccatctgagttgctggatctgtgcgggcggcagaacataccggtccgcctcatcgac 
 F  P  S  E  L  L  D  L  C  G  R  Q  N  I  P  V  R  L  I  D  
tcctcgatcgtcaaccagttgttcaagggggagcggaaggccaagacattcggcatcgcc 
 S  S  I  V  N  Q  L  F  K  G  E  R  K  A  K  T  F  G  I  A  
cgcgtccctcgcccggccaggttcggcgatatcgcgagccggcgtggggacgtcgtcgtt 
 R  V  P  R  P  A  R  F  G  D  I  A  S  R  R  G  D  V  V  V  
ctcgacggggtgaagatcgtcggggacatcggcgcgatagtacgcacgtcgctcgcgctc 
 L  D  G  V  K  I  V  G  D  I  G  A  I  V  R  T  S  L  A  L  
ggagcgtcggggatcatcctggtcgacagtgacatcaccagcatcgcggaccggcgtctc 
 G  A  S  G  I  I  L  V  D  S  D  I  T  S  I  A  D  R  R  L  
caaagggccagccgaggttacgtcttctcccttcccgtcgttctctccggtcgcgaggag 
 Q  R  A  S  R  G  Y  V  F  S  L  P  V  V  L  S  G  R  E  E  
gccatcgccttcattcgggacagcggtatgcagctgatgacgctcaaggcggatggcgac 
 A  I  A  F  I  R  D  S  G  M  Q  L  M  T  L  K  A  D  G  D  
atttccgtgaaggaactcggggacaatccggatcggctggccttgctgttcggcagcgaa 
 I  S  V  K  E  L  G  D  N  P  D  R  L  A  L  L  F  G  S  E  
aagggtgggccttccgacctgttcgaggaggcgtcttccgcctcggtttccatccccatg 
 K  G  G  P  S  D  L  F  E  E  A  S  S  A  S  V  S  I  P  M  
atgagccagaccgagtctctcaacgtttccgtttccctcggaatcgcgctgcacgagagg 
 M  S  Q  T  E  S  L  N  V  S  V  S  L  G  I  A  L  H  E  R  
atcgacaggaatctcgcggcccanccga 
 I  D  R  N  L  A  A  X  R 
Predicted: 29139.2 Da 





 M  T  E  L  D  T  I  A  N  P  S  D  P  A  V  Q  R  I  I  D  
gtcaccaagccgtcgcgatccaacataaagacaacgttgatcgaggacgtcgagcccctc 
 V  T  K  P  S  R  S  N  I  K  T  T  L  I  E  D  V  E  P  L  
atgcacagcatcgcggccggggtggagttcatcgaggtctacggcagcgacagcagtcct 
 M  H  S  I  A  A  G  V  E  F  I  E  V  Y  G  S  D  S  S  P  
tttccatctgagttgctggatctgtgcgggcggcagaacataccggtccgcctcatcgac 
 F  P  S  E  L  L  D  L  C  G  R  Q  N  I  P  V  R  L  I  D  
tcctcgatcgtcaaccagttgttcaagggggagcggaaggccaagacattcggcatcgcc 
 S  S  I  V  N  Q  L  F  K  G  E  R  K  A  K  T  F  G  I  A  
cgcgtccctcgcccggccaggttcggcgatatcgcgagccggcgtggggacgtcgtcgtt 
 R  V  P  R  P  A  R  F  G  D  I  A  S  R  R  G  D  V  V  V  
ctcgacggggtgaagatcgtcgggaacatcggcgcgatagtacgcacgtcgctcgcgctc 
 L  D  G  V  K  I  V  G  N  I  G  A  I  V  R  T  S  L  A  L  
ggagcgtcggggatcatcctggtcgacagtgacatcaccagcatcgcggaccggcgtctc 
 G  A  S  G  I  I  L  V  D  S  D  I  T  S  I  A  D  R  R  L  
caaagggccagccgaggttacgtcttctcccttcccgtcgttctctccggtcgcgaggag 
 Q  R  A  S  R  G  Y  V  F  S  L  P  V  V  L  S  G  R  E  E  
gccatcgccttcattcgggacagcggtatgcagctgatgacgctcaaggcggatggcgac 
 A  I  A  F  I  R  D  S  G  M  Q  L  M  T  L  K  A  D  G  D  
atttccgtgaaggaactcggggacaatccggatcggctggccttgctgttcggcagcgcg 
 I  S  V  K  E  L  G  D  N  P  D  R  L  A  L  L  F  G  S  A  
aanggtgggccttccgacctgntcgaggaggcgtcttccgcctcggtttccatccccatg 
 X  G  G  P  S  D  L  X  E  E  A  S  S  A  S  V  S  I  P  M  
atgagcnngaccgagtctctcaacgtttccnnttccctcggaatcgcgctgcacgagagg 





Predicted for :Histagged-E220Q: 
30932.1 Da 





 M  T  E  L  D  T  I  A  N  P  S  D  P  A  V  Q  R  I  I  D  
gtcaccaagccgtcgcgatccaacataaagacaacgttgatcgaggacgtcgagcccctc 
 V  T  K  P  S  R  S  N  I  K  T  T  L  I  E  D  V  E  P  L  
atgcacagcatcgcggccggggtggagttcatcgaggtctacggcagcgacagcagtcct 
 M  H  S  I  A  A  G  V  E  F  I  E  V  Y  G  S  D  S  S  P  
tttccatctgagttgctggatctgtgcgggcggcagaacataccggtccgcctcatcgac 
 F  P  S  E  L  L  D  L  C  G  R  Q  N  I  P  V  R  L  I  D  
tcctcgatcgtcaaccagttgttcaagggggagcggaaggccaagacattcggcatcgcc 
 S  S  I  V  N  Q  L  F  K  G  E  R  K  A  K  T  F  G  I  A  
cgcgtccctcgcccggccaggttcggcgatatcgcgagccggcgtggggacgtcgtcgtt 
 R  V  P  R  P  A  R  F  G  D  I  A  S  R  R  G  D  V  V  V  
ctcgacggggtgaagatcgtcgggaacatcggcgcgatagtacgcacgtcgctcgcgctc 
 L  D  G  V  K  I  V  G  N  I  G  A  I  V  R  T  S  L  A  L  
ggagcgtcggggatcatcctggtcgacagtgacatcaccagcatcgcggaccggcgtctc 
 G  A  S  G  I  I  L  V  D  S  D  I  T  S  I  A  D  R  R  L  
caaagggccagccgaggttacgtcttctcccttcccgtcgttctctccggtcgcgaggag 
 Q  R  A  S  R  G  Y  V  F  S  L  P  V  V  L  S  G  R  E  E  
gccatcgccttcattcgggacagcggtatgcagctgatgacgctcaaggcggatggcgac 
 A  I  A  F  I  R  D  S  G  M  Q  L  M  T  L  K  A  D  G  D  
atttccgtgaaggaactcggggacaatccggatcggctggccttgctgttcggcagcgaa 
 I  S  V  K  E  L  G  D  N  P  D  R  L  A  L  L  F  G  S  E  
aagggtgggccttccgacctgttcgaggaggcgtcttccgnctcggtttccatccccatg 
 K  G  G  P  S  D  L  F  E  E  A  S  S  X  S  V  S  I  P  M  
atgagccngaccgagtctctcgcggtttccgtttccctcggaatcgcgctgcacgagagg 
 M  S  X  T  E  S  L  A  V  S  V  S  L  G  I  A  L  H  E  R  
atcgacaggaatctcgcggccnaccgat 





 M  T  E  L  D  T  I  A  N  P  S  D  P  A  V  Q  R  I  I  D  
gtcaccaagccgtcgcgatccaacataaagacaacgttgatcgaggacgtcgagcccctc 
 V  T  K  P  S  R  S  N  I  K  T  T  L  I  E  D  V  E  P  L  
atgcacagcatcgcggccggggtggagttcatcgaggtctacggcagcgacagcagtcct 
 M  H  S  I  A  A  G  V  E  F  I  E  V  Y  G  S  D  S  S  P  
tttccatctgagttgctggatctgtgcgggcggcagaacataccggtccgcctcatcgac 
 F  P  S  E  L  L  D  L  C  G  R  Q  N  I  P  V  R  L  I  D  
tcctcgatcgtcaaccagttgttcaagggggagcggaaggccaagacattcggcatcgcc 
 S  S  I  V  N  Q  L  F  K  G  E  R  K  A  K  T  F  G  I  A  
cgcgtccctcgcccggccaggttcggcgatatcgcgagccggcgtggggacgtcgtcgtt 
 R  V  P  R  P  A  R  F  G  D  I  A  S  R  R  G  D  V  V  V  
ctcgacggggtgaagatcgtcgggaacatcggcgcgatagtacgcacgtcgctcgcgctc 
 L  D  G  V  K  I  V  G  N  I  G  A  I  V  R  T  S  L  A  L  
ggagcgtcggggatcatcctggtcgacagtgacatcaccagcatcgcggaccggcgtctc 
 G  A  S  G  I  I  L  V  D  S  D  I  T  S  I  A  D  R  R  L  
caaagggccagccgaggttacgtcttctcccttcccgtcgttctctccggtcgcgaggag 
 Q  R  A  S  R  G  Y  V  F  S  L  P  V  V  L  S  G  R  E  E  
gccatcgccttcattcgggacagcggtatgcagctgatgacgctcaaggcggatggcgac 
 A  I  A  F  I  R  D  S  G  M  Q  L  M  T  L  K  A  D  G  D  
atttccgtgaaggaactcggggacaatccggatcggctggccttgctgttcggcagcgaa 
 I  S  V  K  E  L  G  D  N  P  D  R  L  A  L  L  F  G  S  E  
aagggtgggccttccgacctgttcgaggaggcgtcttccgcctcggtttccatccccatg 
 K  G  G  P  S  D  L  F  E  E  A  S  S  A  S  V  S  I  P  M  
atgagccagaccgagtctctcgacgtttccgtttccctcggaatcgcnctgcacgagagg 
 M  S  Q  T  E  S  L  D  V  S  V  S  L  G  I  X  L  H  E  R  
atcgacaggaatctcgcggccaaccgat 












Predicted: 29139.2 Da 





 M  T  E  L  D  T  I  A  N  P  S  D  P  A  V  Q  R  I  I  D  
gtcaccaagccgtcgcgatccaacataaagacaacgttgatcgaggacgtcgagcccctc 
 V  T  K  P  S  R  S  N  I  K  T  T  L  I  E  D  V  E  P  L  
atgcacagcatcgcggccggggtggagttcatcgaggtctacggcagcgacagcagtcct 
 M  H  S  I  A  A  G  V  E  F  I  E  V  Y  G  S  D  S  S  P  
tttccatctgagttgctggatctgtgcgggcggcagaacataccggtccgcctcatcgac 
 F  P  S  E  L  L  D  L  C  G  R  Q  N  I  P  V  R  L  I  D  
tcctcgatcgtcaaccagttgttcaagggggagcggaaggccaagacattcggcatcgcc 
 S  S  I  V  N  Q  L  F  K  G  E  R  K  A  K  T  F  G  I  A  
cgcgtccctcgcccggccaggttcggcgatatcgcgagccggcgtggggacgtcgtcgtt 
 R  V  P  R  P  A  R  F  G  D  I  A  S  R  R  G  D  V  V  V  
ctcgacggggtgaagatcgtcgggaacatcggcgcgatagtagcgacgtcgctcgcgctc 
 L  D  G  V  K  I  V  G  N  I  G  A  I  V  A  T  S  L  A  L  
ggagcgtcggggatcatcctggtcgacagtgacatcaccagcatcgcggaccggcgtctc 
 G  A  S  G  I  I  L  V  D  S  D  I  T  S  I  A  D  R  R  L  
caaagggccagccgaggttacgtcttctcccttcccgtcgttctctccggtcgcgaggag 
 Q  R  A  S  R  G  Y  V  F  S  L  P  V  V  L  S  G  R  E  E  
gccatcgccttcattcgggacagcggtatgcagctgatgacgctcaaggcggatggcgac 
 A  I  A  F  I  R  D  S  G  M  Q  L  M  T  L  K  A  D  G  D  
atttccgtgaaggaactcggggacaatccggatcggctggncttgctgttcggcagcgaa 
 I  S  V  K  E  L  G  D  N  P  D  R  L  X  L  L  F  G  S  E  
aagggtgggccttccgacctgttcgaggaggcgtcttccgcctcggtttccatccccatg 
 K  G  G  P  S  D  L  F  E  E  A  S  S  A  S  V  S  I  P  M  
atgagcnngaccgagtctctcaacgtttccgnttccctcggaatcgcgctgcacgagagg 
 M  S  X  T  E  S  L  N  V  S  X  S  L  G  I  A  L  H  E  R  
atcgacaggaatctcgcggccnaccga 





 M  T  E  L  D  T  I  A  N  P  S  D  P  A  V  Q  R  I  I  D  
gtcaccaagccgtcgcgatccaacataaagacaacgttgatcgaggacgtcgagcccctc 
 V  T  K  P  S  R  S  N  I  K  T  T  L  I  E  D  V  E  P  L  
atgcacagcatcgcggccggggtggagttcatcgaggtctacggcagcgacagcagtcct 
 M  H  S  I  A  A  G  V  E  F  I  E  V  Y  G  S  D  S  S  P  
tttccatctgagttgctggatctgtgcgggcggcagaacataccggtccgcctcatcgac 
 F  P  S  E  L  L  D  L  C  G  R  Q  N  I  P  V  R  L  I  D  
tcctcgatcgtcaaccagttgttcaagggggagcggaaggccaagacattcggcatcgcc 
 S  S  I  V  N  Q  L  F  K  G  E  R  K  A  K  T  F  G  I  A  
cgcgtccctcgcccggccaggttcggcgatatcgcgagccggcgtggggacgtcgtcgtt 
 R  V  P  R  P  A  R  F  G  D  I  A  S  R  R  G  D  V  V  V  
ctcgacggggtgaagatcgtcgggaacatcggcgcgatagtaaagacgtcgctcgcgctc 
 L  D  G  V  K  I  V  G  N  I  G  A  I  V  K  T  S  L  A  L  
ggagcgtcggggatcatcctggtcgacagtgacatcaccagcatcgcggaccggcgtctc 
 G  A  S  G  I  I  L  V  D  S  D  I  T  S  I  A  D  R  R  L  
caaagggccagccgaggttacgtcttctcccttcccgtcgttctctccggtcgcgaggag 
 Q  R  A  S  R  G  Y  V  F  S  L  P  V  V  L  S  G  R  E  E  
gccatcgccttcattcgggacagcggtatgcagctgatgacgctcaangcggatggcgac 
 A  I  A  F  I  R  D  S  G  M  Q  L  M  T  L  X  A  D  G  D  
atttccgtgaaggaactcggggacaatccggatcggctggccttgctgntcggcagcgaa 
 I  S  V  K  E  L  G  D  N  P  D  R  L  A  L  L  X  G  S  E  
aagggtgggccttccgacctgttcgaggaggcgtcttccgcctcggnttccatccccatg 
 K  G  G  P  S  D  L  F  E  E  A  S  S  A  S  X  S  I  P  M  
atgagccagaccgagtctctcaacgtttccgtttccctcggaatcgcgctgcacgagagg 
 M  S  Q  T  E  S  L  N  V  S  V  S  L  G  I  A  L  H  E  R  
atcgacaggaatctcgcggccaaccga 





Predicted: 29097.2 Da 





 M  T  E  L  D  T  I  A  N  P  S  D  P  A  V  Q  R  I  I  D  
gtcaccaagccgtcgcgatccaacataaagacaacgttgatcgaggacgtcgagcccctc 
 V  T  K  P  S  R  S  N  I  K  T  T  L  I  E  D  V  E  P  L  
atgcacagcatcgcggccggggtggagttcatcgaggtctacggcagcgacagcagtcct 
 M  H  S  I  A  A  G  V  E  F  I  E  V  Y  G  S  D  S  S  P  
tttccatctgagttgctggatctgtgcgggcggcagaacataccggtccgcctcatcgac 
 F  P  S  E  L  L  D  L  C  G  R  Q  N  I  P  V  R  L  I  D  
tcctcgatcgtcaaccagttgttcaagggggagcggaaggccaagacattcggcatcgcc 
 S  S  I  V  N  Q  L  F  K  G  E  R  K  A  K  T  F  G  I  A  
cgcgtccctcgcccggccaggttcggcgatatcgcgagccggcgtggggacgtcgtcgtt 
 R  V  P  R  P  A  R  F  G  D  I  A  S  R  R  G  D  V  V  V  
ctcgacggggtgaagatcgtcgggaacatcggcgcgatagtacgcacgtcgctcgcgctc 
 L  D  G  V  K  I  V  G  N  I  G  A  I  V  R  T  S  L  A  L  
ggagcgtcggggatcatcctggtcgacagtgacatcaccagcatcgcggaccggcgtctc 
 G  A  S  G  I  I  L  V  D  S  D  I  T  S  I  A  D  R  R  L  
caaagggccagcgcgggttacgtcttctcccttcccgtcgttctctccggtcgcgaggag 
 Q  R  A  S  A  G  Y  V  F  S  L  P  V  V  L  S  G  R  E  E  
gccatcgccttcattcgggacagcggtatgcagctgatgacgctcaaggcggatggcgac 
 A  I  A  F  I  R  D  S  G  M  Q  L  M  T  L  K  A  D  G  D  
atttccgtgaaggaactcggggacaatccggatcggctggncttgctgttcggcagcgaa 
 I  S  V  K  E  L  G  D  N  P  D  R  L  X  L  L  F  G  S  E  
aagggtgggccttccgacctgntcgaggaggcgtcttccgcctcggtttccatccccatg 
 K  G  G  P  S  D  L  X  E  E  A  S  S  A  S  V  S  I  P  M  
atgagccagancgagtctctnnacgtttccgtttccctcggaatcgcgctgcacgagagg 
 M  S  Q  X  E  S  X  X  V  S  V  S  L  G  I  A  L  H  E  R  
atcgacaggaatctcgcggccaaccga 





 M  T  E  L  D  T  I  A  N  P  S  D  P  A  V  Q  R  I  I  D  
gtcaccaagccgtcgcgatccaacataaagacaacgttgatcgaggacgtcgagcccctc 
 V  T  K  P  S  R  S  N  I  K  T  T  L  I  E  D  V  E  P  L  
atgcacagcatcgcggccggggtggagttcatcgaggtctacggcagcgacagcagtcct 
 M  H  S  I  A  A  G  V  E  F  I  E  V  Y  G  S  D  S  S  P  
tttccatctgagttgctggatctgtgcgggcggcagaacataccggtccgcctcatcgac 
 F  P  S  E  L  L  D  L  C  G  R  Q  N  I  P  V  R  L  I  D  
tcctcgatcgtcaaccagttgttcaagggggagcggaaggccaagacattcggcatcgcc 
 S  S  I  V  N  Q  L  F  K  G  E  R  K  A  K  T  F  G  I  A  
cgcgtccctcgcccggccaggttcggcgatatcgcgagccggcgtggggacgtcgtcgtt 
 R  V  P  R  P  A  R  F  G  D  I  A  S  R  R  G  D  V  V  V  
ctcgacggggtgaagatcgtcgggaacatcggcgcgatagtacgcacgtcgctcgcgctc 
 L  D  G  V  K  I  V  G  N  I  G  A  I  V  R  T  S  L  A  L  
ggagcgtcggggatcatcctggtcgacagtgacatcaccagcatcgcggaccggcgtctc 
 G  A  S  G  I  I  L  V  D  S  D  I  T  S  I  A  D  R  R  L  
caaagggccagcaagggttacgtcttctcccttcccgtcgttctctccggtcgcgaggag 
 Q  R  A  S  K  G  Y  V  F  S  L  P  V  V  L  S  G  R  E  E  
gccatcgccttcattcgggacagcggtatgcagctgatgacgctcaaggcggatggcgac 
 A  I  A  F  I  R  D  S  G  M  Q  L  M  T  L  K  A  D  G  D  
atttccgtgaaggaactcggggacaatccggatcggctggccttgctgttcggcagcgaa 
 I  S  V  K  E  L  G  D  N  P  D  R  L  A  L  L  F  G  S  E  
aagggtgggccttccgacctgttcgaggaggcgtcttccgcctcggtttccatccccatg 
 K  G  G  P  S  D  L  F  E  E  A  S  S  A  S  V  S  I  P  M  
atgagccngaccgagtctctcaacgtttccgtttccctcggaatcgcgctgcacgagagg 
 M  S  X  T  E  S  L  N  V  S  V  S  L  G  I  A  L  H  E  R  
atcgacaggaatctcgcggncaaccga 






Predicted: 29154.3 Da 





 M  T  E  L  D  T  I  A  N  P  S  D  P  A  V  Q  R  I  I  D  
gtcaccaagccgtcgcgatccaacataaagacaacgttgatcgaggacgtcgagcccctc 
 V  T  K  P  S  R  S  N  I  K  T  T  L  I  E  D  V  E  P  L  
atgcacagcatcgcggccggggtggagttcatcgaggtctacggcagcgacagcagtcct 
 M  H  S  I  A  A  G  V  E  F  I  E  V  Y  G  S  D  S  S  P  
tttccatctgagttgctggatctgtgcgggcggcagaacataccggtccgcctcatcgac 
 F  P  S  E  L  L  D  L  C  G  R  Q  N  I  P  V  R  L  I  D  
tcctcgatcgtcaaccagttgttcaagggggagcggaaggccaagacattcggcatcgcc 
 S  S  I  V  N  Q  L  F  K  G  E  R  K  A  K  T  F  G  I  A  
cgcgtccctcgcccggccaggttcggcgatatcgcgagccggcgtggggacgtcgtcgtt 
 R  V  P  R  P  A  R  F  G  D  I  A  S  R  R  G  D  V  V  V  
ctcgacggggtgaagatcgtcgggaacatcggcgcgatagtacgcacgtcgctcgcgctc 
 L  D  G  V  K  I  V  G  N  I  G  A  I  V  R  T  S  L  A  L  
ggagcgtcggggatcatcctggtcgacagtgacatcaccagcatcgcggaccggcgtctc 
 G  A  S  G  I  I  L  V  D  S  D  I  T  S  I  A  D  R  R  L  
caaagggccagccgaggttacgtcttctcccttcccgtcgttctctccggtcgcgaggag 
 Q  R  A  S  R  G  Y  V  F  S  L  P  V  V  L  S  G  R  E  E  
gccatcgccttcattcgggacagcggtatgcagctgatgacgctcaaggcggatggcgac 
 A  I  A  F  I  R  D  S  G  M  Q  L  M  T  L  K  A  D  G  D  
atttccgtgaaggaactcggggacaatcccggatcggctggncttgctgttcggcagcga 
 I  S  V  K  E  L  G  D  N  P  G  S  A  X  L  A  V  R  Q  R  
aanggtgggccttccgacctgttcgaggangcgtcttccgcctcggnttccntccccatg 
 X  G  G  P  S  D  L  F  E  X  A  S  S  A  S  X  S  X  P  M  
atgagccagaccnaggcgctnannnnnccgtttncctcgggantcncgctgcacgagang 
 M  S  Q  T  X  A  X  X  X  P  F  X  S  G  X  X  L  H  E  X  
natcgacaggaatcnngcggccnancn 






Predicted: 29166.3 Da 
Predicted: 29125.2 Da 
252 
 
  C214A 
  atgggaatcaacctcaccccggaggagaagttcgaggtcttcggcgacttcgaccccgac 
 M  G  I  N  L  T  P  E  E  K  F  E  V  F  G  D  F  D  P  D  
cagtacgaggaggaggtccgggaacgctgggggaacaccgacgcctaccgccagtccaag 
 Q  Y  E  E  E  V  R  E  R  W  G  N  T  D  A  Y  R  Q  S  K  
gagaagaccgcctcgtacaccaaggaggactggcagcgcatccaggacgaggccgacgag 
 E  K  T  A  S  Y  T  K  E  D  W  Q  R  I  Q  D  E  A  D  E  
ctcacccggcgcttcgtcgccctgatggacgcgggtgagcccgccgactccgagggggcc 
 L  T  R  R  F  V  A  L  M  D  A  G  E  P  A  D  S  E  G  A  
atggacgccgccgaggaccaccggcagggcatcgcccgcaaccactacgactgcgggtac 
 M  D  A  A  E  D  H  R  Q  G  I  A  R  N  H  Y  D  C  G  Y  
gagatgcacaccgcgctgggcgagatgtacgtgtccgacgaacgtttcacgcgaaacatc 
 E  M  H  T  A  L  G  E  M  Y  V  S  D  E  R  F  T  R  N  I  
gacgccgccaagccgggcctcgccgcctacatgcgcgacgcgatcctcgccaacgccgtc 
 D  A  A  K  P  G  L  A  A  Y  M  R  D  A  I  L  A  N  A  V  
cggcacaccccc 




 M  G  I  N  L  T  P  E  E  K  F  E  V  F  G  D  F  D  P  D  
cagtacgaggaggaggtccgggaacgctgggggaacaccgacgcctaccgccagtccaag 
 Q  Y  E  E  E  V  R  E  R  W  G  N  T  D  A  Y  R  Q  S  K  
gagaagaccgcctcgtacaccaaggaggactggcagcgcatccaggacgaggccgacgag 
 E  K  T  A  S  Y  T  K  E  D  W  Q  R  I  Q  D  E  A  D  E  
ctcacccggcgcttcgtcgccctgatggacgcgggtgagcccgccgactccgagggggcc 
 L  T  R  R  F  V  A  L  M  D  A  G  E  P  A  D  S  E  G  A  
atggacgccgccgaggaccaccggcagggcatcgcccgcaaccactacgactgcgggtac 
 M  D  A  A  E  D  H  R  Q  G  I  A  R  N  H  Y  D  C  G  Y  
gagatgcacaccagcctgggcgagatgtacgtgtccgacgaacgtttcacgcgaaacatc 
 E  M  H  T  S  L  G  E  M  Y  V  S  D  E  R  F  T  R  N  I  
gacgccgccaagcccgtgcggcacaccccc 




 M  G  I  N  L  T  P  E  E  K  F  E  V  F  G  D  F  D  P  D  
cagtacgaggaggaggtccgggaacgctgggggaacaccgacgcctaccgccagtccaag 
 Q  Y  E  E  E  V  R  E  R  W  G  N  T  D  A  Y  R  Q  S  K  
gagaagaccgcctcgtacaccaaggaggactggcagcgcatccaggacgaggccgacgag 
 E  K  T  A  S  Y  T  K  E  D  W  Q  R  I  Q  D  E  A  D  E  
ctcacccggcgcttcgtcgccctgatggacgcgggtgagcccgccgactccgagggggcc 
 L  T  R  R  F  V  A  L  M  D  A  G  E  P  A  D  S  E  G  A  
atggacgccgccgaggaccaccggcagggcatcgcccgcaaccactacgacgcggggtac 
 M  D  A  A  E  D  H  R  Q  G  I  A  R  N  H  Y  D  A  G  Y  
gagatgcacacctgcctgggcgagatgtacgtgtccgacgaacgtttcacgcgaaacatc 
 E  M  H  T  C  L  G  E  M  Y  V  S  D  E  R  F  T  R  N  I  
gacgccgccaagccgggcctcgccgcctacatgcgcgacgcgatcctcgccaacgccgtc 
 D  A  A  K  P  G  L  A  A  Y  M  R  D  A  I  L  A  N  A  V  
cggcacaccccctga 





















APPENDIX 8: Additives used in screens for TIPAS crystallization 
 
Table A8.1 Additive screen reagents 
Reagent # 
Final Concentration 
of Additive (M) Additive 
1 0.1 Ammonium acetate 
2 0.1 Calcium acetate hydrate 
3 0.1 Potassium acetate 
4 0.1 Potassium hydrate 
5 0.1 Potassium phosphate monobasic 
6 0.1 Sodium acetate trihydrate 
7 0.1 Sodium phosphate dibasic dihydrate 
8 0.1 Sodium phosphate monobasic monohydrate 
9 0.1 Calcium chloride dihydrate 
10 0.1 Manganese chloride tetrahydrate 
11 1.0 Ammonium sulfate 
12 1.0 Potassium chloride 
13 1.0 Lithium chloride 
14 2.0 Sodium chloride 
15 0.5 Sodium fluoride 
16 1.0 Sodium citrate tribasic dihydrate 
17 0.1 Phenol 
18 30 Dimethyl sulfoxide 
19 1.0 Glycine 
20 1.0 Guanidine hydrochloride 
21 0.1 Urea 
22 10 Polyethylene glycol 3,350 
23 10 Polyethylene glycol 8,000 
24 30 D-(+)-Glucose monohydrate 
25 30 Ethylene glycol 
26 30 Glycerol 
27 30 Ethanol 
28 30 2-Propanol 
29 30 Methanol 
30 0.1 Imidazole 
31 30 Tacsimate 
31 0.1 sodium cacodylate trihydrate 
 
